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A BST R A C T 
Pulmonary arterial hypertension (PAH) is a debilitating disease of small pulmonary 
resistance arteries with vasoconstriction and vascular remodelling contributing to the 
disease pathology. A genetic basis for the disease was linked to heterozygous loss of 
function mutations in the bone morphogenetic protein receptor 2 (BMPR2) gene. The 
mutation is found in the majority of familial PAH cases and a significant number of 
apparently sporadic cases. The low penetrance of the disease in families carrying BMPR2 
mutations and the absence of mutations in the majority of idiopathic patients indicates that 
BMPR2 deficiency alone is insufficient to induce PAH. It is generally accepted PAH has a 
multi-factorial pathology with endogenous and environmental factors acting in concert 
with genetic pre-disposition to create the disease phenotype. Enhancement of the serotonin 
(5-HT) system has been implicated in PAH with the 5-HT transporter (5-HTT) receiving 
the most attention as a modifying gene in the development of PAH and there is compelling 
animal and human data implicating a role for increased expression of the 5-HTT as a 
modulating factor.  
 The aim of this study was to investigate if genetic pre-disposition interacts with other 
additional modifying factors to create the symptoms of PAH. Transgenic mice 
overexpressing the 5-HTT (5-HTT+), deficient in BMPR2 (BMPR2+/-) or a double 
transgenic (5-HTT+/BMPR2+/-) were employed in addition to mice lacking tryptophan 
hydroxylase 1 (Tph1), the rate limiting enzyme for the synthesis of 5-HT, and therefore 
lacking peripheral 5-HT (Tph1-/-).  Additional known or suspected modifying factors 
assessed in these genetic models were hypoxia, dexfenfluramine (Dfen) and its major 
metabolite nordexfenfluramine (NDfen), 5-HT, bone morphogenetic protein-2 (BMP-2), 
KCNQ channels and the role of gender. 
 Mice were examined in vivo for evidence of a pulmonary hypertensive phenotype 
following exposure to hypoxia and Dfen. Female 5-HTT+ mice were the only group to 
iii 
 
have a rise in two indices of PAH - namely right ventricular pressure (RVP) and vascular 
remodelling - in room air. Female 5-HTT+ mice also had an exaggerated pulmonary 
hypertensive phenotype in hypoxia. BMPR2+/- mice, were, unexpectedly least susceptible 
to hypoxic induced increases in RVP although female mice deficient in BMPR2 (both 
BMPR2+/- and 5-HTT+/BMPR2+/-) had more extensive vascular remodelling under 
hypoxia compared with WT and 5-HTT+ mice. Male mice did not express the phenotypic 
changes just outlined. No synergistic effect was observed between 5-HTT+ and BMPR2+/- 
that resulted in a more pronounced pulmonary hypertensive phenotype.   
 WT and BMPR2+/- mice were chronically oral-dosed with Dfen. Female mice from both 
genotypes developed similar degrees of PAH. Male mice did not develop elevated RVP but 
BMPR2+/- males did have evidence of vascular remodelling, although at a lower level than 
the females.  Female Tph1-/- mice did not develop PAH following Dfen indicating Dfen 
associated PAH is dependent on peripheral 5-HT synthesis. The presence of intact 5-HT 
synthesis was also associated with an increased vasoconstrictor response to 5-HT in 
isolated intralobar pulmonary arteries (IPAs), a situation not paralleled with the other 
serotonergic vasoconstrictors, Dfen and NDfen, indicating differing mechanisms of action 
underlying the respective vasoconstrictor responses.  
 The vasoconstrictor action of 5-HT, Dfen, NDfen and the KCNQ potassium channel 
blocker linopirdine were all assessed in IPAs. Pulmonary arteries from BMPR2+/- mice 
showed enhanced vasoconstriction to 5-HT and NDfen. 5-HTT+ and 5-HTT+/BMPR2+/- 
mice showed enhanced vasoconstriction to NDfen but decreased vasoconstriction to 5-HT. 
Female 5-HTT+/BMPR2+/- mice were the only group tested to show significantly greater 
vasoconstriction to Dfen compared with WT. The vasoconstrictor response to linopirdine 
was significantly reduced in BMPR2+/- mice but neither linopirdine nor BMP-2 affected 5-
HT induced vasoconstriction. 
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 Female gender is an established risk factor for PAH. To investigate possible events that 
may underlie this risk, male (testosterone) and female (estradiol and 2-methoxyestradiol 
(2-ME)) sex hormones were assessed for their vasoactive properties in IPAs. All three 
hormones relaxed pre-constricted vessels but only at supraphysiological (>0.1 µM) 
concentrations. Each hormone also reduced the vasoconstriction exerted by 5-HT at 10-5 M 
in male mice but not in females. No such effect, however, was observed in either gender at 
a physiological (10-9 M) concentration. NDfen induced vasoconstriction was also 
unaffected by 10-9 M estradiol. Finally, male and female mouse lungs were assessed for 
protein expression of 5-HT and BMPR2 signalling compounds (p-Smad1/5/8, p-ERK1/2 
and p-p38 MAPK). Female mouse lungs displayed higher expression of the mitogenic 
mediator p-ERK1/2 than male mouse lungs with the other proteins unchanged.  
 In conclusion, this study confirms overexpression of the 5-HTT as a trigger for elevated 
RVP and vascular remodelling in mice and a cause of more severe hypoxic PAH. 
BMPR2+/- mice are phenotypically normal in room air and show divergent pulmonary 
effects following hypoxia with loss of BMPR2 seemingly attenuating hypoxic induced 
increases in RVP but causing a simultaneous worsening of vascular remodelling, this latter 
effect consistent with the important role BMPR2 has in maintaining vascular integrity. 
Dfen induced PAH in mice was found to be dependent on peripheral 5-HT synthesis with 
BMPR2 mutation not acting as a risk factor. Loss of BMPR2 can enhance vasoconstriction 
to serotonergic agonists and when combined with overexpression of the 5-HTT, leads to a 
dramatic increase in sensitivity to Dfen induced vasoconstriction. Evidence was also found 
for altered KCNQ channel function in transgenic animals. Unexpectedly, female gender 
emerged as the most crucial risk factor for PAH in this thesis. 
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1.1 The pulmonary circulation 
The human lung is the only organ in the body to receive the entire cardiac output (CO) at 
all times. In healthy adults the pulmonary circulation is a high-flow, low-resistance system 
that is composed of vessels that carry blood from the right side of the heart through the 
lungs and then returning it to the left side of the heart.  Deoxygenated blood from the upper 
body including head, neck and upper limbs is returned to the right atrium via the superior 
vena cava. Deoxygenated blood from elsewhere in the body is returned to the right atrium 
via the inferior vena cava. When the right atrium is filled with blood, it contracts, forcing 
blood though the tricuspid valve into the right ventricle. Blood from the right ventricle is 
pumped through the pulmonary valve and into the main pulmonary artery for distribution 
to the lungs. The main pulmonary artery bifurcates with one branch entering the right lung 
and the other entering the left lung. Inside the lungs, pulmonary arteries run parallel to the 
airways and branches (thought to number 15 orders) run to the level of the terminal 
bronchioles before forming the vast network of capillaries in the alveolar walls. It is in 
these capillaries that the exchange of carbon dioxide (CO2) and oxygen (O2) take place. 
Oxygenated blood from the capillaries is returned to the heart via venules and veins before 
entering the left atrium via four pulmonary veins, two from each lung. 
 
1.1.1 Structure of the pulmonary ci rculation 
Fundamentally, pulmonary arteries, capillaries and veins are structurally similar to their 
systemic counterparts. Pulmonary arteries, like systemic arteries have an innermost layer 
called the tunica intima (figure 1.1). This is composed of a single layer of endothelial cells 
lying on a basement membrane. The endothelial cells are in direct contact with the blood 
flowing through the vessel lumen. Separating the tunica intima from the tunica media is a 
layer of elastic tissue called the internal elastic lamina. The tunica media is principally a 
layer of smooth muscle and is much thinner in healthy pulmonary arteries compared with  
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F igure 1.1 Structure of pulmonary artery . Illustration of the various layers that comprise 
the pulmonary arterial wall. Figure adapted from original image on teachPE.com. 
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corresponding systemic arteries. The role of the smooth muscle is to provide support for 
the vessel wall and to alter vessel diameter to regulate blood flow and pressure. A second 
layer of elastic tissue, the external elastic lamina, separates the tunica media from the 
tunica adventitia, a layer composed of connective tissue, elastic and collagen fibres in 
addition to other components such as dispersed fibroblasts and adipose cells. The 
connective tissue of the adventitia is dense in the region closest to the tunica media but 
becomes thinner towards the outer edges of the vessel wall where it disperses into the 
surrounding area. 
  Although pulmonary arteries are similar to systemic arteries, there are important 
differences between them. The main pulmonary artery is significantly thinner walled than 
the aorta and there is less smooth muscle in the wall of intra-lobar pulmonary arteries than 
in corresponding systemic vessels. Pre-capillary arteries in the lung are only partially 
muscularised and some lack smooth muscle altogether (Levitzky, 2002). 
 
1.1.2 Pulmonary vascular resistance 
One consequence resulting from the above differences in anatomy between the pulmonary 
and systemic circulations is that the pulmonary circulation has a low resistance to blood 
flow. Pulmonary vascular resistance (PVR) is about 1/10th that of systemic vascular 
resistance (SVR) (Levitzky, 2002).  Pulmonary artery pressure (PAP) is normally low with 
a mean pressure of ~15 mm Hg. This differs from a mean of ~100 mm Hg in systemic 
arteries (Hickey, 1996). PAP does, however, vary with age but does not usually exceed a 
mean pressure of 20 mm Hg in people aged below 60. In people aged beyond 60, PAP can 
vary depending on physiological and disease conditions (Mandegar et al., 2004).  In 
addition, PAP in healthy people can be affected by factors such as altitude, sea diving or 
exercise (Mandegar et al., 2004).  PAP is the product of CO and PVR (equation 1). 
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Equation 1                            PAP = C O x PV R 
Equation 1) Relationship of pulmonary artery pressure, cardiac output and 
pulmonary vascular resistance. 
PAP = pulmonary artery pressure, CO = cardiac output, PVR = pulmonary vascular 
resistance 
 
The pulmonary and systemic circulations receive approximately the same CO; therefore, 
the lower PAP in the pulmonary circulation is entirely due to lower PVR.  Even during 
periods of increased CO, PAP remains relatively stable.  There are two mechanisms 
responsible for lowering PVR when intravascular pressures are increased. These are: 
1) Recruitment. Vessels that were previously unperfused now start to conduct blood. 
2) Distension. Vessels expand. A large radius equates with lower resistance (equation 
2). 
 
Equation 2, the Poiseuille equation, is a physical law that describes three factors that 
determine the resistance of a fluid (in this case blood) to flow in a cylindrical tube (such as 
a blood vessel). These factors are vessel length, fluid (blood) viscosity and inner vessel 
radius. The most important of these both quantitatively and physiologically is the vessel 
radius.  Vessel length does not significantly alter and blood viscosity is usually maintained 
within a small range, although there are occasions during which blood viscosity may 
change by a greater degree. These are associated with changes in hematocrit levels or body 
temperature.  Vessel radius can be changed by contraction/relaxation of the smooth muscle 
in the tunica media and as equation 2 shows, PVR is inversely proportional to the fourth 
power of the radius of the vessel (r4), thus PVR is extremely sensitive to changes in vessel 
radius. This is illustrated in a graph of relative radius of a single vessel plotted against 
relative flow (figure 1.2).  From this graph, it is clear that even very small changes in 
vessel radius can have dramatic effects on blood flow. Both equation 2 and figure 1.2 
assume constant laminar flow, constant viscosity and a steady pressure flow. They also 
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assume the length of the vessel to be held constant and the vessel to be rigid. Although 
blood flowing through a vessel does not behave in such an ideal manner i.e. does not 
behave as a Newtonian fluid, the Poiseuille equation is sufficient for conveying the 
importance that vessel radius has on determining PVR.  
  The relationship governing the radius of a single vessel to the total resistance of the lung 
is determined by the structure of the pulmonary arterial tree. In the pulmonary arterial tree 
vessels are arranged either in series or in parallel.  A vessel is in series with its daughter 
branches and each of these branches is in parallel to each other (Richardson et al., 1998).  
The total resistance of vessels connected in series is the sum of each individual vessels 
resistance (equation 3). Conversely, when vessels are connected in parallel, the reciprocal 
of the total resistance is equal to the sum of the reciprocals of each individual vessels 
resistance (equation 4). The total resistance of vessels connected in parallel will, therefore, 
always be less than the resistance of the single vessel with the lowest individual resistance 
(equation 4).  From the resistance equations: 3 and 4, it is deducible that  the greater the 
number of vessels that exist in parallel networks, the lower the overall resistance of the 
system will be, while the greater the number of vessels there are in series, the greater the 
overall resistance. This explains why, as the radius of pulmonary arteries become 
exponentially smaller from order 1 to 15, total resistance does not increase. The radius 
might decrease exponentially but the numbers of branches increase exponentially creating 
a greater number of arteries connected in parallel and thus maintaining a low PVR.  
 
 
Equation 2                            PV R = 8Lŋ 
                                                     r4 
 
Equation 2) T he Poiseuille equation for determining the relationship of pulmonary 
vascular resistance to blood flow 
PVR = pulmonary vascular resistance, L = length of vessel, ŋ = viscosity of blood, r = 
inner radius of vessel 
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Equation 3                            R T = R1 + R2 + R3 …+ Rn                       
 
Equation 3) Relationship of individual vessel resistance to total resistance for a ser ies 
networ k 
 
 
 
 
 
Equation 4                            1   = 1    + 1   + 1   + … +   1         
                                               R T    R1     R2     R3             Rn 
                    
Equation 4) Relationship of individual vessel resistance to total resistance for a 
parallel networ k 
 
1.1.2.1 Regulation of pulmonary vascular resistance 
The regulation of vascular resistance in the pulmonary circulation is different to the 
systemic circulation due to the unique properties of the pulmonary vasculature. In the 
systemic circulation arterioles are the major site of vascular resistance whereas in the lung, 
vessels of all sizes contribute to PVR. Unlike the systemic circulation, pulmonary vessels 
have a low basal tone, display little or no autoregulation and their response to autonomic 
neuronal control is not well understood (Richardson et al., 1998). It is generally accepted 
that PVR is regulated by mechanisms that fall into two categories: 1) passive control and 
2) active control. 
 
1.1.2.1.1 Passive control 
Passive control involves changes in vessel radius/diameter independent of a change in 
vascular tone. Distension and recruitment of vessels is able to occur due to the low basal 
tone of pulmonary vessels. Small pulmonary vessels also have a larger radius than their 
systemic counterparts and these properties allow the lung to accommodate greater CO; for 
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F igure 1.2 Relationship of relative radius to relative flow in a single vessel.  
Graph illustrating the mathematical relationship between radius of vessel to flow within 
that vessel. PVR is inversely proportional to the fourth power of the radius of the vessel 
(r4), F = blood flow, r = vessel radius. Reproduced from Klabunde, 2004. 
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example, during times of exercise, while maintaining a low PVR. 
 Gravity has a significant effect on the distribution of blood within the lung. In an upright 
person of average height the lowest point of the lungs is approximately 30 cm lower than 
the highest point. The consequence of gravity on the lung is a pressure difference between 
the top part and the bottom part of the lungs. The top part will have a PAP 15 mmHg lower 
than the mean PAP and in the lower part of the lung, PAP will be 8 mmHg higher than 
mean PAP (Guyton, 1981).  These pressure differences have important effects on blood 
flow within the lung.  In an upright person, there is low blood flow in the top section of the 
lung. Conversely, in the lower lung, blood flow may be 5-10 times greater than at the top 
(Guyton, 1981). As a consequence of hydrostatic pressure, the lung can be divided into 
three zones to represent the different dynamics of pulmonary blood flow: 
 
Zone 1: The apical regions of the lung which are predominately above the level of the 
heart. At this level, pulmonary vascular pressure tends to be lower than alveolar pressure 
(mean of ~ 0 mmHg) at both arterial and venular ends of the pulmonary capillaries.  This 
results in collapse of a large number of capillaries shutting off blood flow. Zone 1 therefore 
is an area of no blood flow.  
 
Zone 2: Vessels in this region lie just above heart level. Arterial pressure is positive (higher 
than alveolar pressure) and higher than venous pressure which remains negative (lower 
than alveolar pressure). Therefore the venous ends of capillaries remain collapsed. In Zone 
2 blood flows intermittently, with capillaries open during systole and collapsed during 
diastole. 
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Zone 3: In the lowest region of the lung, pulmonary venous pressure is generally higher 
than alveolar pressure and consequently capillaries are open at all times and blood flows 
continuously from the arteries to the veins.  
 
1.1.2.1.2 Active control 
Active control involves a wide range of biological factors capable of altering smooth 
muscle contraction/relaxation and consequently vascular tone. The mechanisms by which 
vascular tone is actively regulated are:  
1) Neuronal control 
2) Humoral and endothelial derived factors 
3) Oxygen tension 
 
1.1.2.1.2.1 Neuronal control 
The autonomic nervous system is composed of sympathetic (adrenergic) and 
parasympathetic (cholinergic) nerves and both are found in the pulmonary vasculature; 
however, their relative contribution to the regulation of vascular tone has proved difficult 
to ascertain (Downing and Lee, 1980). Using fluorescent imaging, adrenergic nerves are 
easily indentified in the adventitia of human pulmonary arteries and veins. In large elastic 
pulmonary arteries, nerve fibres penetrate the outer third of the media but in smaller 
muscular arteries, there is no such innervation of the smooth muscle layer. No adrenergic 
fibres are found in human pulmonary arteries smaller than 30 µM (Downing and Lee, 
1980).  Fluorescent histochemistry in other mammals has shown that adrenergic nerves 
also penetrate medial smooth muscle in cats, rabbits, guinea pigs and hares although the 
levels of innervation vary between species and some species such as the hedgehog, rat and 
mouse display no sympathetic fluorescent staining at all in pulmonary arteries (Cech, 
1969; Knight et al., 1981) .  
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 Pulmonary arterial smooth muscle cells (PASMCs) express 1 and 2-ardrenoceptors 
(with 1 mediating vasoconstriction) in addition to 2-adrenoceptors that mediate 
vasorelaxation (Porcelli and Bergofsky, 1973; Hyman et al., 1981; Hyman et al., 1986).  
 Release of noradrenaline from sympathetic nerve terminals or an increase in circulating 
catecholamine levels leads to vasoconstriction through activation of post-synaptic 1-
ardrenoceptors. In the healthy lung, a 2-adrenergic effect helps maintain a vasodilator, 
anti-proliferative balance (Salvi, 1999) but during periods of stress such as alveolar 
hypoxia and hypercapnic acidosis, a pro-vasoconstrictor effect results, mediated in part, by 
1-adrenoceptors (Porcelli et al., 1977).  1-Adrenoceptors in pulmonary arteries show an 
increased affinity to noradrenaline compared with other vessels (Bevan et al., 1986) and 
this may be important in the regional regulation of vascular tone within the lung. 
 Morphological analysis of cholinergic innervation of the pulmonary vasculature has 
largely relied on acetylcholinesterase staining as the most practical and reliable means of 
identifying cholinergic nerves. As with adrenergic nerves, cholinergic nerves have been 
found in association with pulmonary arteries in many species (Downing and Lee, 1980), 
where they are found in the adventitia and medial smooth muscle (Cech, 1973; Al-Wiel-
Bermani et al., 1982; Wojtarowitz et al., 2003) with the greatest density of innervation 
occurring in larger vessels (Downing and Lee, 1980; Haberberger et al., 1997). Inter-
species differences are pronounced, with rats and mice showing little intra-pulmonary 
cholinergic innervation (Cech, 1973), unlike larger mammals such as rabbits and pigs that 
have a greater density of cholinergic nerves (Al-Wiel-Bermani et al., 1982; Wojtarowitz et 
al., 2003). The extent of cholinergic innervation in the human lung is not well understood. 
Amenta et al., 1983 found cholinergic innervation in human pulmonary arteries where it 
was found to be denser than in veins. Partanen et al., 1982, however, found no cholinergic 
nerves associated with blood vessels in the human lung. Regardless of cholinergic 
innervation, pulmonary arteries in the human and other mammals are responsive to 
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acetylcholine (Ach). Under conditions of low basal tone, Ach exerts a vasoconstrictor 
effect on pulmonary arteries. However, when vascular tone is increased, Ach exerts a 
vasodilator effect (Nandiwada et al., 1983; Hyman and Kadowitz, 1988). Ach induced 
relaxation is endothelium dependent and involves activation of M1 and M3 muscarinic 
receptors whereas Ach induced vasoconstriction involves activation of M1 receptors on 
smooth muscle (Norel et al., 1996).  
 There are other neuronal influences within the pulmonary vasculature that are neither 
adrenergic nor cholinergic. These are known as nonadrenergic, non cholinergic (NANC) 
nerves and can have vasoconstrictor and vasodilator effects (Inoue and Kannaan, 1988; Liu 
et al., 1992). Adenosine triphosphate (ATP) is involved in both the vasoconstrictor and 
vasodilator effect while nitric oxide (NO) is involved in the vasodilator response (Inoue 
and Kannan, 1988; Liu et al., 1992; Gumusel et al., 2001). NO dilates both systemic and 
pulmonary vessels and is synthesised in the vessel wall from L-arginine by NO synthase 
(NOS) of which there are three isoforms (endothelial (eNOS), inducible (iNOS) and 
neuronal (nNOS)) and all three are expressed in the lung (Le Cras and McMurtry, 2001).  
eNOS is the major isoform responsible for NO synthesis in pulmonary arteries with the 
other two isoforms making minor contributions (Strange et al., 2002). The extent to which 
NO produced in the airways can influence vascular tone is not clear. The vasodilator effect 
of NO is mediated by cyclic guanosine monophosphate (cGMP) and protein kinase G 
(PKG). 
 
1.1.2.1.2.2 Humoral and endothelial der ived factors 
In addition to adrenergic, cholinergic and NANC factors the pulmonary vasculature  is 
exposed to many other vasoactive compounds and a tight regulation between those that are 
vasoconstrictors and those that are vasodilators is essential for maintaining low vascular 
tone.  Important vasoconstrictors of the pulmonary circulation include angiotensin II, a key 
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effector of the renin-angiotensin system and a potent pulmonary vasoconstrictor. 
Angiotensin-converting enzyme (ACE) generates angiotensin II from angiotensin I and the 
capillaries in the lung have a high expression of ACE (Studdy et al., 1983).  
 Thromboxane A2 (TXA2) is derived from arachidonic acid metabolism in platelets and is a 
constrictor of pulmonary vessels (Buzzard et al., 1993).  
 In contrast to its role as a vasodilator in the systemic circulation, histamine acts as a 
vasoconstrictor in pulmonary vessels, acting via H1 receptors (Tucker et al., 1975).                                  
 Endothelin – 1 (ET-1) is a member of a family of vasoconstrictor peptides termed the 
endothelins that are synthesised from large precursor molecules: the big endothelins, by 
endothelin-converting enzymes (ECEs) present in endothelial cells (Yanagisawa et al., 
1988). Vascular smooth muscle cells can also synthesise ET-1 under inflammatory 
conditions (Woods et al., 1999). ET-1 acts via ETA and ETB receptors to induce 
vasoconstriction. Which of these receptors mediates the response is dependent on the 
species being assessed, the size of the blood vessel and the local concentration of ET-1 
(Fukuroda et al., 1994; Maclean et al., 1994; McCulloch et al., 1996).  
 Serotonin (5-HT) which is stored primarily in platelets is a pulmonary vasoconstrictor 
(Gruetter et al., 1981; McGoon and Vanhoutte, 1984). The major site of serotonin 
synthesis is in the enterochromaffin cells of the intestine, however serotonin is also 
released locally in the lung from neuroendocrine and neuroepithelial cells in the airways 
(MacLean et al., 2000) and from pulmonary arterial endothelial cells (PAECs) (Eddahibi et 
al., 2006). 5-HT induced vasoconstriction occurs through the 5-HT1B receptor in human 
pulmonary resistance vessels (Morecroft et al., 1999) with both 5-HT1B and 5-HT2A 
receptors contributing to vasoconstriction in rats (MacLean et al., 1996).    
 There are other circulating factors including prostaglandins of the F series and 
leukotrienes that also act as pulmonary vasoconstrictors (Back et al., 2002; Snetkov et al., 
2006). 
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  In addition to NO, whose vasodilator action was discussed in relation to NANC agents, 
important vasodilators include prostacyclin (PGI2) which is a vasodilator in all vascular 
tissues including the lung (Vane and Botting, 1995). Like TXA2, PGI2 is derived from 
arachadonic acid and is, in fact, the major product of this metabolic pathway in all vascular 
tissues tested (Vane and Botting, 1995).  PGI2 is a short acting but potent vasodilator 
synthesised in endothelial cells that induces vasodilation through increasing cyclic 
adenosine monophosphate (cAMP) and protein kinase A (PKA).               
 Vasoactive intestinal peptide (VIP) belongs to the glucagon-growth hormone-releasing 
factor secretion superfamily and acts as a pulmonary vasodilator by activating VIP 
receptors (VPAC-1 and VPAC-2) that are present on the surface of smooth muscle cells in 
pulmonary blood vessels (Busto et al., 2000). Stimulation of these receptors leads to 
activation of both cAMP and cGMP.  
  A related compound with similar sequence homology to VIP is pituitary adenylate 
cyclase-activating peptide (PACAP) and it possesses similar activity to VIP (Bruch et al., 
1998; Cardell et al., 1997). PACAP also binds to VPAC-1 and VPAC-2 in addition to the 
PAC1 receptor which is widely expressed in the lung (Busto et al., 2000). PAPAC 
unsurprisingly signals mainly via cAMP but some of its actions appear mediated by other 
mechanisms (Said, 2006).  
 Natriuretic peptides (NPs) are a family of peptides comprised of atrial or A-type NP 
(ANP), brain or B- type NP (BNP) and C-type NP (CNP) that interact with three receptor 
subtypes, NPR-A, NPR-B and NPR-C and mRNA for all three receptors has been found in 
the lung (Li et al., 1995).  ANP and BNP are responsible for the vasodilation seen in the 
lung (Lindberg and Andersson, 1988; Zhao et al., 1999), an effect occurring through an 
increase in cGMP following ligand activation of the guanylate cyclase-linked NPR-A and 
NPR-B receptors. Knockout mice studies have shown that NPR-A is solely responsible for 
the vasorelaxant effect of ANP and BNP in this species (Zhao et al., 1999).      
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 Adrenomedullin is a 52-amino acid peptide originally isolated from human 
pheochromcytoma. It is produced by vascular smooth muscle and endothelial cells (Sugo 
et al., 1994) in addition to many other cell types (Marutsuka et al., 2003). It is expressed at 
high levels in the lung (Kitamura et al., 1993) and is a vasodilator in both the pulmonary 
and systemic circulation (Marutsuka et al., 2003), an action mediated by cAMP. 
 
1.1.2.1.2.3 Oxygen tension 
Changes in the partial pressure of O2 (PO2) has the opposite effect on the pulmonary 
circulation to that on the systemic circulation. In the systemic circulation, a decrease in 
PO2  (hypoxia) induces vasodilation which increases blood flow to hypoxic regions. In 
contrast, when alveoli are poorly ventilated resulting in a low PO2, pulmonary arteries 
constrict, preventing blood flow to hypoxic regions and diverting blood to better ventilated 
regions (George et al., 2005). O2 diffuses through the alveoli wall and into surrounding 
smooth muscle cells and a reduction in PO2 in the air spaces of the alveoli results in 
vasoconstriction of arteries in the hypoxic region (hypoxic pulmonary vasoconstriction; 
HPV). HPV occurs primarily in small pre-capillary arterioles in the hypoxic region when 
PO2 falls below 60 mmHG (Yuan, 2004). The size of the hypoxic region can vary 
enormously from a lobule to the entire lung. If only a small region is hypoxic, then blood 
flow can be diverted to more compliant, better perfused areas with only small rises in PAP. 
If, however, the vast majority of the lung is hypoxic, the result is widespread HPV and a 
rise in PAP, causing the heart to pump faster to overcome the associated rise in PVR 
(Yuan, 2004).   
 In the clinical setting, widespread alveolar hypoxia can occur as acute HPV (AHPV) in 
rapidly progressing acute lung conditions including asthma, pneumonia and acute 
respiratory distress syndrome (Dumas et al., 1999). The resulting AHPV can have 
detrimental effects including reduced CO, increased vascular permeability and right 
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ventricular failure (Leach and Treacher, 1995). AHPV is rapidly reversible if alveolar 
oxygenation is restored to normal physiological values.  
 Widespread, sustained chronic HPV (CHPV) occurs in people living at high altitudes, as a 
result of diseases associated with decreased ventilation such as chronic obstructive 
pulmonary disease (COPD) and sleep apnea or in association with diseases that cause 
progressive lung destruction such as emphysema and fibrosing alveolitis (Dumas et al., 
1999). CHPV does not just cause an increase in vascular tone but also vascular 
remodelling (see section 1.2.3.2.1) and together, they lead to a sustained increase in PAP 
(pulmonary hypertension) that is not reversible on return to normal alveolar PO2. 
  The processes underlying HPV are not well understood and in many experiments HPV 
presents a biphasic response (depending on experimental preparation and species tested). 
There is an initial transient vasoconstriction (phase 1) followed by vasorelaxation before a 
sustained period of vasoconstriction (phase 2). If this sustained vasoconstriction exists for 
a prolonged period of time then the symptoms associated with CHPV manifest.  HPV must 
involve an O2 sensor in addition to signal transduction to the contractile machinery of the 
smooth muscle.  Evidence suggests that the O2 sensor mediating phase 1 HPV is present on 
the smooth muscle cells themselves as both isolated pulmonary arteries (Madden et al., 
1985) and subsequently isolated PASMCs (Madden et al., 1992) were found to contract 
when exposed to hypoxic conditions.  This would rule out neuronal or circulating 
vasoactive mediators as the O2 sensor and narrow the search to factors intrinsic to 
PASMCs. Many factors have been put forward as candidates for the O2 sensor including 
O2-sensitive calcium (Ca2+) channels, O2-sensitive potassium (K+) channels and the 
mitochondria, through changes in mitochondrial reactive oxygen species (ROS) production 
(Dumas et al., 1999). Whichever mechanism is involved in detecting changes in PO2, it 
ultimately leads to an increase in intracellular calcium concentration [Ca2+]i, a critical 
component of HPV and PASMC contraction in general. There is extensive evidence 
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supporting the theory that hypoxia inhibits voltage-gated K+ (Kv) channels causing 
membrane depolarisation and opening of L-type Ca2+ channels causing Ca2+ influx across 
the membrane and into the PASMC. The method by which hypoxia inhibits Kv channels is 
controversial. Some researchers believe Kv channel inhibition to be a consequence of 
reduced hydrogen peroxide (H2O2). Low H2O2 levels result from a reduction in 
mitochondrial electron transport and superoxide ion production, a direct consequence of 
decreased O2 (Aaronson et al., 2006). Evidence exists, however, to support an alternative 
theory also involving a change in redox state, this time involving an increase in 
mitochondrial ROS production and release of Ca2+ from intracellular stores and store 
operated Ca2+ entry (SOCE) (Aaronson et al., 2006; Waypa and Schumacker, 2005). 
Despite the differences in these two theories, phase 1 vasoconstriction may be dependent 
on both voltage-gated Ca2+ channels and SOCE (Weigand et al., 2005).  
 Unlike the transient phase 1, the sustained muscle contraction of phase 2 requires more 
than a high [Ca2+]i, which stays constant in phase 2 as tension rises (Robertson et al., 
2003).  Phase 2 is dependent on the presence of endothelium and removal of the 
endothelium abolishes the sustained phase but not the initial transient phase of HPV.  
[Ca2+]i is unaffected by endothelial removal (Robertson et al., 2003). Phase 2 may then 
involve two processes: one that maintains [Ca2+]i, at the increased level induced during 
phase 1 and a second, endothelium dependent process, that increases Ca2+ sensitisation in 
PASMCs. An increase in Ca2+ sensitisation would mean that agonists binding to G-protein 
coupled receptors would induce greater smooth muscle contraction at a constant [Ca2+]i. 
This process is thought to involve Rho-A mediated activation of Rho kinase (ROCK) 
(Loirand et al., 2006) and inhibition of ROCK with the ROCK antagonist Y-27632 
prevents the sustained HPV in CHPV (Robertson et al., 2000).  The question then 
becomes: what is the endothelial derived vasoconstrictor that causes ROCK dependent 
Ca2+ sensitisation and sustained HPV? The primary candidate is ET-1 which can increase 
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the sensitivity of the contractile apparatus to hypoxic induced increases in [Ca2+]i. (Waypa 
and Schumacker, 2005). Hypoxia also increases ET-1 expression and secretion in cultured 
endothelial cells and BQ-123, an ETA receptor antagonist inhibits CHPV in isolated 
vessels and whole lung (Waypa and Schumacker, 2005). Additionally, the promoter of the 
ET-1 gene contains a hypoxia-inducible factor (HIF) response element (HRE; Hu et al., 
1998).  HIF-1  along with HIF-2  and HIF-3  regulate the expression of most hypoxic-
dependent and many hypoxic-independent genes involved in physiological and 
pathophysiological lung states (Tuder et al., 2007) (See section 1.2.3.2.1). In contrast to a 
supportive role for ET-1 in CHPV, Roberston et al., 2003 found that CHPV in the rat was 
unaffected by combined ETA and ETB receptor blockade and CHPV in salt-solution 
perfused lungs is not significantly affected by ET-1 receptor antagonists (Aaronson et al., 
2002) so there maybe additional hypoxic induced vasoconstrictor substances released from 
the endothelium that are yet to be determined and experimental evidence exists to support 
this idea (Gaine et al., 1998; Robertson et al., 2001).  
 Research into the underlying mechanisms of HPV over the past 30 years has yielded 
diverse and often contradictory theories regarding the mediators and modifiers of HPV. 
Many of these differences are likely due to differences in preparation  e.g. location and size 
of pulmonary artery, species, blood or salt perfused lung, duration of hypoxia and 
importantly, the  level of pre-tone in the vessel being studied. The level of existing tone in 
a muscle preparation and the stimulus used to induce that tone can have dramatic effects on 
the subsequent response to hypoxia (Aaronson et al., 2006). Figure 1.3 illustrates the 
possible mechanisms currently thought to occur in both phase 1 and phase 2 of HPV.  In 
addition to the mediators of HPV outlined in figure 1.3 there are a host of other vasoactive 
factors already mentioned previously capable of modulating either positively or negatively 
the degree of HPV. These include NO, prostaglandins, angiotensin II and of particular 
relevance to this investigation, 5-HT (Dumas et al., 1999; Aaronson et al., 2002). Hypoxia 
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can increase circulating 5-HT levels (Callebert et al., 2006) and increase expression of 
tryptophan hydroxylase 1 (TPH1) (Pan et al., 2006), the rate-limiting enzyme in 5-HT 
synthesis in the periphery. An increase in 5-HT could result in increased activation of the 
vasoconstrictor receptors, 5-HT1B and 5-HT2A, which can interact with many of the 
pathways thought to mediate HPV (figure 1.3).  (See section 1.2.3.1 for more information 
on the role of 5-HT in hypoxia). HPV only occurs in the pulmonary circulation and is the 
most important regulatory mechanism for controlling vascular tone.  Sustained HPV over a 
prolonged period of time (CHPV) is a major contributing factor to pulmonary arterial 
hypertension (PAH) associated with several hypoxic lung diseases and PAH induced by 
 hypoxia is a model often used to study PAH in rodents and will be used in this 
investigation (see sections 1.2.3.2.1 and 2.1.5). 
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F igure 1.3 Possible signalling mechanisms involved in phase 1 and phase 2 of hypoxic 
induced vasoconstr iction in pulmonary arter ies. 
Solid arrows represent pathways suggested to contribute to the physiological regulation of 
pulmonary artery tone during hypoxia. Dashed arrows represent the possible modulating 
influence of 5-HT signalling on these pathways.  
ROS, reactive oxygen species; HIF-1, hypoxia-inducible factor-1; ET-1, endothelin-1; 
ETA, endothelin receptor A; RhoK, Rho kinase; MLCK, myosin light chain kinase; MLCP, 
myosin light chain phosphatase; SR, sarcoplasmic reticulum; SOCC, store-operated 
calcium channel; RyR, ryanodine receptor; AC, adenylate cyclase; TPH1, tryptophan 
hydroxylase 1 
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1.2 Pulmonary arterial hypertension 
PAH is characterised by an elevation in PAP and PVR. The raised PVR increases the work 
load of the right ventricle which is required to overcome the pressure increases. Over time 
this causes right ventricular failure. Clinically, PAH is defined by a mean PAP > 25 mmHg 
at rest or > 30 mmHg during exercise (Rich et al., 1987). There are often few symptoms in 
the early stages but as the disease progresses, patients present with symptoms including 
dyspnea, fatigue, edema and syncope (Rich et al., 1987). The non specific nature of these 
symptoms often means diagnosis is delayed and the progressive nature of the disease 
means, that if left untreated, death usually occurs within 3 years of diagnosis (D’Alonzo et 
al., 1991).  Sporadic PAH is rare with an incidence of 1-2 cases per million per year 
(Abenhaim et al., 1996; Gaine and Rubin 1998). The mean age at diagnosis is 36 and the 
disease occurs more frequently (~2:1) in women than in men (Loyd et al., 1984; Rich et al., 
1987). 
 Over five decades ago, the term primary pulmonary hypertension (PPH) was introduced to 
describe the condition of increased PAP and associated vascular changes occurring 
exclusively in the pulmonary circulation without an identifiable cause. Additionally, 
secondary pulmonary hypertension (SPH) was the term used to describe pulmonary 
hypertension associated with an underlying disease condition. Over the past few decades, 
advancements in our understanding of both the clinical and pathological aspects of 
pulmonary hypertension has led to the need for a more useful and accurate classification 
system. A revised classification for pulmonary hypertension was introduced following a 
World Health Organisation symposium on the condition in Evian, France in 1998.  The 
term SPH was abandoned and the new classification comprised five groups to reflect 
similarities in clinical and etiological features. The first group was PAH which included 
PPH. The other four groups included conditions that predominately affected the venous 
circulation or conditions that affected the pulmonary circulation through changes in 
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respiratory structure or function (Mandegar et al., 2004). These groups were pulmonary 
venous hypertension, pulmonary hypertension associated with disorders of the respiratory 
system and/or hypoxaemia, pulmonary hypertension due to chronic thrombotic and/or 
embolic disease and pulmonary hypertension due to disorders affecting the pulmonary 
vasculature directly. Further advancements in understanding the pathophysiology of 
pulmonary hypertension including the uncovering of a genetic basis for PAH meant that a 
second revision to the classification system was necessary and this took place at the third 
World Conference on Pulmonary Hypertension in Venice, Italy in 2003. The most 
important revision was the replacement of the term PPH with idiopathic PAH (IPAH) or 
familial PAH (FPAH) when an identifiable genetic cause is found. All other forms of PAH 
that are related to risk factors and disease conditions were termed associated PAH 
(APAH). The revised Venice classification is presented in table 2.1.  Despite the different 
clinical classifications of PAH, it is often difficult, if not impossible, to distinguish PAH of 
a particular etiology with that from another based on histopathological evidence alone.  
 
1.2.1 Pathophysiology of PA H 
Pulmonary arterial vasoconstriction, remodelling of the pulmonary vasculature and in situ 
thrombosis all contribute to an increase in PVR. As discussed previously, this increase in 
PVR increases the work load on the right ventricle and progressively leads to right 
ventricular hypertrophy (RVH) and heart failure. Of these three contributing factors, 
vascular remodelling is the most important pathological change in PAH and the extent of 
remodelling at diagnosis will determine the prognosis for the patient.  
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Revised Clinical Classification of Pulmonary Hypertension (Venice 2003) 
 
1. Pulmonary arterial hypertension (PA H) 
1.1. Idiopathic (IPAH) 
1.2. Familial (FPAH) 
1.3. Associated with (APAH): 
       1.3.1. Collagen vascular disease 
       1.3.2. Congenital systemic-to-pulmonary shunts 
       1.3.3. Portal hypertension 
       1.3.4. HIV infection 
       1.3.5. Drugs and toxins 
       1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher disease,    
       hereditary hemorrhagic telangiectasia,         
       hemoglobinopathies, myeloproliferative disorders, splenectomy) 
1.4. Associated with significant venous or capillary involvement 
       1.4.1. Pulmonary veno-occlusive disease  
       1.4.2. Pulmonary capillary hemangiomatosis  
1.5. Persistent pulmonary hypertension of the newborn 
 
2. Pulmonary hypertension with left heart disease 
2.1. Left-sided atrial or ventricular heart disease 
2.2. Left-sided valvular heart disease 
 
3. Pulmonary hypertension assoc iated with lung diseases and/or hypoxemia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Sleep-disordered breathing 
3.4. Alveolar hypoventilation disorders 
3.5. Chronic exposure to high altitude 
3.6. Developmental abnormalities 
 
4. Pulmonary hypertension due to chronic thrombotic and/or embolic 
disease 
4.1. Thromboembolic obstruction of proximal pulmonary arteries 
4.2. Thromboembolic obstruction of distal pulmonary arteries 
4.3. Non-thrombotic pulmonary embolism (tumor, parasites, foreign 
material) 
 
5. M iscellaneous 
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of 
pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis)  
 
 
 
Table 1.1 Revised C linical C lassification of Pulmonary Hypertension (Venice, 2003). 
The classification system contains groups classified according to clinical and etiological 
parameters.  
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1.2.1.1 Pulmonary vascular remodelling  
In the non-hypertensive lung, the thickness of the pulmonary arterial wall is maintained 
relatively constant by the balance between proliferation and apoptosis of the cells present 
in the vessel wall i.e. PASMCs, PAECs and pulmonary arterial fibroblasts (PAFs). Any 
disruption in this balance towards a pro-proliferative phenotype will lead to vascular wall 
thickening, lumen occlusion and loss of vascular compliance (Mandegar et al., 2004).  
Together, these cellular changes create the vascular remodelling that occurs in PAH and 
has the ultimate effect of progressively increasing PVR (Mandegar et al., 2004). 
Morphological analysis of pulmonary hypertensive lungs reveals distal extension of 
smooth muscle into previously non muscularised vessels, obliteration of small pulmonary 
arteries associated with adventitial and medial hypertrophy, concentric laminar intimal 
lesions and fibrosis. Also present may be complex plexiform lesions which occur more 
frequently in severe PAH and are associated with a poor prognosis for the patient (Strange 
et al., 2002). The cellular processes governing the vascular remodelling in PAH are still to 
be fully elucidated with complex vascular changes occurring. These changes include 
vascularisation of the adventitia and outer media, cell proliferation and differentiation 
within all levels of the vessel wall, altered apoptosis and recruitment of circulating 
inflammatory cells. The cellular changes associated with vascular remodelling are now 
summarised.  
 
1.2.1.1.1 Intimal thickening and plexiform lesions 
Intimal thickening may be eccentric or concentric, resulting in narrowing and obliteration 
of the lumen and occurs most frequently in arteries <200 µm, with no intimal thickening 
seen in arteries >400 µM (Yi et al., 2000). Intimal thickening is the greatest contributor to 
the reduction of luminal area seen in PAH with the thickness of the intima increasing, on 
average, 30 fold (Chazova et al., 1995). Intimal lesions display varying levels of 
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complexity with localised thrombi thought to contribute to the formation of some, while 
more advanced lesions can become fibrotic in nature (Tuder et al., 2007). In general, 
concentric lesions are more pathological than eccentric lesions and characterise severe 
PAH. Concentric lesions can completely obliterate the vessel lumen whereas eccentric 
lesions cause only partial luminal obstruction (Yi et al., 2000) (figure 1.4 A-C).  
 Plexiform lesions are complex intimal lesions that occur at arterial branching points in 
arteries >200 µM (Chazova et al., 1995) (figure 1.4 D) and are glomeruloid structures 
containing a network of small vessels lined with PAECs (Tuder et al., 1994). Additionally, 
myofibroblasts are present in the core of plexiform lesions and there is some debate 
regarding the relevant importance of both cell types in the origin of these lesions. Smith et 
al., 1990 and Yi et al., 2000 suggest that myofibroblast proliferation is the key initiator in 
the formation of the plexiform lesions while others believe dysfunctional PAEC growth 
following vascular injury or stimulation by growth factors is the essential mediator (Tuder 
et al., 1994; Cool et al., 1999). There is growing evidence to support the latter viewpoint 
and that plexiform lesions may be a form of angiogenesis related to phenotypic changes in 
PAECs (Cool et al., 1999). PAECs within plexiform lesions of IPAH patients display 
monoclonal expansion whereas expansion is polyclonal in patients with PAH secondary to 
other diseases (Lee et al., 1998). The polyclonal PAEC expansion in APAH is likely due to 
PAEC growth induced by high shear stress or an inflammatory response (Lee et al., 1998). 
The growth factors, platelet-derived growth factor (PDGF) and fibroblast growth factor 
(FGF) can be increased in vascular endothelium following high shear stress (Malek et al., 
1993) and these growth factors may contribute to PAEC growth. FGF and PDGF gene 
expression increases with increasing shear stress and can be as much as 4.8 fold higher 
during periods of high shear stress (Malek et al., 1993). The monoclonal PAEC expansion 
seen in plexiform lesions in IPAH cases results from a somatic mutation in one PAEC that 
confers a growth advantage. The process therefore resembles the neoplastic growth  
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F igure 1.4 Micrographs of pulmonary arter ies from pulmonary hypertensive 
patients. A: Concentric intimal thickening in a pulmonary artery (~180 μM diameter; 
magnification x 100). B: Obliteration of lumen in a pulmonary artery (~ 80 μM diameter; 
magnification x 260). C: Eccentric intimal thickening (at arrow) in a pulmonary artery 
(~220 μM diameter; magnification x 130). D: Plexiform lesion (at arrow) associated with a 
muscular pulmonary artery (magnification x 110). Reproduced from Chazova et al., 1995.  
 
A B 
C D 
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processes common in cancer and somatic mutations in genes associated with cellular 
proliferation and apoptosis have indeed been found in PAECs within plexiform lesions 
from PAH patients (Yeager et al., 2001).  Plexiform lesions are extremely detrimental to 
normal blood flow with a single lesion blocking blood flow for the length of the vessel 
(Cool et al., 1999). PAECs are also present in the concentric intimal lesions and these 
occur in association with plexiform lesions (Cool et al., 1997; Cool et al., 1999) often 
forming hybrid lesions in the pulmonary hypertensive lung that share both concentric and 
plexiform lesion features (Cool et al., 1997). It may be that rather than existing as distinct 
lesions, a number of the intimal lesions seen in PAH are lesions at different stages of 
evolution and that distinct endothelial cell phenotypes determine the development of the 
lesion (Cool et al., 1999). Contrary to a role for PAECs in concentric lesions, other studies 
have suggested concentric intimal lesions are composed of myofibroblasts (Atkinson et al., 
2002); however, the origin of these myofibroblasts is unknown. Endothelial cells can 
transdifferentiate into smooth muscle cells when stimulated with growth factors such as 
transforming growth factor-  (TGF- ) (Frid et al., 2002); therefore, it is possible, although 
speculative, that the PASMC composed and PAEC composed lesions derive from common 
progenitor cells. Although the cellular and molecular determinants of the intimal lesions in 
PAH remains largely unknown they are likely to involve some or all of the following 
depending on lesion type and form of PAH;   
• Injury to vascular endothelium  
• Increase proliferation and reduced apoptosis of PAECs 
• Smooth muscle cell growth, migration and reduced apoptosis 
• Extracellular matrix (ECM) deposition 
• Reorganised thrombi 
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1.2.1.1.2 Medial thickening 
The smooth muscle layer that comprises the medial layer of pulmonary arteries provides 
support and strength to the vessel wall in addition to being the contractile machinery of the 
arteries. The media is composed of distinct subpopulations of PASMCs that exist in 
different layers within the media (Frid et al., 1997). The subpopulations are functionally 
and phenotypically unique, each with different expression levels of contractile and 
cytoskeletal proteins in addition to inter-population variations in response to hypoxia and 
growth factors (Frid et al., 1994; Dempsey et al., 1997; Frid et al., 1997).  Heterogeneous 
subpopulations of non-muscle like cells have also been identified in the media that have 
unique characteristics including a proliferative response to hypoxia, mimicking the in vivo 
effect of hypoxia on vascular remodelling. Certain populations of these cells are also able 
to  secrete mitogens  that may directly  affect proliferation of  ‘classical’ PASMCs  (Frid et 
al., 1994; Frid et al., 1997).    
  In PAH, thickening of the media occurs in pulmonary arteries >50 µM with the increase 
in the medial layer reaching 5 fold that of control values (Chazova et al., 1995). Both 
hypertrophy and hyperplasia of PASMCs contribute to medial thickening. PASMC 
hypertrophy is the dominant factor with hyperplasia playing a lesser role (Tuder et al., 
2007). In addition to an increase in muscularisation of small pulmonary arteries a layer of 
smooth muscle also appears in the small, previously non-muscularised  pre-capillary 
vessels <50 µM (Chazova et al., 1995). As there are no existing PASMCs in these arteries, 
hypertrophy and hyperplasia are unlikely to be essential factors in the distal extension of 
smooth muscle into previously non-muscularised vessels. One possibility which has 
already been mentioned in relation to plexiform lesion formation is the transdifferentiation 
of PAECs into PASMCs. Frid et al., 2002 found that cultured bovine PAECs could 
transdifferentiate into PASMCs when cell-cell contact was disrupted or when cells were 
exposed to TGF- . The process was not dependent on PAEC proliferation. Moreover, 
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exposure of porcine PAECs to hypoxia for 7 days resulted in the emergence of smooth 
muscle like cells (Zhu et al., 2006). Only a small number (0.01-0.03%) of PAECs undergo 
transdifferentiation into PASMCs and it has been postulated that cells undergoing 
transdifferentiation are bone-marrow derived progenitor cells that have been incorporated 
into the endothelial monolayer (Frid et al., 2002; Zhu et al., 2006). Other candidates for 
emergence of smooth muscle in the precapillaries include hypertrophy of pericytes and 
migration/recruitment of interstitial fibroblasts (Zhu et al., 2006; Tuder et al., 2007) and 
there is extensive evidence that fibroblasts have a unique and critical role in vascular 
remodelling (See next section). 
 Apoptosis is a highly regulated process for maintaining normal vascular structure by 
removing unwanted cells such as those that have migrated into the vascular lumen or cells 
that have accumulated within the vessel wall. Cell survival depends on a delicate balance 
between expression of gene families that are pro-apoptotic or anti-apoptotic. The most 
important anti-apoptotic family is the Bcl-2 family with important pro-apoptotic genes 
including Bax and Bad (Gurbanov and Shiliang, 2006). Apoptosis is impaired in PASMCs 
from PAH patients (Zhang et al., 2003) and Bcl-2 is overexpressed in the lungs of both 
FPAH and IPAH patients (Geraci et al., 2001). Survivin is a potent inhibitor of apoptosis 
and is found in pulmonary arteries from pulmonary hypertensive patients but not from 
control subjects (McMurty et al., 2005). Adenovirus mediated overexpression of survivin 
in rats results in mild PAH and inhibition of endogenous survivin reduces PAH induced by 
monocrotaline (MCT) in rats. Tenascin-C, a component of the ECM is an important 
survival factor for PASMCs and is induced by matrix metalloproteinases (MMPs) and 
elastase. Tenascin-C is increased in vessels undergoing remodelling in pulmonary 
hypertensive patients (Jones et al., 1997). Blockade of tenascin-C or its production by the 
use of elastase inhibitors results in PASMC apoptosis and regression of medial thickening 
in cultured rat pulmonary arteries (Cowan et al., 1999; Cowan et al., 2000a). Moreover, 
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elastase inhibitors can reverse remodelling and improve survival in rats with MCT induced 
PAH (Cowan et al., 2000b). The importance of impaired apoptosis in pulmonary vascular 
remodelling has further become evident since the discovery that FPAH was related to 
mutations in the gene for the apoptotic mediator: bone morphogenetic protein receptor 2 
(BMPR2) (See section 1.2.2). 
 
1.2.1.1.3 Adventitial thickening 
The adventitia is a connective tissue layer containing elastic and collagen fibres and is 
populated by PAFs. The adventitial thickening associated with vascular remodelling is 
associated with PAF hyperplasia and collagen deposition (Chazova et al., 1995; Sartore et 
al., 2001). The adventitia can reach 6 times the thickness of normal in PAH patients 
(Chazova et al., 1995). PAFs have important roles in response to injury (Sartore et al., 
2001) and following such an injury, they undergo significant changes. Such changes are 
possible due to PAFs being less differentiated than PASMCs or PAECs and they can 
undergo proliferation, migration and transdifferentiation into myofibroblasts in addition to 
synthesising cytokines and ECM proteins (Mandegar et al., 2004). Myofibroblasts which 
express PASMC contractile proteins are able to migrate into the media where they may 
contribute to remodelling.  
Hypoxia is a potent stimulus for PAFs and can modulate most of the PAF functions 
outlined above.  PAF proliferation is the most pronounced feature of early hypoxic induced 
PAH in animal models (Belknap et al., 1997). The number of PAFs in the vessel wall of 
the hypoxic rat has shown to be increased 3 fold within 24 hours of hypoxic treatment and 
this was  followed  by  transdifferentiation  into  ‘transitional  cells’  displaying  both  smooth 
muscle and fibroblast characteristics before complete transdifferentiation into mature 
PASMCs by the 7th day of hypoxia (Sobin et al., 1983). Further work on hypoxic rats has 
shown that PAFs from these animals show an enhanced proliferative phenotype that 
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continues even if the cells are returned to normoxic conditions (Welsh et al., 2001). 
Hypoxia also triggers the release of paracrine mitogenic agents from PAFs that induce 
proliferation of PASMCs (Rose et al., 2002). The specific mitogenic compounds released 
by the PAFs are not known but may include ROS, PDGF and FGF (Rose et al., 2002; 
Stenmark et al., 2006). Like the PASMCs in the media, PAFs appear to exist as 
heterogeneous subpopulations (at least in the neonatal calf) with varying sensitivities to 
hypoxia (Das et al., 2002).  
 The vasa vasorum micro-circulation borders the adventitia of pulmonary arteries and 
brings oxygenated blood and nutrients to the outside of the vessel wall. Hypoxia increases 
the size of the vasa vasorum with the greatest increase occurring in more distal regions of 
the arterial tree. This vascularisation results in incomplete and fragile vessels which may 
allow plasma proteins, blood cells and circulating progenitor cells into the adventitia 
(Davie et al., 2004). Progenitor cells derived from the bone marrow could infiltrate the 
vascular wall and contribute to the adventitial thickening observed in hypoxic PAH. Indeed 
bone marrow derived cells expressing myofibroblast or smooth muscle like phenotype 
have been found in the adventitia of hypertensive pulmonary arteries where they contribute 
to vascular remodelling (Hayashida et al., 2005).This process is thus similar to the theory 
discussed in the previous section proposing a role for bone marrow derived progenitor cells 
in smooth muscle formation. 
 
1.2.1.1.4 Contr ibution of inflammatory cells to vascular remodelling 
T- and B- lymphocytes, in addition to macrophages have been found in plexiform lesions, 
supporting a role for these inflammatory cells in PAH (Tuder et al., 1994; Cool et al., 
1999).  Pro-inflammatory cytokines including interleukin-1 (IL-1) and interleukin-6 (IL-6)  
are increased in the serum of pulmonary hypertensive patients (Humbert et al., 1995) and 
IL-6 is increased in both the hypoxic and MCT animal models of PAH (Bhargava et al., 
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 1999; Wang et al., 2003). Additional evidence for an inflammatory component to 
pulmonary vascular remodelling comes from the increased expression of the 
chemoattractant RANTES that is predominately expressed in vascular lesions composed of 
proliferating PAECs (Dorfmuller et al., 2002).  
 The recently discovered chemokine: fractalkine (FKN) has the unique properties of 
existing either as a soluble form where it acts as a chemokine or as a membrane bound 
form on PAECs (that have been activated by inflammatory cytokines) where it acts as an 
adhesion molecule (Bazan et al., 1997).  The membrane bound form mediates the 
recruitment and capture of leukocytes expressing the FKN receptor CX3CR1 (Foussat et 
al., 2000). The FKN-CX3CR1 interaction between endothelium and leukocytes is 
sufficient to cause cellular adhesion with no apparent involvement of integrins or other 
adhesion molecules even under conditions of high blood flow (Fong et al., 1998).  FKN 
appears to be unique amongst chemokines in being able to mediate firm leukocyte 
adhesion and has, therefore, come under attention in the investigation of several vascular 
disorders. Two polymorphisms (V249I and T280M) have been found in  CX3CR1 
resulting in reduced FKN binding to CX3CR1 and decreased risk for atherosclerosis 
(McDermott et al., 2001) and coronary artery disease (Moatti et al., 2001) indicating a 
possible pathological role for CX3CR1 in these diseases. More recently, it was discovered 
that circulating T-lymphocytes from PAH patients show elevated expression of CX3CR1 
(Balabanian et al., 2002) and contrary to the protective role of the V249I and T280M 
polymorphisms in the diseases just mentioned, they are associated with an increased risk of 
systemic sclerosis associated PAH (Marasini et al., 2005). The reasons why the two 
polymorphisms are protective in atherosclerosis and coronary artery disease but are 
associated with an increased risk of systemic sclerosis PAH is not known but the situation 
is more complex than first thought. The presence of V249I and T280M does not protect 
against ischaemic stoke (Hattori et al., 2005) or peripheral artery disease (Gugl et al., 2003) 
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and the V249I variant has been shown to display enhanced adhesive properties (Daoudi et 
al., 2004).  Tissue specific differences in the role/response to CX3CR1 in addition to the 
large individual differences noted in the expression of CX3CR1 within groups with the 
same genotype may account for some of the differences observed (Marasini et al., 2005).  
 The excess infiltration of leukocytes and the release of inflammatory mediators may 
contribute to vascular remodelling. Inhibition of IL-6 attenuates MCT induced PAH in rats 
(Bhargava et al., 1999) and mice deficient in the macrophage derived leukotriene: 5-
lipooxygenase (5-LO), develop less severe hypoxic PAH than control mice (Voelkel et al., 
1996). RANTES may indirectly modulate vascular tone/remodelling through release of 
ET-1 (Molet et al., 2000) and the CX3CR1 receptor has been found on PASMCs in MCT 
induced PAH where its activation induced PASMC proliferation (Perros et al., 2007).  The 
enhanced immune response, both at the cellular and molecular level coupled with the close 
relationship often found between PAH and inflammatory/auto-immune conditions provides 
compelling evidence for at least a modulating role for inflammation in PAH.  
 
1.2.1.2 Pulmonary vasoconstr iction 
Vasoconstriction of pulmonary arteries can contribute significantly to an increase in PAP 
and PVR. The importance of vasoconstriction in the pathology of PAH is evident by the 
response of some patients to vasodilators such as prostacyclin, NO and endothelin receptor 
antagonists (See section 1.2.3.2.5).  The majority of patients, however, do not respond to 
current vasodilator treatment. This may be a consequence of vascular remodelling that is so 
advanced by diagnosis and the commencement of treatment that vascular reactivity is 
impaired or it may be that in these patients, vasoconstriction does not contribute 
significantly to PVR. At this stage in our understanding of the disease, it is unknown if 
vasoconstriction is involved in the initiation of PAH or if it merely acts as a contributing 
factor. As mentioned previously, sustained vasoconstriction in HPV results in vascular 
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remodelling but even in the absence of hypoxia, increased PAP such as that induced by 
vasoconstriction can induce vascular smooth muscle cell proliferation (Hishikawa et al., 
1994).  
 
1.2.1.3 In situ thrombosis  
In situ thrombosis in PAH is thought to occur following abnormal changes to the vascular 
endothelium and/or changes in platelets and clotting factors (Humbert et al., 2004). 
Thrombotic lesions are found in lung samples from up to 50% of PAH patients and are 
often associated with plexiform lesions (Welsh et al., 1996). There are noticeable 
differences in procoagulant and fibrinolytic agents in PAH patients with a decrease in 
natural anti-coagulation factors in association with a decrease in fibrinolysis (Welsh et al., 
1996). The coagulation promoting agent von Willebrand factor is upregulated in PAH and 
high circulating plasma levels are correlated with lower life expectancy (Lopes et al., 
1998). Von Willebrand factor promotes platelet aggregation and the increased levels of 
thromboxane metabolites seen in PAH patients are evidence of platelet aggregation 
(Christman et al., 1992).   Thrombotic lesions are not thought to be an initiating factor in 
PAH but to occur secondary to endothelial injury and to gain in severity with disease 
duration (Wagenvoort et al., 1993). The accumulation of platelets at a vascular lesion can 
enhance vascular remodelling by the release of vasoconstrictor and mitogenic mediators 
including TXA2, 5-HT, vascular endothelial growth factor (VEGF), PDGF and TGF-  
(Humbert et al., 2004). 
 
1.2.2 The genetic basis of PA H 
A familial basis for PAH was first proposed in 1954 but it was not until 1984 that a 
detailed account was produced that indicated many cases previously thought to be 
idiopathic did in fact have a familial basis (Loyd et al., 1984). Observations emerged that 
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illustrated why the familial basis of PAH had not been well characterised previously. The 
disease showed an autosomal dominant pattern of inheritance with incomplete penetrance 
which varied significantly between families. An interesting observation in this study was 
that the disease showed a female to male predominance of 2:1 (Loyd et al., 1984). The 
inheritance patterns just outlined in addition to incomplete family records makes a precise 
calculation of the number of familial cases difficult; however, a national prospective study 
in 1984 involving analysis of 187 families with PAH identified ~6% of cases as familial 
i.e. having two or more family members with PAH (Rich et al., 1984). The accumulation 
of family registries allowed linkage analysis studies that localised a marker for the disease 
to chromosome 2q31-32 (Nichols et al., 1997; Morse et al., 1997) and candidate genes 
were tested and identified by DNA sequencing. This resulted in the discovery of mutations 
in the BMPR2 gene. To date, over 140 mutations have been discovered in up to 70% of 
familial cases (Machado et al., 2001; Morisaki et al., 2004; Aldred et al., 2006) and 11 - 
40% of apparently idiopathic cases (Thomson et al., 2001; Morisaki et al., 2004; Koehler et 
al., 2004). The relatively large number of IPAH patients with BMPR2 mutations is partly 
related to the incorrect classification of patients as having IPAH when in fact a genetic 
basis does exist (Newman et al., 2001). Other mutations are likely to be de novo mutations 
(Aldred et al., 2006; Morrell et al., 2006). The large number of BMPR2 mutations in both 
FPAH and other non familial forms coupled with the complete absence of these mutations 
in the control population (Deng et al., 2000; Lane et al., 2000; Machado et al., 2001) makes 
the presence of a BMPR2 mutation the largest known risk factor for the development of 
PAH. The mutations uncovered occur along the entire length of the gene, affecting the 
extracellular domain, transmembrane domain, kinase domain and the long cytoplasmic 
domain (Machado et al., 2006). About 30% of coding region mutations are missense 
mutations (Machado et al., 2006) occurring in highly conserved amino acid sequences, 
resulting in a failure of protein trafficking to the cell membrane or impaired signalling in 
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those proteins that do integrate into the cell membrane (Machado et al., 2001; Nishihara et 
al., 2002; Rudarakanchana et al., 2002; Machado et al., 2006). 70% of coding region 
mutations are frame shift or nonsense mutations that would result in premature truncation 
of the protein and loss through nonsense-mediated mRNA decay (Machado et al., 2006; 
Morrell, 2006). No gain of function mutation in BMPR2 has been discovered (Newman et 
al., 2008). The heterozygous loss of function mutations in carriers with a BMPR2 mutation 
supports haploinsufficiency as the predominant genetic process in inherited PAH. Not 
every case of FPAH has an identifiable BMPR2 mutation. This may be due to mutations in 
exonic coding regions yet to be studied or in intronic or regulatory regions.  Recently, an 
analysis of familial and idiopathic patients who were negative for coding region mutations 
identified gene rearrangements in 28% of FPAH and in 5.7% of IPAH patients (Aldred et 
al., 2006). These were predicted to have deleterious effects on protein structure and 
function and it is likely that with further investigation, the number of familial PAH cases 
linked to BMPR2 mutations will rise still further.  
 
1.2.2.1 B MPR2 
Bone morphogenetic proteins (BMPs) are the largest group of growth factors belonging to 
the TGF-  superfamily. In addition to BMPs, this family also includes the TGF-  isoforms 
(TGF-  1-3), activins, Mullerian inhibiting substance (MIS) and other growth and 
differentiation factors (Kingsley, 1994). BMPs were first discovered as molecules that 
induce bone and cartilage formation but are also now known to be involved in 
proliferation, differentiation and apoptosis of many cell types and have a vital role in 
embryogenesis (Morrell et al., 2006). This latter role explains why BMPR2 mutations are 
only found in the heterozygous state, as BMPR2 has a critical role in early vascular 
development. This is confirmed by the death of BMPR2-/- mice before gastrulation (Beppu 
et al., 2000). 
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 Members of the TGF-  superfamily bind to two forms of cell surface receptors, termed 
type I and type II receptors, that both contain serine/threonine kinase domains. Both type I 
and type II receptors are required for signal transduction and they exist as either oligomeric 
complexes or in monomeric form on the cell surface. As oligomers, they may be type I 
homomers, type II homomers or type I-type II heteromers (Miyazono et al., 2001). BMPs 
bind to three different type I receptors (BMPR1A/ALK-3, BMPR1B/ALK-6 and ActR-
IA/ALK-2) and three different type II receptors (BMPR2, ActR-IIa and ActR-IIb) and 
different tissues display different expression levels of the receptor types.  Like other type II 
receptors, BMPR2 is a constitutively active serine/threonine kinase. It exists as two 
isoforms: a long form and a short form. The long form is unique within the TGF-  family 
in having a long cytoplasmic tail region rich in serine and threonine residues (Kawabata et 
al., 1998).  
 There are over 30 members of the BMP family with binding affinities to type I and type II 
receptors varying significantly amongst member proteins. The most well known BMPs; 
BMP-2, BMP-4, BMP-7, growth differentiation factor-5 (GDF-5) and growth 
differentiation factor-6 (GDF-6) bind with high affinity to BMPR1A and BMPR1B but 
with low affinity to BMPR2 (Morrell et al., 2006). Their respective affinities for type I 
receptors also differ, with BMP-7 and GDF-5 having higher affinities for BMPR1B than 
BMPR1A (Nishitoh et al., 1996). Other BMPs including BMP-5 and BMP-6 show higher 
affinity for BMPR2 over type I receptors (Yu et al., 2005; Morrell et al., 2006) and BMP-2 
and BMP-7 can also bind the activin receptors ActRIIa and ActRIIb albeit with lower 
affinity than activins (Kawabata et al., 1998). Although ActRIIa and ActRIIb can bind 
BMPs and transduce signals in co-operation with type I receptors, it is BMPR2 that is the 
predominant type II receptor mediating BMP signalling under normal physiological 
conditions (Yu et al., 2005).  Over recent years it is emerging that such receptor selectivity 
and differences in spatial expression patterns of each receptor allows a high degree of 
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plasticity in BMP signalling which likely underlies the tissue specific functions of BMPs in 
addition to their role in pathological conditions.  
 The TGF-  superfamily signal through a remarkably simple phosphorylation cascade that 
is highly conserved across mammals and involves the major TGF-  superfamily specific 
signalling molecules: the Smads. BMPs acting via type I and type II receptors are able to 
signal via this well documented Smad dependent pathway but also via Smad independent 
pathways that have been linked to mitogen-activated protein kinase (MAPK) activation 
(Nohe et al., 2002). Which of these pathways is activated is related to the nature of ligand 
binding to receptor complex. As mentioned, type I and type II receptors can exist as 
oligomers on the cell surface in addition to existing in free form. If a ligand binds to a 
preformed heterodimeric complex of one type I receptor and one type II receptor 
(predominately  BMPR2)  then  signalling  occurs  via  the  ‘traditional’  Smad  pathway.  If, 
however, a ligand binds to a monomeric type I receptor, then this is thought to cause 
homodimerisation with another type I receptor and subsequent recruitment of a type II 
receptor. Therefore the receptor signalling complex is distinct from the preformed 
heterodimeric complex of type I and type II receptors and this ligand-heteromeric complex 
results in Smad independent signalling via MAP kinases (figure 1.5) (Nohe et al., 2002). 
 
1.2.2.1.1 Smad dependent signalling 
Following ligand binding to receptor complex, BMPR2 phosphorylates a glycine-serine 
rich domain on the proximal intracellular region of the type I receptor causing activation of 
the type I receptor kinase domain. The type I receptor phosphorylates and activates a group 
of  Smad  proteins  termed  ‘receptor  activated’  or  R-Smads. This group is composed of 
Smad1, Smad5 and Smad8 that are often grouped together as Smad1/5/8 as the functional 
differences between them are not well characterised.  Smad1/5/8 must form a complex 
with the common partner Smad (co-Smad), Smad4 to allow translocation to the nucleus 
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where they regulate gene transcription in association with transcriptional activators and co-
repressors (Humbert et al., 2004).  
 
1.2.2.1.2 Smad independent signalling 
Signalling via phosphorylated Smad1/5/8 (p-Smad1/5/8) cannot explain all the cellular 
effects of BMPs and it is now recognised that other Smad independent pathways exist. 
Following ligand binding to a type I receptor followed by homodimerisation and 
recruitment of a type II receptor, a p38 MAPK dependent pathway is activated (Nohe et al., 
2002). Activation of p38 is thought to be dependent on the prior activation of the MAPK, 
TAK1, whose activity is enhanced by interaction with the TAK binding protein, TAB1. 
TAB1 may provide the link to the BMPR1A/1B receptors through the adaptor protein 
XIAP (Nohe et al., 2004). In addition to p38, another major MAPK, extracellular regulated 
kinase (ERK) can be activated by BMPs (Lai and Cheng, 2002; Yang et al., 2005) although 
the molecular mechanism responsible for p-ERK1/2 activation is currently unknown. The 
long cytoplasmic tail region of BMPR2 is capable of binding a multitude of proteins 
(Hassel et al., 2004) of which several have been investigated in relation to BMPR2 
signalling (Foletta et al., 2003; Machado et al., 2003; Wong et al., 2005; Chan et al., 2007) 
and these provide another level of complexity to BMPR2 mediated intracellular signalling 
(figure 1.5). 
 
1.2.2.1.3 Regulation of B MP signalling 
There are several levels of regulation to BMP signalling including the BMP antagonists 
noggin, chordin and members of the DAN family, the presence of accessory receptors such 
as the endoglin receptor or inhibitory proteins such as BAMBI (BMP and activin 
membrane bound inhibitor) and Smurf-1 (Smad ubiquitination regulatory factor-1) 
(Massague and Chen, 2000). Moreover, phosphatases have recently been discovered 
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capable of dephosphorylating and inactivating Smad-1 (Chen et al., 2006). In addition to 
Rmads and co-smads that are a third group termed inhibitory Smads comprised of Smad6 
and Smad7. Smad6 inhibits BMP signalling through competition with co-Smad4 for 
Smad1 binding yielding inactive Smad1-Smad6 complexes. Smad6 and Smad7 are thought 
to function as a negative feedback system to control signal strength (Massague and Chen, 
2000). 
 
1.2.2.2 Role of B MPR2 in the pathogenesis of PA H  
 
Mutations and dysfunctional TGF-  receptors have been associated with many diseases 
involving deregulated cellular proliferation including over a dozen cancers, pulmonary 
fibrosis and atherosclerosis (Miyazono et al., 2001), so it was perhaps not surprising that 
BMPR2 as a member of the TGF-  superfamily should be implicated in PAH. Unlike 
mutations in TGF-  receptors that are implicated in many disease conditions, BMPR2 
mutations have only been associated with PAH. As already stated, BMPR2-/- mice die 
during early embryogenesis and Smad5 mutant embryos have malformed vasculature 
associated with defective angiogenesis (Yang et al., 1999) illustrating the importance of the 
BMPR2/Smad pathway in vascular development. BMPR2 is expressed on PAEC with 
lower levels of expression in PASMCs and macrophages (Atkinson et al., 2002). BMPR2 
expression is decreased in FPAH/IPAH with the greatest reductions found in patients  
harbouring BMPR2 mutations or in those patients that display evidence of linkage to 2q33. 
Patients with PAH secondary to other illnesses also express BMPR2 at lower levels than 
control patients (Atkinson et al., 2002) indicating a pathological role for dysfunctional 
BMPR2 in pulmonary hypertensive patients not carrying a BMPR2 mutation. The low 
level expression of BMPR2 in PAH patients who are wild-type (WT) BMPR2 carriers 
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F igure 1.5 Possible signalling mechanisms of B MPR2. 
A BMP (in this case BMP-2) may bind to a preformed receptor complex of type I (BR1) 
and type II (BR2) receptors inducing a Smad dependent pathway. Alternatively, a ligand 
may bind to a type I receptor causing homodimerisation and subsequent recruitment of a 
type II receptor. This activates the p38 dependent pathway. Both pathways may utilise 
additional adaptor proteins (X, Y and Z). p-ERK1/2 can also be activated by BMP ligands, 
however, it is not known which receptor complex mediates this activation. The 
cytoplasmic tail of BMPR2 interacts with cytoplasmic signalling molecules offering the 
potential for additional signalling pathways.  
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coupled with levels of BMPR2 lower than that predicted by haploinsufficiency in mutant 
carriers indicate there are other, as yet undetermined factors, that suppress BMPR2 
expression in PAH. BMPR1A receptors are also downregulated in patients with PAH of 
various etiologies (Du et al., 2003). It is not just receptor expression that is reduced but 
also the activated (phosphorylated) forms of downstream Smads. In FPAH and IPAH 
patients (with and without BMPR2 mutations) p-Smad1 was found to be reduced in the 
media and intima of small pulmonary arteries (Yang et al., 2005). In contrast to these 
results, Richter et al., 2004 found no difference in p-Smad1/5/8 between PAH and control 
patients but did note a lack of expression in PAECs at the core of plexiform lesions which 
supports the concept that PAECs involved in vascular lesions have phenotypic 
heterogeneity.  
 Investigations of both the hypoxic and MCT animal models of PAH have yielded diverse 
results with regard to BMP signalling molecules. Hypoxia has been shown to increase p-
smad1/5/8 and inhibitor of differentiation (Id1), a downstream target of BMP signalling in 
mice (Frank et al., 2005; Long et al., 2006) but to decrease these parameters in hypoxic rats 
(Takahashi, 2007).  Moreover, BMPR2 is reduced in the lungs of rats following 1-3 weeks 
of hypoxia (Takahashi et al., 2005). Hypoxia induced PAH can also be attenuated through 
gene delivery of BMPR2 into the vascular endothelium resulting in an overexpression of 
BMPR2 (Reynolds et al., 2007). Such an approach however was unable to attenuate MCT 
induced PAH (McMurty et al., 2007). BMPR1B, BMPR2, p-Smad1 and Smads 4,5,6 and 8  
have all been found to be decreased in MCT PAH however ERK1/2 and p38 levels were 
found to be unchanged (McMurty et al., 2007; Morty et al., 2007).  
Work on cells isolated from PAH and control patients has helped understand the role that 
BMPs, BMP receptors and downstream effectors may play in PAH. One important 
conclusion that can be drawn from the work to date is that the effect of BMP signalling is 
highly context specific. The nature of ligand, cell type, cellular location within vessel and 
43 
 
species all determine the response recorded. BMP-2, BMP-4 and BMP-7 induce apoptosis 
of PASMCs from non hypertensive patients (Zhang et al., 2003), a process involving 
phosphorylation of Smad1, activation of caspases and downregulation of Bcl-2 (Zhang et 
al., 2003; Lagna et al., 2006). BMPs also inhibit proliferation of PASMCs in healthy 
patients (Morrell et al., 2001; Takeda et al., 2004). The effects of BMPs are, however, very 
different in PASMCs from pulmonary hypertensive patients.  Zhang et al., 2003 found that 
PASMCs from FPAH/IPAH but not APAH patients were more resistant to BMP induced 
apoptosis and PASMCs expressing a mutant form of BMPR2 are resistant to BMP induced 
apoptosis (Lagna et al., 2006). The anti-proliferative effect of BMPs are also lost in 
PASMCs from patients with PAH (Morrell et al., 2001) with BMP-2 and BMP-7 actually 
inducing proliferation of pulmonary hypertensive PASMCs, a process dependent on p38 
and ERK1/2 (Takeda et al., 2004).  It has been proposed that p38 and p-ERK1/2 signalling 
opposes p-Smad1/5/8 signalling and that an imbalance between proliferative p38/p-
ERK1/2 pathways and the apoptotic p-Smad1/5/8 pathway contributes to proliferation in 
BMPR2 mutant PASMCs (Yang et al., 2005). 
 Generally speaking, BMPs have the opposite effect on PAECs than they do on PASMCs, 
namely a decrease in apoptosis and stimulation of proliferation (Valdimarsdottir et al., 
2002; Teichert-Kuliszewska et al., 2006). One speculative theory regarding the initiation of 
PAH in the presence of dysfunctional BMPR2 is that apoptosis of PAECs leads to 
endothelial damage and exposure of underlying smooth muscle to mitogenic agents such as 
TGF-  (Morrell et al., 2006). The smooth muscle cells would undergo proliferation and 
perhaps migration, unchecked by the pro-apoptotic effect of BMPR2 mediating signalling. 
In addition, rapid apoptosis of PAECs could lead to the emergence of apoptosis resistant 
cell populations which would contribute to intimal lesions.   
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1.2.3 Modifying factors in PA H 
The discovery of BMPR2 mutations in patients with PAH was a significant breakthrough 
in the understanding of the disease. The low penetrance of the disease in families 
harbouring BMPR2 mutations coupled with the fact that the majority of IPAH patients do 
not have BMPR2 mutations suggest that dysfunctional BMPR2 alone is insufficient to 
induce PAH. Current thinking points towards a disease created by ‘multiple hits’; that is, 
an underlying genetic pre-disposition coupled with other endogenous or environmental 
factors that act in concert to create the disease phenotype. The search for an additional 
modifying gene for PAH has focused intensively on the 5-HT transporter (5-HTT).  
 
1.2.3.1 5-H T and PA H 
As mentioned previously, 5-HT is synthesised primarily in the enterochromaffin cells of 
the intestine. However, the lung also contains several sites for local 5-HT synthesis 
including the neuroendocrine and neuroepithelial cells in the airways (MacLean et al., 
2000) and PAECs (Eddahibi et al., 2006). 5-HT is a product of the essential amino acid L-
tryptophan. In 5-HT producing cells, L-tryptophan undergoes hydroxylation of the benzene 
ring by TPH to yield 5-hydroxytryptophan (5-HTP). 5-HTP then undergoes 
decarboxylation via L-amino acid decarboxylase to form 5-HT. 5-HT is a pulmonary 
vasoconstrictor (MacLean et al., 1996; Morecroft et al., 1999) and PASMC mitogen 
(Fanburg et al., 1997); however, normal physiological plasma concentrations are kept low 
(nanomolar concentrations) due to uptake and storage in platelets. The first indicator that 
elevated plasma levels of 5-HT may be a contributing factor in the pathology of PAH came 
following the association of PAH with ingestion of the anorexigen, aminorex fumurate 
(aminorex). Aminorex is a substituted amphetamine that was used in several European 
countries during the 1960s. It soon became clear that people ingesting aminorex were 20 
times more likely to develop PAH than the general population (Kay et al., 1971) and 5 
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years after its discontinuation, levels of PAH had returned to the levels seen prior to the 
introduction of aminorex (Kramer and Lane, 1998). While the exact mechanism of action 
of aminorex was not known, it was discovered that aminorex released 5-HT from platelets 
to a greater degree than other sympathomimetics and phenethylamines. It was also found to 
be a monoamine oxidase (MAO) inhibitor (Fristrom et al., 1977). Further support for the 
role of 5-HT in PAH came from the fawn-hooded rat, a strain with a genetic deficiency in 
platelet storage and that has high circulating plasma levels of 5-HT. The fawn-hooded rat 
develops spontaneous PAH (Kentera et al., 1988; Ashmore et al., 1991) and an 
exaggerated pulmonary hypertensive response to hypoxia compared with other rat strains 
(Nagaoko et al., 2001). A causative role for 5-HT  in  the  fawn  hooded  rats’  heightened 
response to hypoxia was supported when it was shown that infusion of 5-HT for 2 weeks 
aggravates hypoxic PAH in rats (Eddahibi et al., 1997). In 1990 PAH was discovered in a 
patient with a rare familial platelet storage disease that results in elevated plasma 5-HT 
levels (Herve et al., 1990).  Elevated plasma 5-HT levels were subsequently found in a 
group of FPAH/IPAH patients that persisted even after heart-lung transplant indicating the 
increased plasma [5-HT] was not a secondary phenomenon (Herve et al., 1995). This data 
coupled with another outbreak of PAH related to an anorexigen with serotonergic effects, 
this time dexfenfluramine (Dfen) (see section 1.2.3.2.3), formed the basis of the ‘serotonin 
hypothesis’  of  PAH  in which  5-HT plays a causative or modulating role in the disease 
pathology.  The mechanisms by which 5-HT contributes to the vascular changes in PAH 
are still being elucidated but both 5-HT receptors and 5-HTT are thought to contribute.  
 
1.2.3.1.1 5-H T receptors in PA H 
5-HT induced vasoconstriction occurs through the 5-HT1B receptor in human pulmonary 
resistance vessels (Morecroft et al., 1999) with both 5-HT1B and 5-HT2A receptors 
contributing to vasoconstriction in rats (MacLean et al., 1996). The 5-HT1B mediated 
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contraction is greater in the pulmonary vessels of chronic hypoxic rats, an effect attenuated 
by the 5-HT1B/1D antagonist GR127935 (Keegan et al., 2001). This same antagonist also 
reduced the pulmonary vascular remodelling that occurs in hypoxic rats. The 5HT1B/1D 
knockout mouse paralleled the antagonist studies with reduced vascular remodelling and 
attenuated vasoconstriction compared to WT hypoxic mice (Keegan et al., 2001). In 
addition to its role as a mediator of vasoconstriction in rats, the 5-HT2A receptor also 
contributes to hypoxic induced fibroblast proliferation (Welsh et al., 2004). The 5-HT2B 
receptor has also been implicated in the pathogenesis of PAH with 5-HT2B knockout mice 
showing reduced parameters of vascular remodelling following hypoxia compared with 
WT hypoxic animals and the major metabolite of Dfen, nordexfenfluramine (NDfen) is a 
high affinity 5-HT2B agonist (Launay et al., 2002). The effect of the 5-HT2B receptor on the 
pulmonary circulation appears to be species dependent as the 5-HT2B receptor is associated 
with a vasodilator effect in pigs (Glusa and Pertz, 2000). Support for a role for this receptor 
in PAH comes from the finding that a loss of function 5-HT2B receptor mutation was found 
in a patient with Dfen associated PAH. The mutation was not found in 80 control patients 
(Blanpain et al., 2003). The contribution of 5-HT receptors to the pathogenesis of PAH is 
likely to involve the vasoconstriction element of the disease more than vascular 
remodelling; however, recent evidence indicates that stimulation of 5-HT receptors may be 
necessary for vascular remodelling when coupled with 5-HTT activation (see section 
1.2.3.1.3) and there is convincing evidence that the 5-HTT is critical to 5-HT induced 
vascular remodelling.  
 
1.2.3.1.2 The 5-H T T and PA H 
The ‘serotonin hypothesis’  initially came into being  through studies  implicating a  rise  in 
circulating 5-HT as a factor in PAH; however, the data regarding plasma 5-HT levels in 
PAH is not clear. In contrast to earlier studies, Lederer et al., 2007 found that plasma 5-HT 
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levels were normal in PAH patients. People with carcinoid tumours of the 5-HT producing 
enterochromaffin cells have high plasma [5-HT] but are not at an increased risk of PAH 
and neither are users of selective serotonin reuptake inhibitors (SSRIs) which increase 
plasma 5-HT levels. If, however, 5-HT induced pulmonary hypertension is dependent on 
cellular internalisation of 5-HT via the 5-HTT then the expression and activity of the 5-
HTT may be a better indicator of the involvement of the serotonergic system in PAH than 
plasma 5-HT levels and may also explain why SSRIs are not associated with an elevated 
risk of the disease. 
 The 5-HTT belongs to a large family of membrane proteins including dopaminergic, -
aminobutyric acid, noradrenaline and other transporters. The principal action of these 
transporters is to mediate cellular uptake of neurotransmitters. The 5-HTT is expressed on 
several cell types including neurons, platelets, PAECs, PASMC and PAFs. Experiments in 
bovine and rat PASMCs have demonstrated that the mitogenic action of 5-HT on these 
cells is dependent on uptake via the 5-HTT (Lee et al., 1991; Eddahibi et al., 1999) and the 
proliferative effect of 5-HT + serum on PAFs is blocked by the 5-HTT inhibitor, fluoxetine 
(Welsh et al., 2004). Levels of the 5-HTT are increased in the pulmonary arteries of 
hypoxic rats and hypoxic PASMCs have increased expression of 5-HTT coupled with an 
increased proliferative effect to 5-HT (Eddahibi et al., 1999). 5-HTT inhibitors attenuate 
vascular remodelling in hypoxic induced pulmonary hypertensive mice (Marcos et al., 
2003) and mice lacking the 5-HTT (5-HTT-/- mice) also develop less severe hypoxic PAH 
than WT mice (Eddahibi et al., 2000). Conversely, mice overexpressing the 5-HTT (5-
HTT+ mice) have higher pulmonary pressures and a greater degree of remodelling and 
right ventricular hypertrophy following hypoxia than WT mice. Interestingly, normoxic 5-
HTT+ mice have a higher (up to 3 fold) right ventricular pressure (RVP) than WT mice 
(MacLean et al., 2004).  
 Human data has helped support the animal studies, with 5-HTT mRNA levels two-fold 
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greater in FPAH/IPAH patients than in control subjects (Eddahibi et al., 2001). 5-HTT 
expression was shown to be greater in vessels undergoing remodelling, particularly in the 
medial smooth muscle and in regions of concentric intimal lesions associated with 
proliferating PASMCs. PASMCs isolated from the pulmonary hypertensive patients 
showed a doubling of proliferation to 5-HT + serum, an effect that was abolished by 
fluoxetine and another 5-HTT inhibitor, citalopram.  The proliferative response was unique 
to 5-HT with several other growth factors including PDGF and TGF-  having similar 
effects on PASMCs from PAH patients and control subjects (Eddahibi et al., 2001). 
 The reasons for the increased levels of the 5-HTT in pulmonary hypertensive patients are 
unclear. A polymorphism exists in the promoter region of the human 5-HTT gene that 
alters its transcriptional activity. The polymorphism involves two alleles, a 44 base pair 
insertion and deletion, termed the L and S allele respectively. The L allele is associated 
with a 2 to 3 fold higher level of 5-HTT transcription than the S allele. Eddahibi et al., 
2001 found that the L/L allele was present in 27% of the control population but was 
present in 69% of patients with either FPAH, IPAH or PAH associated with Dfen. The L/L 
genotype is also present in the majority of lung transplant patients with PAH secondary to 
other diseases (Marcos et al., 2004).  This data suggests that the L/L genotype confers a 
genetic susceptibility to PAH. Two recent studies, however, found no difference in allele 
distribution between FPAH/IPAH patients and control subjects (Willers et al., 2006; 
Machado et al., 2006) but Willers et al., 2006 did find that the L/L genotype correlated 
with an earlier age of diagnosis in FPAH patients, possibly indicating an interaction 
between overexpression of 5-HTT with a BMPR2 mutation. The L/L genotype is 
correlated with higher PAP in patients suffering from PAH associated with COPD 
(Eddahibi et al., 2003) and PAH associated with heart failure (Olson et al., 2007) 
supporting a role for the 5-HTT in modulating disease severity.  
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1.2.3.1.3 5-H T signalling in the pulmonary vasculature 
5-HT can activate several signalling systems depending on whether 5-HT acts via one of 
the many 5-HT receptors or through the 5-HTT. The relative contribution of 5-HT 
receptors and 5-HTT to pulmonary vasoconstriction and remodelling is uncertain and 
likely differs between species. 
 The 5-HT receptors mentioned above in relation to PAH are all G-protein coupled 
receptors. The 5-HT1B and 5-HT2A receptors are thought to be the most important 5-HT 
receptors with regards to PAH and these receptors are expressed on pulmonary smooth 
muscle with lower expression on endothelium (Marcos et al., 2004). 5-HT1B and 5-HT2A 
receptors signal via distinct pathways. 5-HT1B receptors are coupled to Gi and inhibit 
adenylate cyclase and cAMP production resulting in vasoconstriction (Weir et al., 2004). 
5-HT2A receptors couple to Gq and activate phospholipase C (PLC) leading to an increase 
in inositol triphosphate (IP3) levels which induces release of Ca2+ from intracellular stores 
causing vasoconstriction (Weir et al., 2004). Alternatively, 5-HT can act intracellularly 
following uptake via the 5-HTT. The 5-HTT parallels 5-HT1B and 5-HT2A expression in 
pulmonary arteries with the 5-HTT being expressed predominately in smooth muscle with 
weaker expression in the endothelium (Eddahibi et al., 2001; Marcos et al., 2004). 5-HT, 
once taken up into cells via the 5-HTT can be degraded via MAO, packaged into vesicles 
or it can initiate signalling pathways leading to proliferation and possibly vasoconstriction. 
Experiments in bovine PASMCs have shown that once inside a PASMC, 5-HT activates 
ROS which phosphorylates and activates ERK1/2 which enters the nucleus and induces 
proliferation (Lee et al., 1999) via the transcription factor, GATA-4 (Suzuki et al., 2003).  
For  ERK1/2 to translocate to the nucleus it requires the presence of ROCK and ROCK is 
increased by 5-HT stimulation of 5-HT1B/1D receptors (Liu et al., 2004). Not only does this 
provide an additional mechanism of 5-HT induced vasoconstriction through ROCK 
mediated Ca2+ sensitisation, it also allows cross-talk between the 5-HT1B/1D receptor and 5-
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HTT in relation to PASMC proliferation (figure 1.6).  In fact, blockade of either 5-HT1B/1D 
receptors or 5-HTT prevents 5-HT mediated proliferation of bovine PASMCs (Liu et al., 
2004). The situation appears different, however, in human PASMCs. In these cells it is the 
5-HTT that is required for nuclear translocation of ERK1/2 and 5-HT1B receptors that 
activate ERK1/2 (Lawrie et al., 2005). It may be that cellular and species differences are 
important in the relative contributions made by receptors and 5-HTT to PASMC 
proliferation. In human lung samples and isolated PASMCs from PAH patients, the 5-HTT 
was overexpressed, whereas the 5-HT1B, 5-HT2A and 5-HT2B receptors were expressed at 
similar levels to samples from control patients. Inhibition of the 5-HTT, but not the 
receptors prevented the augmented proliferative response to 5-HT in PASMCs from PAH 
patients (Marcos et al., 2004). Like the BMPR2 receptor, the expression level of the 5-HTT 
in PAH patients is different to that predicted by genetic factors alone. In the case of the 5-
HTT, PASMCs from PAH patients have higher levels of 5-HTT than control patients with 
the same genotype indicating that other factors must act to increase 5-HTT expression in 
PAH (Marcos et al., 2004).   
 
1.2.3.1.4 T ryptophan hydroxylase 1 
There are two isoforms of TPH. The first, TPH1, is present in the periphery and is the rate 
limiting enzyme for 5-HT synthesis outside the central nervous system (CNS). The second, 
TPH2, is present only in the CNS and is the rate-limiting enzyme for central 5-HT 
synthesis. There exists, therefore, two independent 5-HT systems allowing the generation 
of viable Tph1-/- mice that lack peripheral 5-HT but have only minor reductions in brain 5-
HT (Walther and Bader, 2003). PAECs express TPH1 and levels of TPH1 are increased in 
PAECs from IPAH patients compared to control subjects and this is associated with 
increased 5-HT release (Eddahibi et al., 2006). Hypoxia increases TPH1 expression in 
rabbit lung 3 fold (Pan et al., 2006) and hypoxic PAH is attenuated in Tph1-/- mice 
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(Morecroft et al., 2007; Izikki et al., 2007) indicating the importance of TPH1 and 5-HT in 
the development of hypoxic PAH.  
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F igure 1.6 C ross-talk between the 5-H T T and 5-H T1B/1D receptor in 5-H T induced 
proliferation in bovine PASM Cs. Following cellular uptake by the 5-HTT, 5-HT 
activates reactive oxygen species (ROS) which phosphorylates and activates the MAPK, 
ERK1/2. Rho Kinase (ROCK) which is increased by 5-HT1B/1D  receptor activation enables 
p-ERK1/2 translocation to the nucleus and subsequent induction of proliferation via 
GATA-4.  
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1.2.3.2 Endogenous and E xogenous Modifying Factors in PA H 
1.2.3.2.1 Hypoxia 
As mentioned previously, hypoxic induced pulmonary vasoconstriction is a physiological 
regulatory mechanism for maintaining adequate oxygenation of blood. Sustained HPV and 
the development of chronic HPV are associated with several lung diseases including 
COPD and sleep apnea. Hypoxic induced PAH is also an important model for studying 
PAH. This process involves exposing rodents to 50% atmospheric oxygen levels for a 
period of at least 2 weeks. The result of the hypoxic exposure is an increase in RVP, RVH 
and vascular remodelling (MacLean et al., 2004). The extent of the vascular changes 
observed is dependent on sex, species and developmental stage of the animal (Stenmark et 
al., 2006). Hypoxia has profound effects on cells within pulmonary arteries. PAECs 
undergo phenotypic changes involving the upregulation of inflammatory markers, 
increased release of growth factors and ECM proteins. Cell surface receptor expression and 
plasma membrane structure also undergo pronounced alterations. The net result of the 
PAEC changes are an increase in production of growth factors and vasoconstrictors such as 
5-HT and ET-1 and decreased production of vasodilators including prostacyclin and NO. 
The release of interleukins and leukocyte adhesion molecules facilitates attraction and 
capture of leukocytes to the vessel wall and recruitment of circulating progenitor cells 
(Stenmark et al., 2006; Nicolls and Voelkel, 2007). PASMCs also change towards a 
proliferative phenotype with many of the changes observed being a direct consequence of 
the action of the endothelial derived mitogenic factors. Two important effects of hypoxia 
on PASMCs have already been mentioned, namely the effect on cellular ROS production 
and subsequent K+ channel inhibition (See next section) and the effect on the 5-HTT. The 
role of PAFs in hypoxic PAH was briefly discussed earlier and as an early mediator of the 
hypoxic response they are involved in promoting PASMC growth and contraction through 
the release of the paracrine growth factors outlined in section 1.2.1.1.3. The mitogenic 
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effect that PAFs exert on PASMCs is dependent on HIF supporting a role for PAFs as an 
oxygen sensor in hypoxic PAH (Rose et al., 2002). There are three HIF subtypes known 
(HIF-1 , HIF-2  and HIF-3 ) all acting via the HRE to induce gene transcription. HIF-1  
is expressed in the lung under normoxic conditions and is upregulated during hypoxia. 
HIF-2  is only expressed under hypoxic conditions and HIF-3  is expressed at lower 
levels than HIF-1  under normoxia but increases under hypoxia (Rose et al., 2002). The 
importance of HIF-1  in the role of PAH was evaluated in studies using heterozygous 
mice (HIF-1 +/-). These mice were found to develop less severe hypoxic PAH than WT 
mice (Yu et al., 1999). Subsequently, it was also shown that HIF-2 +/- mice were protected 
against hypoxic PAH (Brusselmans et al., 2003). The proliferative effect that hypoxia has 
on PAFs seems to be dependent exclusively on HIF-2  with both HIF-1  and HIF-2  
contributing to PAF migration (Eul et al., 2005).  
 The hypoxic model of PAH mimics many of the vascular changes of severe PAH in 
human patients but often lacks the complex intimal lesions seen in these patients. 
Plexiform lesions, for example, are not a feature of hypoxic PAH in animal models but 
HIF-1  is overexpressed in PAECs from plexiform lesions in PAH patients. HIF-1  is 
necessary for the production of VEGF, which is also upregulated in plexiform lesions 
indicating an angiogenic like process within the lesion. It is not clear, however, whether 
HIF-1  expression in plexiform lesions is increased by hypoxia or by other factors such as 
growth factors or mutations (Tuder et al., 2001). 
  
1.2.3.2.2 K + channels 
Cell membrane potential (Vm) is regulated by the permeability of Kv channels. Inhibition 
of Kv channel activity reduces K+ efflux causing depolarisation of the cell membrane 
resulting in increased cytosolic [Ca2+] caused by Ca2+ entry through voltage-dependent 
calcium channels (VDCC) and Ca2+  release from the sarcoplasmic reticulum (SR). As 
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discussed previously, K+ channel inhibition by hypoxia is involved in HPV and HPV is 
reduced in mice deficient in Kv1.5 channels (Archer et al., 2001). Both Kv1.5 and Kv2.1 
channels are present on PASMCs and both are downregulated in hypoxia causing reduced 
Kv current (Archer et al., 1998a). The importance of Kv1.5 channels in hypoxic PAH was 
revealed when gene transfer of Kv1.5 into hypoxic rats reduced pulmonary hypertensive 
parameters including RVH and arterial remodelling, offering a new potential avenue for 
therapeutic investigation (Pozeg et al., 2003).  It is not clear why some Kv channels are 
altered by hypoxia and not others but the mechanism appears to involve HIF-1 . HIF-1 +/- 
mice do not have dysfunctional Kv currents following hypoxia and inhibition of HIF-1  
restores Kv1.5 channel current in PASMCs from pulmonary hypertensive fawn-hooded 
rats (Bonnet et al., 2006). It maybe the case that certain Kv channels have HREs in their 
promoter that, when activated by HIF-1 , cause a decrease in gene transcription. 
 PASMCs from FPAH/IPAH patients have a higher cytosolic [Ca2+] than cells from APAH 
patients or control subjects. This is associated with decreased Kv current and cell 
membrane depolarisation (Yuan et al., 1998).  The elevated [Ca2+] concentration in the 
PASMCs would facilitate both agonist induced vasoconstriction and cellular proliferation.  
 In addition to their role in regulating intracellular [Ca2+] and hence vasoconstriction and 
proliferation, K+ channels also regulate apoptosis. K+ channels control the rate of apoptotic 
volume decrease (AVD), an early feature of apoptosis. Cellular volume is controlled by ion 
concentration gradients and K+, being the major cation in the cytosol, has a critical role in 
determining cell volume. When K+ channels are activated, K+ ions pass out of the cell into 
the intercellular space. This results in a corresponding efflux of chloride ions (Cl-) out of 
the cell along its electrochemical gradient, a process that is further enhanced by the 
membrane hyperpolarisation caused by the K+ efflux. The accumulation of KCl outside the 
cell shifts the osmotic balance so that H20 is drawn out of the cell causing AVD, a process 
which results in activation of cytochrome-c, caspases and apoptosis (Platoshyn et al., 2002; 
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Remillard and Yuan, 2004). Staurosporine (ST), a known inducer of apoptosis activates Kv 
currents in PASMCs and Bcl-2, an anti-apoptotic protein prevents apoptosis by reducing 
Kv current (Ekhterae et al., 2001). A decrease in K+ channel function would, therefore, 
prevent the reduction in cell volume thus preventing apoptosis. In PAH this is likely to 
alter the balance between proliferation/apoptosis in PASMCs towards proliferation and 
subsequent vascular remodelling. Conversely, restoration of Kv current by Kv1.5 gene 
transfer reduces PVR and remodelling after 14 days in rats despite continuing hypoxia 
(Pozeg et al., 2003).   Any deviation in Kv channel function and current can influence three 
major contributors to PAH, namely vasoconstriction, cellular proliferation and apoptosis so 
Kv channels are likely to be important mediators in the disease.  
 There are three groupings of Kv channels. The first group, containing Kv1-6 and Kv8-9 is 
the group that has been most studied in relation to PAH. Another group is comprised of 
Kv10-12 and the final group is composed of Kv7.1-7.5, also called KCNQ channels. In 
PASMCs the K+ current is composed of many Kv channels with similar attributes and the 
relative contribution of the various Kv channel subunits to K+ current differs between cell 
types (Bonnet and Archer, 2007). The development of more specific Kv channel 
antagonists and inactivating antibodies is helping to unravel the composition of the whole 
cell K+ current which will enable better targeting of therapeutics. Although Kv1.5 and 
Kv2.1 are well established as important contributors to PASMC K+ current, other Kv 
channels also contribute and recently, KCNQ channels were found to contribute to the 
resting Vm of PASMCs. This information was derived from the use of two selective KCNQ 
channel inhibitors (linopirdine and XE991) that caused powerful vasoconstriction of 
isolated pulmonary arteries, an effect caused by a direct action on the PASMCs (Joshi et 
al., 2006). KCNQ channels have recently been found to also contribute to the resting Vm of 
rat mesenteric arteries (Mackie et al., 2008). It is only within the last five years that KCNQ 
channels have been thought of as among the group of functional K+ channels in vascular 
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smooth muscle cells and hence their functional status or role in PAH is unknown.  
 
1.2.3.2.3 Appetite suppressants  
Appetite suppressants, specifically substituted amphetamine appetite suppressants are 
important risk factors for the development of PAH. Aminorex was the first such drug to be 
associated with the disease and gave the first indication that 5-HT may be involved in the 
pathophysiology of PAH. Subsequently, it was found that fenfluramine and its more active 
dextro-isomer, Dfen were associated with an increased risk of PAH. In people who used 
fenfluramines for more than three months, the risk of PAH increased 23 fold (Abenhaim et 
al., 1996). While the risk of PAH increases with increasing exposure, even short term use 
(<1 month) can induce fatal PAH (Mark et al., 1997). Dfen is now known to have a 
complicated mechanism of action that is not fully understood. Along with other common 
appetite suppressants, Dfen is a 5-HTT substrate causing 5-HT cellular efflux while being 
taken up by the 5-HTT into the cell. Similar compounds to Dfen that are not 5-HTT 
substrates are not associated with PAH and so it seems likely that Dfens mechanism of 
action is, at least in part, due to its role as a 5-HTT substrate (Rothman et al., 1999). 5-
HTT substrates also cause far greater release of 5-HT than non substrate 5-HTT inhibitors 
such as fluoxetine (Zolkowska et al., 2006) adding further support to the serotonin 
hypothesis of PAH. In addition to its interaction with the 5-HTT, Dfen also inhibits K+ 
channels in PASMCs (Weir et al., 1996; Perchenet et al., 2001) and the Dfen metabolite 
NDfen is an arterial vasoconstrictor acting via 5-HT2A receptors (Ni et al., 2005). Only a 
minority of Dfen users develop PAH and of those that do, some develop the disease after a 
relatively short exposure time while others may only develop the disease after years of use. 
This suggests that other underlying susceptibilities exist that predispose certain individuals 
to Dfen associated PAH. BMPR2 mutations have been found in 9% of fenfluramine users 
with PAH and these patients develop PAH after a relatively short exposure time (Humbert 
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et al., 2002).  This suggests an interaction between genetic pre-disposition and Dfen to 
initiate the disease in these patients.  
 
1.2.3.2.4 Female gender as a r isk factor for PA H 
PAH occurs more commonly in women than men (Loyd et al., 1984: Rich et al., 1987; 
Loyd et al., 1995), a situation paralleled in other lung conditions including idiopathic 
pulmonary fibrosis, COPD in non smokers and asthma (Carey et al., 2007). Interestingly, 
the epidemiological data for asthma show that there is a higher prevalence in males during 
childhood but this reverses to a female predominance at the time of puberty and continues 
till the fifth or sex decade after which the female predominance disappears (Carey et al., 
2007). This strongly suggests an influence of female sex hormones on the progression of 
asthma. The fact that the majority of PAH cases occur in women of child-bearing age has 
also caused speculation that female sex hormones may be responsible for the increased risk 
of PAH seen in this population. Experiments that have assessed the role of female sex 
hormones in animal models of PAH have, more often than not, shown that female 
hormones actually reduce the symptoms of PAH. For example, 17 -estradiol (estradiol) 
protects rats against MCT induced PAH (Farhat et al., 1993) and estradiol attenuates 
persistent PAH in fetal lambs (Parker et al., 2000). 2-methoxyestradiol (2-ME), a major 
metabolite of estradiol is involved in the protective effect that female hormones have in 
protecting animals against MCT induced PAH (Tofovic et al., 2005; Tofovic et al., 2006).  
Gender differences have also been noted in the response to hypoxia. During one study, 
female mice were found to be more resistant to hypoxia than males and administration of 
estradiol prolonged survival times under hypoxia (Stupfel et al., 1984). In relation to PAH, 
female rats were shown to develop less severe PAH following hypoxia than males 
(Rabinovitch et al., 1981) and ovariectomized rats develop more severe hypoxic PAH than 
rats with intact ovaries (Resta et al., 2001).  
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 It is not known how female sex hormones may influence the progression of PAH in 
animal models of PAH or in human PAH patients. Estradiol and its metabolites can 
influence vascular tone, cellular proliferation and apoptosis through both genomic and non 
genomic mechanisms.  
 
1.2.3.2.5 Endothelial der ived factors 
PAECs secrete a wide variety of vasoactive mediators that directly influence 
vasoconstriction and cellular growth in pulmonary arteries. Some of these have been 
mentioned previously and many are altered in PAH. A tight balance between 
vasoconstrictors and mitogenic agents against vasodilators and pro-apoptotic factors 
controls vascular homeostasis, low vascular tone, inflammation and tissue repair. In PAH, 
the balance is thought to favour proliferation and vasoconstriction and there have been 
many experimental observations that support this view. This is a brief summary of some of 
those observations: 
 
1.2.3.2.5.1 Nitr ic oxide 
As an important regulator of vascular tone (Cooper et al., 1996), NO has come under 
attention from PAH researchers but the expression and role of NOS in the pulmonary 
hypertensive lung is not clear. One study found NOS to be dramatically downregulated in 
the lungs of PAH patients compared with control subjects (Giaid and Saleh, 1995). Other 
human studies have found increased expression of eNOS in small resistance arteries in 
pulmonary hypertensive patients although with large individual variability (Mason et al., 
1998).  In this study, plexiform lesions were found to have high levels of eNOS, perhaps 
indicating proliferating PAECs. It is uncertain what the role of NO might be in the 
endothelium of plexiform lesions and whether its effects are beneficial or detrimental 
(Mason et al., 1998). eNOS deficient mice have increased PAP and PVR compared with 
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WT mice (Steudel et al., 1997). Mice lacking eNOS develop severe PAH following mild 
hypoxia (Fagan et al., 1999) and conversely, increased levels of eNOS attenuate hypoxic 
PAH in mice (Ozaki et al., 2001). Administration of the NO precursor, L-arginine reduces 
PAH following hypoxia and MCT in rats (Mitani et al., 1997) and reduces PAP and PVR 
in human patients with PAH (Mehta et al., 1995; Nagaya et al., 2001).   
 While there is some uncertainty as to any pathological role NO dysfunction may play in 
the development of PAH, its potent effect as a pulmonary vasodilator has led to NO 
inhalation being tested as a therapy for PAH (Pepke-Zaba et al., 1991; Goldman et al., 
1995; Hoeper et al., 2000; Krasuski et al., 2000) with results often comparable to other  
treatments currently used as inhalable vasodilators such as certain prostacyclin analogues. 
cGMP is the main signalling molecule mediating the vasodilator effect of NO and is 
degraded in the lung by phosphodiesterase type 5, (PDE5). Sildenafil, a PDE5 inhibitor is 
currently a therapeutic candidate for the treatment of PAH. Sildenafil inhibits hypoxic 
PAH in humans and mice (Zhao et al., 2001) and can reduce PVR in humans with chronic 
PAH (Ghofrani et al., 2004). 
 
1.2.3.2.5.2 Prostacyclin 
PGI2 is a potent vasodilator that acts to counteract vasoconstriction and proliferation 
(Budhiraja et al., 2004). It is produced by prostacyclin synthase (PGI2-S) and this enzyme 
is decreased in pulmonary arteries from PAH patients, with the most pronounced reduction 
occurring in vessels with concentric intimal lesions (Tuder et al., 1999). Overexpression of 
PGI2-S protects mice against hypoxic PAH (Geraci et al., 1999) and administration of 
PGI2-S via gene transfer attenuates MCT induced PAH in rats (Nagaya et al., 2000). 
Prostacyclin and its analogues have been the most successful treatments for attenuating the 
symptoms of PAH in humans to date. Epoprostenol (intravenous PGI2 analogue), beraprost 
(orally active PGI2 analogue), iloprost (inhalation carbacyclin PGI2 analogue) and 
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treprostenil (PGI2 analogue that is room temperature stable allowing subcutaneous 
infusion) have all been used successfully on PAH patients in all clinical categories (Saji et 
al., 1996; McLaughlin et al., 1998; Nagaya et al., 1999; Rosenzweig et al., 1999; Robbins 
et al., 2000; Olschewski et al., 2000; Hoeper et al., 2000; Simonneau et al., 2002).  
 
1.2.3.2.5.3 Endothelin-1 
ET-1, a pulmonary vasoconstrictor (Deuchar et al., 2002) and PASMC mitogen (Davie et 
al., 2002) is upregulated in both hypoxic (Li et al., 1994) and MCT (Frasch et al., 1999) 
animal models of PAH and also in the endothelium of remodelled vessels in PAH patients 
(Giaid et al., 1993). ET-1 receptor antagonists such as bosentan and sitaxsentan have 
shown promise in improving symptoms and exercise capacity in PAH patients (Channick 
et al., 2001; Rubin et al., 2002; Barst et al., 2002). 
 
1.2.3.2.5.4 Thromboxane 
Produced by PAECs and platelets, TXA2 is a pulmonary vasoconstrictor, PASMC mitogen 
and activator of platelet aggregation (Tuder and Hassoun, 2004). Patients with PAH show 
elevated excretion rates of 11-dehydro-thromboxane B2, a metabolite of TXA2, in addition 
to decreased excretion of the PGI2 metabolite, 2,3-dinor-6-keto-prostaglandin F1 . 
(Christman et al., 1992). This is evidence for an imbalance between vasoconstrictors and 
vasodilators in PAH. Terbogrel, a combined TXA2 synthetase inhibitor and TXA2 receptor 
antagonist was tested unsuccessfully in one clinical trial as a treatment for PAH and caused 
significant side effects leading to premature termination of the study (Langleben et al., 
2002). 
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1.2.3.2.6 Non-endothelial der ived factors 
1.2.3.2.6.1 Vascular endothelial growth factor 
VEGF is highly expressed in the lungs and is the most important growth factor for PAECs, 
promoting PAEC survival and tissue homeostasis (Said, 2006). VEGF is upregulated by 
hypoxia in human hepatoma cells via HIF-1  activation of a HRE (Forsythe et al., 1996). 
The role of VEGF in hypoxic PAH, however, is uncertain. Two groups found that 
circulating levels of VEGF and lung VEGF mRNA levels are increased in hypoxic rats 
(Christou et al., 1998) and that overexpression of VEGF protects rats against hypoxic PAH 
(Partovian et al., 2000). Contradictory findings include unchanged VEGF expression in rat 
lung following hypoxia and a 90% decrease in rat lungs following MCT (Partovian et al., 
1998). Pfeifer and colleagues could also find no change in VEGF gene expression in 
hypoxic rat lungs (Pfeifer et al., 1998). Due to the critical role VEGF has in preventing 
PAEC apoptosis, it is reasonable to assume that loss of VEGF would promote PAEC 
apoptosis, thus having a detrimental effect on vascular integrity. Indeed, it has been 
demonstrated that blockade of the VEGF receptor induces mild PAH in rats and when 
combined with hypoxia induces severe irreversible PAH associated with initial PAEC 
apoptosis, followed by proliferation of apoptosis resistant cell populations and formation of 
obliterative intimal lesions (Taraseviciene-Stewart et al., 2001). There is also evidence that 
VEGF receptor blockade can induce transdifferentiation of endothelial derived precursor 
cells into PASMC like cells (Sakao et al., 2007) which is also thought to occur in the 
vascular remodelling associated with PAH. 
 
1.2.3.2.6.2 Platelet-der ived growth factor 
PDGF is a PASMC mitogen (Yu et al., 2003) and its expression is increased in the lungs of 
PAH patients compared with control subjects (Perros et al., 2008). The PDGF receptor 
antagonist, imatinib reverses both hypoxic and MCT induced PAH in rats (Schermuly et 
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al., 2005) and imatinib has been used successfully in the treatment of one isolated case of 
severe PAH (Ghofrani et al., 2005). 
 
1.2.3.2.6.3 Adrenomedullin 
Adrenomedullin was first isolated in 1993 from human pheochromocytoma cells 
(Kitamura et al., 1993). It has now been found in a multitude of tissues in both animals and 
humans, including the lung, which also contains a dense number of adrenomedullin 
receptors, a number that is unusually high for peptide receptors (Ichiki et al., 1994; Sakata 
et al., 1994; Owji et al., 1995). Adrenomedullin is a systemic and pulmonary vasodilator, 
acting via cAMP and is also an inhibitor of vascular smooth muscle cell proliferation 
(Kano et al., 1996). Plasma levels of adrenomedullin are increased in patients with PAH 
(Kakishita et al., 1999), the reasons for which are unclear. It perhaps acts as a 
compensatory mechanism against the increased PVR. The high potency of adrenomedullin 
coupled with its high expression in the lung led to its testing in animal models of PAH.  
Both subcutaneous and inhaled adrenomedullin attenuates MCT induced PAH in rats 
(Yoshihara et al., 1998; Nagaya et al., 2003). Adrenomedullin is also effective in reducing 
the parameters of PAH in hypoxic rats (Qi et al., 2006) and mice deficient in 
adrenomedullin develop more severe PAH following hypoxia than WT mice (Matsui et al., 
2004). In human IPAH patients, adrenomedullin improves pulmonary haemodynamics and 
exercise capacity (Nagaya et al., 2004) and is a more effective treatment used in 
combination with NO than NO alone (Dani et al., 2007).  
 
1.2.3.2.6.4 Vasoactive intestinal peptide 
VIP is a pulmonary artery vasodilator (Sago and Said, 1984; Shahbazian et al., 2007) and 
PASMC growth inhibitor (Petkov et al., 2003). Pre-treatment with VIP attenuates MCT 
induced PAH in rabbits (Gunaydin et al., 2002) and also reduces PVR in pulmonary 
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hypertensive piglets (Haydar et al., 2007). There is growing evidence that VIP has a role in 
controlling vascular stasis in the lung. VIP knockout mice (VIP-/-) develop pulmonary 
arterial remodelling and RVH in normal air and the symptoms are reduced in mice 
receiving VIP (Said et al., 2007).  VIP serum levels are lower in PAH patients than control 
subjects (Haberl et al., 2007) and VIP, which is moderately expressed in pulmonary 
arteries from control subjects, is absent in pulmonary arteries from PAH patients. This was 
associated with an upregulation of VPAC-1 and VPAC-2 (Petkov et al., 2003). Petkov and 
colleagues also administered inhalation VIP to PAH patients daily for 3 months. This 
resulted in significant improvements in PAP, CO and a 50% reduction in PVR. A 
corresponding increase in exercise tolerance was also measured. The success of this 
preliminary study coupled with the lack of side effects has led to the undertaking of further 
clinical trials studying the therapeutic potential for VIP in PAH (Said, 2006). 
 
1.2.3.2.6.5 Angiopoietin-1 
Angiopoitein-1 is secreted by smooth muscle cells during development and is involved in 
angiogenesis. It binds to the endothelial-specific tyrosine kinase (TIE2) receptor which is 
present only on vascular endothelial cells and helps co-ordinate cells during vascular 
development. In 2003, Du and colleagues (Du et al., 2003) found that angiopoietin-1 
protein and mRNA expression were increased in the lungs of patients with PAH and that 
angiopoietin-1 levels correlated with disease severity. Angiopoietin-1 also decreased 
BMPR1A expression when incubated in cultured PAECs. Further work from this group 
showed that overexpression of angiopoietin-1 in rat lungs induced muscularisation of 
pulmonary arteries and PAH (Sullivan et al., 2003). Cell culture experiments using human 
PASMCs and PAECs showed that angiopoietin-1 induced PAECs to release 5-HT that 
induced proliferation of PASMCs. The growth of the PASMCs was inhibited by fluoxetine 
(Sullivan et al., 2003). In contrast to these results, Zhao et al., 2003 put forward evidence 
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for a protective role for angiopoietin-1 in PAH. They found that angiopoietin-1 gene 
transfer into rat PASMCs increased eNOS expression while reducing RVP, EC apoptosis 
and mortality in rats with MCT induced PAH. More recent studies support the former 
hypothesis for a deleterious action of angiopoietin-1 in PAH. Dewachter et al., 2006 also 
obtained the result that angiopoietin-1 induces PAECs from both IPAH patients and 
control subjects to release 5-HT with more 5-HT being released from PAECs from IPAH 
patients. PAECs from IPAH patients also released ET-1 following angiopoietin-1. The 
greater release of growth factors from PAECs was attributable to heightened expression of 
the TIE2 receptor (Dewachter et al., 2006).  
 
1.3 A im of thesis 
It is generally accepted that PAH is a multi-factorial disease with known genetic risk 
factors such as mutations in BMPR2 coupled with possible genetic risk factors (5-HTT+ 
polymorphisms) interacting with one or several of the physiological and exogenous 
modifying factors outlined in the previous sections. The aim of this thesis is to investigate 
modifying factors that may interact with genetic predisposition to trigger the phenotypic 
changes associated with PAH. This will involve a combination of in vivo, in vitro 
pharmacological and biochemical/histological techniques. Transgenic (TG) mice 
overexpressing the 5-HTT (5-HTT+), deficient in BMPR2 (BMPR2+/-) or a double (cross) 
transgenic 5-HTT+/BMPR2+/- (Cross TG) will be employed in addition to mice lacking 
peripheral 5-HT (Tph1-/-).   Additional modifying factors assessed in these transgenic 
models were: 
• Hypoxia 
• Dfen and NDfen 
• 5-HT  
• BMP-2 
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• KCNQ channels 
• Gender 
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Chapter 2 
Mater ials and methods 
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2.1 Animals 
All animals were bred in the Central Research Facility, University of Glasgow and when 
required for experimental use, were housed in a holding room with a controlled 
environment: temperature (21 C), humidity (60%) and regular cycling of filtered air. A 12 
hour light/dark cycle was maintained. Animals were kept in cages with a suitable supply of 
water and diet and checked daily. All experiments were conducted under a HO Project 
Licence number 60/3773 granted to Prof M MacLean. 
 
2.1.1 W T mice 
WT mice were C57BL/6 strain. 
 
2.1.2 The 5-H T T+ mouse 
5-HTT+ mice were donated to Prof M MacLean by Prof A Harmar, Edinburgh University. 
The C57BL/6xCBA WT strain was employed to generate the 5-HTT+ mouse. The 
transgene was a 500-kb yeast artificial chromosome (YAC35D8) containing the h5-HTT 
gene  flanked  by  150  kb  of  5’  and  300  kb  of  3’  sequence with  the  short  allele  of  the  5-
HTTLPR in the promoter region and the 10-repeat allele of the variable-number tandem 
repeat (VNTR) in intron 2 (Shen et al., 2000a). YAC35D8 was modified to include a 
hemagglutinin epitope tag at the C-terminus of the 5-HTT protein and a lacZ promoter 
gene downstream of an internal ribosomal entry site as described previously (Shen et al., 
2000b). The phenotype was verified by RT-PCR by Mrs Lynn Loughlin in Prof MacLean’s 
laboratory. 
 
2.1.3 The B MPR2+/- mouse 
The BMPR2+/- mice were donated to Prof M MacLean by Prof N Morrell, University of 
Cambridge. 
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The C57BL/6 WT strain was employed to generate the BMPR2+/- mouse. A replacement 
gene targeting vector was constructed with exons 4 and 5 (which encode the entire 
transmembrane domain and the amino-terminal region of the kinase domain respectively) 
deleted and replaced by a cassette of SE IRED/LacZ/loxP/pgk neo/loxP. The targeting 
vector was transfected into embryonic stem cells by electroporation. Positive recombinant 
clones were injected into blastocysts from C57BL/6 mice. These chimeric mice were then 
bred with C57BL/6 females and offspring analysed for presence of the BMPR2 mutation 
by southern blotting. Mice positive for the BMPR2 mutation were BMPR2+/- (Beppu et al., 
2000). The phenotype was verified by RT-PCR by Mrs Lynn Loughlin in Prof MacLean’s 
laboratory. 
 
2.1.4 The 5-H T T+ x B MPR2+/- mouse 
5-HTT+ and BMPR2+/- mice were bred together (usually 1 male to 2 females) to produce a 
double (cross) TG strain that are 5-HTT+/BMPR2+/- and will be referred to in this thesis as 
Cross TG mice. This cross breeding was carried out under the supervison of Dr Yvonne 
Dempsie and Dr Ian Morecroft and the phenotype verified by Mrs Lynn Loughlin in Prof 
MacLean’s laboratory. 
 
2.1.5 The Tph1-/- mouse 
Tph1-/- mice were donated by Prof M Bader, Max-Delbrück-Center for Molecular 
Medicine Berlin-Buch, Germany. 
The C57BL/6 WT strain was employed to generate the Tph1-/- mouse. A 1 kb (short arm) 
and 5.2 kb (long arm) fragment were used to construct a targeting vector containing a 
neomycin-resistance cassette and a thymidine kinase cassette. The construct was 
transfected in embryonic stem cells by electroporation. Positive recombinant clones were 
injected into blastocysts from C57BL/6 mice. These chimeric mice were then bred with 
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C57BL/6 females and offspring analysed for presence of the targeted Tph1 mutation by 
southern blotting. Mating of the resulting Tph1+/- mice generated Tph1-/- mice (Walther et 
al., 2003).  
 
2.1.6 Animal weights 
2-3 months mice: 15-40 grams 
5-6 months mice: 25- 50 grams 
 
2.2 Hypoxic model of PA H 
As covered extensively during the preceding chapter, hypoxia is one of two principal 
methods commonly used to induce PAH in animals.  For the purposes of this investigation 
hypoxia involved housing mice in an atmosphere of approximately 10% O2 for a period of 
14 days. To achieve hypoxia, mice were kept in a hypobaric chamber. The chamber is built 
from perspex with a removable door.  Caged mice were placed into the hypobaric chamber 
and a pump activated that continuously removes air at a constant rate. The chamber door is 
sealed by the pressure gradient between the chamber and outside environment which is 
created by a small controllable inlet valve on the door that controls air flow into the 
chamber. By opening and closing the valve, chamber pressure can be raised and lowered 
respectively. As the atmospheric pressure of the chamber decreases, the partial pressure of 
the chamber gases decreases and so controlling chamber pressure allows the control of O2 
concentration. The chamber pressure was lowered by 50 mbar per hour over two days to 
550 mbar at which point, the O2 concentration is ~ 10%. The chamber was in an animal 
holding room which was continuously ventilated with room air at 45 L per minute to 
prevent accumulation of CO2 and to maintain low humidity. Chamber temperature was 
monitored by two thermometers, one inside the chamber and one resting on the outside of 
the chamber. Internal chamber temperature was within 2 C of the outside temperature 
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which was maintained at approximately 21 C. Chamber conditions and status of mice were 
checked daily and information logged.  The chamber was briefly recompressed every 3 
days to clean cages and replenish food and water.  
 
2.3 In vivo haemodynamic measurements 
Anaesthesia of mice was induced by 3% isoflurane in O2 and body weight measured. Mice 
were then placed in a supine position with limbs secured by tape. Anaesthesia was 
maintained by 1 – 1.5% isoflurane in O2 supplied via a face mask. Sufficient level of 
anaesthesia was determined by absence of hind limb and tail reflex.  
 A small area of fur and skin was removed over the sternum in preparation for 
transdiaphragmatic cardiac puncture that would allow recording of RVP. Right ventricular 
haemodynamic function is the most critical factor in determining survival in patients with 
PAH (D’alonzo et al., 1991) and elevated RVP has been used extensively as an index of 
PAH (Eddahibi et al., 2000; Launay et al., 2002; Maclean et al., 2004).  These reasons 
coupled with the relative simplicity of measuring RVP through cardiac puncture compared 
with measuring PAP led to RVP being the haemodynamic measurement of choice in this 
thesis.  The procedure employs a polypropylene hypodermic needle (25 gauge) attached to 
a an E751A pressure transducer (Elcomatic, Glasgow, UK) which is mounted onto a 
micromanipulator (Stoelting Co., Wood Dale, IL). The needle and transducer are filled 
with 0.9% saline solution containing heparin (25 units/ml) (LEO Pharma Inc, Princes 
Risborough, UK). The tip of the needle was aligned with the mid point of the sternum and 
then adjusted approximately 2 mm to the right. The needle was advanced under the rib 
cage, through the diaphragm and into the right ventricle (RV). Entry of the needle into the 
RV was confirmed by the waveform trace on the computer screen. 
 Systemic arterial pressure (SAP) was measured by carotid artery cannulation. A small area 
of fur was removed at the top of the thorax and blunt dissection was used to expose and 
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isolate the right carotid artery. Surgical thread was used to tie off the distal end of the 
artery. A small clip was placed over the proximal end of the artery to prevent blood loss 
following arterial incision. The incision was made towards the distal end of the artery and a 
cannula (0.75 mm OD, Portex) was advanced in the proximal direction. A second piece of 
thread was used to tie around the cannula and artery and the arterial clip removed to allow 
blood flow into the vessel. Both SAP and RVP were recorded by a MP100 data acquisition 
system (BIOPAC Systems Inc, Santa Barbra, CA) and relayed to a computer. Following 
completion of the haemodynamic measurements, the animal was euthanised by 5% 
isoflurane in O2 followed by cervical dislocation. The thorax was opened and hearts and 
lungs from each animal were removed and placed in ice cold Krebs solution (Composition 
(mM): NaCL 118, NaHCO3 25, D-glucose 11, KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4 1.2 
(pH7.4)) for further analysis.   
 
2.3.1 Data analysis of in vivo data 
Results were analysed using the Acquiknowledge 3.7 software package (BIOPAC Systems 
Inc, Santa Barbra, CA). A minimum of 5 minutes telemetry data was acquired per animal 
for both RVP and SAP. Figure 2.1 displays a sample screenshot of approximately 15 
seconds of telemetry data. Data acquisition involved the analysis of data in three separate 
10 second segments spread over the 5 minutes of telemetry. The highlighted area in figure 
2.1 represents one of these 10 second segments.  The top half of the screen displays RVP 
and the bottom SAP. Systolic RVP (sRVP) was calculated by recording the value of 4 
peaks during systole in each of the three 10 second segments giving 12 values in total 
which were averaged to give the final sRVP value. Mean RVP (mRVP) was taken from the 
automatic calculation, provided by the software, for each three segments and then averaged  
to give the final mRVP. Heart rate (HR) was calculated by highlighting 10 systolic peaks 
within the 10 second segment and recording the time in seconds for 10 systolic peaks 
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F igure 2.1 Sample of R VP and SAP telemetry trace. 
RVP is displayed in red and SAP in blue. Highlighted segment is approximately 10 
seconds of data. Three of these segments taken during 5 minutes of data recording were 
used to derive sRVP, mRVP, mSAP and HR. 
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(beats) to occur. By dividing 60 (seconds) by this value and multiplying by 10 gives the 
HR in beats per minute. This was repeated for the two additional segments and averaged to 
give the final HR.  mSAP was recorded in the same manner as mRVP. 
 
2.4 Measurement of r ight ventr icular hypertrophy 
Adipose and connective tissue were carefully removed from around the heart and lungs 
and hearts separated from the lungs. Atria and large calibre blood vessels were dissected 
from the rest of the heart. The RV free wall was then dissected away from the left ventricle 
(LV) and septum. The LV + septum along with the RV were blotted dry and weighed 
separately. The ratio of RV/(LV+S) was used as an index of RVH.  
 
2.5 Lung H istology 
One sagittal section was obtained from either the left or right lungs. Sections were paraffin 
wax fixed and stained with Elastica-Van Gieson stain (by Mrs M Nilsen in Prof MacLean’s 
laboratory) and microscopically assessed for evidence of muscularisation of small 
pulmonary arteries (<80 µm diameter). Arteries were considered muscularised if they 
possessed a distinct double-elastic lamina visible around at least 70% of the vessel 
circumference. At least 150 vessels per section were counted. The percentage of 
muscularised (remodelled) vessels was calculated as the number of remodelled 
vessels/total number of vessels counted x 100. 
 
2.6 In vitro pharmacological studies 
2.6.1 Wire myography 
Myography is a technique for pharmacological investigation of small vessels and was first 
described by Bevan and Osher (1972) and developed in 1976 by Mulvany and Halpern, 
allowing analysis of contractile response in vessels with 100-400 µM internal diameter. 
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Vessels of this size are studied by wire myography, a relatively atraumatic technique 
providing accurate measurements of muscle contraction.  
 
2.6.1.1 Wire myography equipment 
For this study, the Mulvany/Harpern small vessel wire myograph (model 610M) was used; 
purchased from Danish Myo-technology Ltd, Aarhus, Denmark. The unit has four 
individual stainless steel organ chamber baths, each capable of holding one vessel. Each 
organ bath chamber contains two vessel support heads, one is attached to a highly sensitive 
isometric force transducer and the other to a metal support arm. The metal support arm is 
connected to a micropositioner which allows adjustment of the support arm and hence the 
distance between the two support heads. When a vessel is mounted in the chamber, the 
alteration in distance between support heads alters the tension applied to the vessel.  Each 
chamber has a moveable metal swing arm that enters the top of the chamber and has a dual 
function. The first is a pipe to control gas flow into the organ bath and the second is a 
suction pipe for removing fluid from the chamber. Myograph chamber temperature control 
(± 0.1 C) is maintained by electronic internal heating units. Temperature and force from 
each chamber are digitally displayed on the base unit. The myograph is connected to a 
computer and all information is recorded using Myodaq20 software (Danish Myo-
technology Ltd, Aarhus, Denmark) and analysed using Myodata (Danish Myo-technology 
Ltd, Aarhus, Denmark). 
 
2.6.1.2 Intralobar pulmonary artery dissection 
Lungs were obtained from freshly culled mice (intraperitoneal injection of 200 mg/kg 
sodium pentobarbitone (Euthatal) (Merial Ltd, Harlow, UK) or from mice following in 
vivo procedure. The larger left lung was separated from the rest of the lungs and fixed to a 
dissecting dish using pins. The lung was orientated with the parietal surface lying in an 
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inferior position. The tissue was regularly washed with ice cold Krebs during dissection to 
keep tissue hydrated.  Using a dissecting microscope (Zeiss), an incision was made at the 
opening of the airway, cutting down the airway length from the large proximal airway, 
along the bronchial tree to the distal bronchiole. Remaining bronchiole tissue lying directly 
above the intralobar pulmonary artery (IPA) was carefully removed exposing the 
underlying IPA. Surrounding connective tissue was dissected free and up to two 2 mm 
strips of IPA were cut from the lung attached IPA and placed into ice cold Krebs solution.  
 
2.6.1.3 Vessel mounting procedure 
Each myograph chamber was filled with 5mls of Krebs solution and bubbled with a gas 
mixture containing 16% O2/ 5% CO2 (balance N2). This mixture is set to mimic the arterial 
partial pressure of each gas in vivo. Gas was fed to each myograph chamber from a pre-
filled Douglas bag via an electronic Dymax 30 pump (Charles Austen Pumps Ltd, Byfleet, 
UK). 2 mm sections of IPA dissected previously were placed into a petri dish containing 
cold Krebs solution. A 40 µm steel wire was slowly advanced through the vessel lumen 
using two pairs of fine forceps, one pair holding the steel wire and the other gently holding 
the other end of the vessel. The wire and vessel were then placed into the myograph organ 
chamber and positioned between the two mounting head jaws.  The wire was secured in 
place by advancing the adjustable mounting head towards the other till there was sufficient 
pressure between the two sets of jaws to hold the wire in place. The vessel is situated in a 
space between the mounting head jaws. The steel wire was then secured at each end of the 
left mounting head (the head attached to the micropositioner) by wrapping each end of the 
wire around top and bottom screws which were tightened to create tension (figure 2.2A). 
The two mounting heads were then separated and another section of 40 µm steel wire 
inserted through the vessel lumen (figure 2.2B). The two heads were once again brought 
together until the second wire was securely fixed (figure 2.2C) and the wire secured 
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F igure 2.2 Mounting procedure for a vessel on a wire myograph. A 2mm section of 
IPA containing a steel wire through vessel lumen is secured between mounting jaws to 
mounting head (A). A second wire is threaded through vessel lumen (B) and attached to 
other mounting head (C-E). Mounting jaws are then separated slightly in preparation for 
normalisation.  
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in place around the two screws on the right  mounting head (the head attached to the force 
transducer) (figure 2.2D and E). The heads were then separated slightly (figure 2.2F) 
before the chamber was replaced back onto the myograph base unit and the heating unit 
initialised to maintain temperature at 37 C.  
 
2.6.1.4 Vessel normalisation 
Normalisation is a procedure for setting vessels to standard initial conditions to mimic, as 
closely as possible, the in vivo environment. This is achieved by setting an optimal 
transmural pressure that matches the in vivo transmural pressure of the vessel studied. The 
Laplace equation, which links the wall tension in a cylinder with its internal radius and 
transmural pressure, can be modified to convey the relationship between variables for a 
blood vessel on a myograph (equation 2.1). 
 
Equation 2.1)                    Pi =       T 
                                                       I C/2π 
 
Equation 2.1 Laplace equation for calculation of effective pressure in a cylinder 
Pi = effective pressure (the pressure required to extend vessel to the measured internal 
diameter,) T = wall tension, IC = internal circumference 
 
Wall tension is calculated from the following equation: 
 
Equation 2.2)                    T =  F  
                                                  2L 
 
Equation 2.2 Calculation of vessel wall tension 
T = wall tension, F = force, L = vessel wall length 
Each vessel has an upper and lower wall thus the equation requires vessel length to be 
multiplied by 2. 
The internal circumference is calculated from the micropositioner readings and by 
incorporating the size of diameter of each steel wire within the vessel lumen (40 m): 
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Equation 2.3)                 IC = (π + 2)d + 2 (Xi  - Xo) 
Equation 2.3 Calculation of vessel internal ci rcumference 
IC = internal circumference, d = diameter of wire, (Xi - Xo) = distance between the 40 m 
steel wires 
 
To calculate Xo, the two mounting head jaws are brought together until they gently touch 
causing a negative pressure trace on the computer screen. The reading is taken at this point 
from the reading on the micropositioner. Xi is the value recorded from the micropositioner 
at any given amount of stretch applied to the vessel by adjusting the distance between 
mounting jaws.  
Equation 2.1 can be rearranged to give: 
 
Equation 2.4)                   Pi = 2πT 
                                                   I C 
 
 
Equation 2.4 Rear ranged Laplace equation for calculation of effective pressure 
 
Using the value of IC calculated above, this can be used, together with the substituted 
values for wall tension to give the following equation: 
 
 
Equation 2.5)                   Pi =   2πF 
                                                   2L x I C 
 
Equation 2.5 Calculation of transmural pressure of vessel by its relationship to wall 
tension and internal ci rcumference 
 
                   
 
This equation allows the calculation of transmural pressure for a vessel. By adjusting the 
level of stretch on a vessel by small increments, pressure can be increased or decreased 
until the optimum physiological pressure is achieved which in mouse pulmonary  vessels is 
~15 mmHg. A range of 12-16 mmHg was considered acceptable.  
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2.6.1.5 General exper imental procedure 
Following mounting and normalisation, vessels were left to equilibrate for approximately 
30 minutes in Krebs solution (37ºC; 16% O2/ 5% CO2 (balance N2) gas mixture infused). A 
final bath concentration (FBC) of 50 mM potassium chloride (KCl) was added to each 
chamber to stimulate vessels and to assess their viability. Once contractile response was 
maximal and stable, the vessels were washed 6-8 times with fresh Krebs solution and left 
to return to baseline tension. The KCl procedure was then repeated and this contractile 
response was used as a reference response. Further experiment specific details can be 
found in the methods section of individual results chapters. 
 
2.6.1.6 Data analysis of pharmacological studies 
The output from the myograph was recorded on a computer using Myodaq20 software 
(Danish Myo-technology Ltd, Aarhus, Denmark) and analysis of the data performed using 
Myodata software (Danish Myo-technology Ltd, Aarhus, Denmark). When data produced 
sigmoidal concentration-response curves, analysis of the data was performed by fitting the 
data with a Hill equation model using Graphpad Prism 4 (GraphPad Software Inc, CA, 
USA) This provided values for pEC50 (a measure of drug potency) and Emax (the 
maximum response induced by a drug). The Hill equation also provides a value derived 
from the steepness of the slope of the curve. This is called the slope function or Hill 
coefficient. The Hill coefficient was found to be generally uniform across experiments. In 
those instances where significant differences were observed, these are stated in the results 
section.  Where concentration-response curves clearly did not follow the classical 
sigmoidal shape or where maximal contractile response was not achieved at concentrations 
tested, the contractile response at each concentration tested was measured and analysed for 
intergroup differences.  
For all the above measurements, individual concentration-response curves were 
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constructed for each experimental group and mean ± SEM calculated for each group of 
vessels. 
 
2.7 Biochemical analysis 
2.7.1 Preparation of tissue  
2.7.1.1 W T and T ph1-/- male mice (for p-E R K1/2 and p-Smad1/5/8 analysis) 
Each mouse was killed by intraperitoneal injection of 200 mg/kg Euthatal and heart and 
lungs immediately dissected out and placed in ice cold Krebs solution. Heart and lungs 
were fixed with pins to a dissecting dish and washed regularly with ice cold Krebs. 
Adipose and connective tissue were dissected from around the heart and lungs to expose 
the main pulmonary artery. The main pulmonary artery was cut at the entry point to the 
heart and at the entry point of both the left and right lung. The artery was then transferred 
into several drops of ice cold Krebs on a petri dish. The lungs were placed into a beaker of 
ice cold Krebs and the heart and remaining tissue discarded. Once in the petri dish, the 
main artery was cut into small pieces using dissection scissors before being transferred into 
a small plastic dish containing lysis buffer (20 mM Tris (Fisher Scientific, Loughborough, 
UK), 1 mM dithiothreitol (Melford Laboratories Ltd, Ipswich, UK) and a Complete, Mini, 
EDTA-free serine/cysteine protease inhibitor (Roche Applied Science, Burgess Hill, UK)). 
The IPA from the left lung was then dissected out as described previously, placed into a 
few drops of Krebs on a petri dish, cut into small segments and placed into the ice cold 
lysis buffer. The IPA from the right lung was processed in a similar manner. This process 
was completed for 24 WT animals and 24 Tph1-/- animals so that there were 3 groups of 8 
animals for each genotype.  Each group contained IPAs + main pulmonary arteries in 200 
l of lysis buffer. The lysis buffer + tissue samples were transferred into 12 x 75 mm 
culture tubes (WWR International, Lutterworth, UK) and homogenised using a Miccra-D1 
homogeniser (ART Moderne Labortechnik, Mulheim, Germany) for 30 seconds. Samples 
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 were then placed in ice cold sealed eppendorf tubes and stored at - 80 C. 
 
2.7.1.2 W T and T ph1-/- male mice (for B MPR2 analysis) 
Procedure as above except lysis buffer was composed of 125 mM Tris, 10% glycerol 
(Riedel-de Haen, Seelze, Germany), 2% Sodium dodecyl sulphate (SDS) (Fisher Scientific, 
Loughborough, UK) and Complete, Mini, EDTA-free serine/cysteine protease inhibitor. 
Experiment utilised 3 groups of 4 animals for each genotype.  Quantity of lysis buffer used 
was reduced proportionally. 
 
2.7.1.3 Male and female W T mice (for p-E R K1/2, p-p38 and p-Smad1/5/8 analysis) 
Each mouse was killed by intraperitoneal injection of 200 mg/kg of Euthatal and heart and 
lungs immediately dissected out and placed in ice cold Krebs solution. Heart and lungs 
were placed into a petri dish containing a small quantity of cold Krebs solution. The left 
lung alone would yield sufficient tissue for analysis (personal communication, Lynn 
Loughlin). The left lung was dissected free of the remaining heart and lung tissue and 
placed onto a separate petri dish containing a small quantity of cold Krebs. The left lung 
was cut into small pieces using scissors and transferred into 250 l of lysis buffer (20 mM 
Tris, 1 mM dithiothreitol and a Complete, Mini, EDTA-free serine/cysteine protease 
inhibitor). The lysis buffer + left lobe was transferred into a 12 x 75 mm culture tube and 
homogenised for 30 seconds. Sample was placed into an ice cold sealed eppendorf tube 
and stored at -80 C. This process was repeated to give a total of 6 male and 6 female tissue 
samples.  
 
2.7.2 Preparation of samples and running of acrylamide gel 
It was not possible to determine protein concentration of tissue samples using the Bradford 
assay. Protein concentration was found to be below the level of detection. Subsequently the 
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plate reader was found to be malfunctioning and further attempts to obtain protein 
concentration were not possible.  It was deemed sufficient to use GAPDH and α – tubulin 
as loading controls to which western results could be normalised to. The volume of tissue 
sample + lysis buffer and sample buffer used in the experiments outlined below have 
previously been shown to be appropriate for reliable detection of proteins (personal 
communication, Lynn Loughlin). 
 Tissue samples were removed from -80 C freezer and kept on ice (0 C). To pre-cooled, 
labelled, top-pierced eppendorf tubes 8 l (for experiments performed in the smaller 
volume 12 well polyacrylamide gels) or 10 l (for experiments performed in the larger 
volume 10 well polyacrylamide gels) of Nupage 4x LDS sample buffer (Invitrogen, 
Paisley, UK) was added followed by 3 l of Nupage (10x) sample reducing agent 
(Invitrogen, Paisley, UK). Finally, protein samples were added to the eppendorf tubes so 
that protein sample and sample buffer were in a 1:1 ratio. Samples were then placed in a 
heating block (Grant Instruments, Cambridge, UK) pre-heated to 70 C for 10 minutes 
before being centrifuged (Biofuge 15 centrifuge, Heraeus Sepatech GmbH, Osterode, 
Germany) at 10,000 rpm for 60 seconds. Samples were then placed back on ice in 
preparation for gel loading. Running buffer containing 5% NuPage MOPS SDS running 
buffer (20x) (Invitrogen, Paisley, UK) and 95% water was prepared. 200 mls of buffer was 
placed into a separate beaker and 500 l of antioxidant (Invitrogen, Paisley, UK) added. 
 The electrophoresis cell (X Cell, Novex, San Diego, CA) was prepared according to the 
manufacturer’s instructions and contained either 1 or 2 10 well or 12 well Nupage 10-12% 
Bis-Tris polyacrylamide gels (Invitrogen, Paisley, UK) depending on experimental 
requirements. Gels were removed from their protective packaging and briefly rinsed with 
cold water. The casting comb was gently removed and wells washed with running buffer + 
antioxidant before being placed into the cell. The outer chamber of the cell contained the 
running buffer and the inner chamber containing the gels contained running buffer + 
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antioxidant. Using long gel loading pipette tips 10 l of SeeBlue® Plus2 prestained 
standard (1x) (Invitrogen, Paisley, UK) followed by 19 l (12 well gels) or 23 l (10 well 
gels) of tissue sample/sample buffer/reducing agent was loaded to the gel. The lid was 
placed over the cell electrodes and attached to an E861 electrophoresis power supply 
(Consort, Belgium). The gel was run at 150 volts until the dye had reached the bottom of 
the gel. This process usually required 1 – 1½ hours.  
 
2.7.3 Protein transfer  
This protocol is for experiments using 2 gels in one cell. 
In preparation for protein transfer from gel to transfer membrane, 4 sheets of  3mm 
Whatman filter paper (Whatman plc, Maidstone, UK) and 6 foam sponges were pre-soaked 
in transfer buffer (750 mls distilled water, 50 mls Nupage transfer buffer (20x), 200 mls 
methanol (Riedel-de Haen, Seelze, Germany) and 1ml Nupage antioxidant). Two 8cm x 8 
cm sections of Immobilon-P polyvinylidene difluoride (PVDF) Transfer Membrane 
(Sigma-Aldrich, Poole, UK) were cut and activated by immersion in methanol for 1 minute 
before being transferred into the transfer buffer. In an X Cell II transfer module (Novex, 
San Diego, CA) 2 soaked sponges were placed. Gel 1 was removed from its plastic casing 
and placed onto a sheet of Whatman paper with the PVDF membrane placed on the other 
side of the gel and placed face up into the cassette. A second sheet of Whatman paper was 
placed over the PVDF membrane, followed by 2 more sponges. Gel 2 was then removed 
from its casing and orientated on top of the sponges in the same manner as Gel 1. To 
complete the setup two final sponges were placed over the final piece of Whatman paper 
on top of the second PVDF membrane and the module lid was fitted in place and the entire 
transfer module placed into the electrophoresis cell. Both the inner and outer chambers of 
the cell were filled with transfer buffer. The lid was fitted and the gels run at 30 volts for 1 
hour.  
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2.7.4 Blocking of PV D F membrane  
Tris buffered saline (TBS) solution was prepared from a TBS stock (0.2 M Tris, 1.37 M 
sodium chloride (Riedel-de Haen, Seelze, Germany) in 5 litres of distilled water). The TBS 
stock solution was diluted 1:10 with distilled water and the pH adjusted to 7.6 using 
concentrated 37% hydrochloride acid (Riedel-de Haen, Seelze, Germany). Tween (Sigma-
Aldrich, Poole, UK) was added at 0.1% giving a Tween-TBS solution (TBST) that would 
be used as a buffer for washing the PVDF membrane.  
Following protein transfer, the gels were safely disposed of and the PVDF membranes 
were washed in TBST for 5 minutes before blocking of unoccupied protein binding sites in 
5% skimmed milk powder (Marvel, Premier Brands, Spalding, UK) in TBST for 1 hour at 
room temperature under gentle rocking. Membranes were then washed (3 x 15 minutes) in 
TBST. 
 
2.7.5 Detection 
After blocking, primary antibody was added at the appropriate dilution and in the 
appropriate dilutent (table 2.1). The incubation was carried out overnight at 4 C under 
moderate agitation. Membranes were then washed (3 x 15 minutes) in TBST before being 
incubated with the appropriate secondary antibody (table 2.1) diluted in 5% Marvel at 
room temperature for 1 hour under gentle rocking. Membranes then had a final round of 
TBST washing (3 x 15 minutes) before being immersed and shaken gently for 1 minute in 
ECL Western Blotting chemoluminescent substrate (Pierce, Rockford, IL). Membranes 
were then placed in a hypercassette (Amersham International plc, Little Chalfont, UK) and 
in a dark room were exposed to x-ray film (Kodak, Hemel Hempstead, UK) for ~1-5 s (α- 
Tubulin), ~5-60 s (GAPDH), ~10-60 s (p-ERK1/2) and ~5-30 mins (p-p38 and BMPR2) 
before being developed by a Kodak X-omat imaging machine. 
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2.7.6 Data analysis of western blots 
For WT and Tph1-/- comparison experiments (p-ERK1/2 and p-Smad1/58) there were three 
lots of samples for each genotype, each containing IPAs and main pulmonary arteries from 
8 mice. Each of these samples was run 4 times giving a total of 12. For WT and Tph1-/- 
comparison experiments (BMPR2) there were 3 lots of samples for each genotype, each 
containing IPAs and main pulmonary arteries from 4 mice. Each of these samples was run 
3 times giving a total of 9. Not all results were useable, however, due to poor detection of 
protein bands or too high a background signal. This is reflected in the n numbers for 
experiments being lower than 12 and 9 for respective experiments. For male and female 
comparison experiments whole lung was used for efficiency, yielding a greater volume of 
tissue for analysis. In these experiments there were 6 males and 6 females, each run on 
separate lanes in the one experiment yielding an n of 6 of each gender. Densitometric 
analysis of films following exposure was performed to determine the normalised level of 
protein expression using TotalLab version 2 (TotalLab Ltd, Newcastle, UK). 
 
2.8 Statistical analysis 
When  comparing  two  groups  of  data,  a  Student’s  unpaired  two-tailed t-test was used. 
When comparing three or more groups of data, analysis of variance (ANOVA) was used. 
ANOVA was either one-way (when comparing one variable) or two-way (when comparing 
two variables). Newman-Keuls multiple comparison post test was applied to investigate 
statistical differences following one-way ANOVA and Bonferroni multiple comparison 
post test was applied to investigate statistical differences following two-way ANOVA.  
P<0.05 was deemed to indicate statistical significance. All statistics were calculated using 
GraphPad Prism 4. 
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1  Antibody 
 
Company 
 
 Dilution 
 
Dilutent 
 
2  Antibody 
 
Company 
 
Dilution 
Phospho-
ERK1/2 
Cell Signalling 
Technology Inc, 
Beverly, MA 
 
1:1000 TBST/BS
A* 
Anti-rabbit 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:1500 
Phospho-p38 Cell Signalling 
Technology Inc, 
Beverly, MA 
 
1:500 TBST/BS
A* 
Anti-rabbit 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:1500 
Phospho-
Smad 1/5/8 
Millipore (UK) 
Ltd, Croxley, UK 
1:1000 TBST/BS
A* 
Anti-rabbit 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:1500 
BMPR2 BD Biosciences, 
Oxford, UK 
1:500 5% 
marvel 
Anti-mouse 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:3000 
 - Tubulin Abcam Ltd, 
Cambridge, UK 
1:5000 5% 
marvel 
Anti-mouse 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:5000 
GAPDH Abcam Ltd, 
Cambridge, UK 
1:20000 5% 
marvel 
Anti-mouse 
IgG 
Sigma-
Aldrich Ltd, 
Poole, UK 
1:5000 
* 1.5 mls TBST + 1.5 mls (10% bovine serum albumin (BSA) made in TBST) 
 
Table 2.1 Primary and secondary antibodies used for Western blotting. 
p-Smad1/5/8 and BMPRR2 1º and 2º dilutions were pre-determined by a series of 
optimisation experiments until distinct protein bands were observed against a clear 
background. p-ERK1/2, p-p38,  α-tubulin and GAPDH optimal dilutions had been 
experimentally derived previously (personal communication, Yvonne Dempsie).  
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Chapter 3 
E ffect of hypoxia on transgenic mice 
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3.1 Introduction 
Genetic manipulation of mice has provided a vast amount of information for the study of 
human disease and many genes implicated in PAH have been altered in mice to assess 
what, if any, role they may have in the pathogenesis of PAH. As discussed previously, 
these include NOS (Fagan et al., 1999; Ozaki et al., 2001), PGI2-S (Geraci et al., 1999), 
adrenomedullin (Matsui et al., 2004), VIP (Said et al., 2007) and K+ channels (Archer et 
al., 2001; Pozeg et al., 2003). Of importance to this investigation has been the development 
of BMPR2+/- mice and 5-HTT+ mice.  The BMPR2+/- mouse developed by Beppu et al., 
2000 that is used in this investigation and another BMPR2 deficient heterozygous mouse 
line (carrying an in-frame deletion of exon 2 resulting in the loss of the extracellular ligand 
binding domain) (Delot et al., 2003) both may mimic the heterozygous loss of BMPR2 
function associated with PAH and hence provide a suitable genetic model for studying the 
disease. Results from the BMPR2+/- mouse used in this investigation to date have been 
inconclusive with an early study indicating a mild pulmonary hypertensive phenotype in 
normal air (Beppu et al., 2004) but a later study by a different group finding no evidence of 
PAH under normoxia (Long et al., 2006).  There have also been some discrepancies in data 
between Beppu et al., 2004 and Long et al., 2006 derived from BMPR2+/- mice following 
exposure to hypoxia. Neither of these studies, however, found a greater susceptibility to 
hypoxic PAH in BMPR2+/- mice compared with WT.  
 Given the conflicting results obtained so far with this BMPR2+/- mouse and the 
importance that both BMPR2 deficiency and hypoxia have in PAH, there is a need for 
greater characterisation of the BMPR2+/- mouse phenotype under both normoxia and 
hypoxia and this investigation will continue the analysis of these mice for susceptibility to 
PAH. The normoxic 5-HTT+ mouse has increased PAP and under hypoxia, has elevated 
PAP, vascular remodelling and RVH compared with WT mice (MacLean et al., 2004). 
This investigation will analyse the 5-HTT+ mice again for evidence of PAH. 
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The limited animal data gathered so far on the BMPR2+/- mouse does not suggest a strong 
association with a pulmonary hypertensive phenotype in either normoxia or hypoxia. The 
human and animal data outlined previously supporting a modulating role for the 5-HTT in 
the development of PAH created the rationale of developing a mouse model that was 
BMPR2+/- and 5-HTT+, mimicking a human with BMPR2 mutation and who had the L/L 
genotype for the 5-HTT. This model would allow assessment of whether the two genetic 
factors act synergistically to increase the risk of PAH under normoxia or under challenge 
from an environmental stimulus, in this case hypoxia.  
 One important aspect that has to be taken into account when interpreting the in vivo results 
just outlined in relation to the BMPR2+/- and 5-HTT+ mice is the role that gender plays in 
determining the phenotypic outcome. Beppu et al., 2004 used both males and females with 
the majority being females and found no gender differences in results. Long et al., 2006 
used exclusively males. The 5-HTT+ mice used by MacLean et al., 2004 were exclusively 
females. In this study, both male and female WT, 5-HTT+, BMPR2+/- and Cross TG mice 
will be assessed allowing the interaction of gender with genetic predisposition to be 
determined. 
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3.2 R ESU L TS 
All mice were age 5-6 months. 
 
3.2.1 Pulmonary and systemic haemodynamics in male mice 
sRVP and mRVP were assessed in male mice under both normoxic and hypoxic 
conditions. The results are shown in figure 3.1. WT mice had higher sRVP than Cross TG 
mice under normoxia (WT: 25.6 ± 0.9 mmHg, n=5, Cross TG: 15.8 ± 1.0 mmHg, n=6) and 
5-HTT+ mice had significantly higher sRVP (23.5 ± 2.4 mmHg, n=5) than Cross TG 
normoxic animals (5-HTT+: 23.5 ± 2.4 mmHg, n=5, Cross TG: 15.8 ± 1.0 mmHg, n=6). 
Inter-group differences were also observed for sRVP in hypoxic mice. WT mice (38.4 ± 
2.2 mmHg, n=6) had significantly higher sRVP than both BMPR2+/- (15.1 ± 1.0 mmHg, 
n=5) and Cross TG (25.3 ± 2.2 mmHg, n=6) mice. 5-HTT+ hypoxic mice had similar 
sRVP (39.2 ± 1.5 mmHg, n=8) to WT mice which was greater than the sRVP recorded in 
BMPR2+/- and Cross TG animals. No significant inter-group differences in mRVP were 
found for either normoxic or hypoxic animals. 
 Hypoxia caused a significant rise in sRVP in WT, 5-HTT+ and Cross TG mice (WT: 
p<0.001, 5-HTT+: p<0.001, Cross TG: p<0.01) but not in BMPR2+/- mice (figure 3.1A). 
Similar results were obtained for mRVP with hypoxia causing a significant increase in 
mRVP in WT (p<0.001), 5-HTT+ (p<0.001) and Cross TG (p<0.05) mice (figure 3.1B). 
 No inter-group differences were observed for either mSAP or HR and these parameters 
were not significantly altered by hypoxia (figure 3.2) 
 
3.2.2 Pulmonary and systemic haemodynamics in female mice 
The results are shown in figure 3.3. In normoxic conditions, unlike male mice, 5-HTT+ 
female mice had higher sRVP than both WT and BMPR2+/- (5-HTT+: 29.0 ± 3.4 mmHg, 
n=6, WT: 15.9 ± 2.1 mmHg, n=4, BMPR2+/-: 16.8 ± 3.2, n=4) mice. No inter-group 
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differences were observed in hypoxic animals. The only significant difference in mRVP 
was between normoxic 5-HTT+ and WT with the 5-HTT+ group having the higher 
pressure (5-HTT+: 19.8 ± 3.1 mmHg, n=6, WT: 8.3 ± 1.9, n=4).  
 Hypoxia increased sRVP in WT (p<0.01), BMPR2+/- (p<0.05) and Cross TG (p<0.05) 
mice (figure 3.3A) and mRVP was increased in WT (p<0.01), 5-HTT+ (p<0.05) and Cross 
TG (p<0.05) mice (figure 3.3B). 
 No significant differences were observed in mSAP under normoxia. Under hypoxia, 5-
HTT+ mice had elevated mSAP compared with the other three groups (5-HTT+: 99.0 ± 3.6 
mmHg, n=6, WT: 84.5 ± 2.2 mmHg, n=6, BMPR2+/-: 75.1 ± 3.8 mmHg, n=4, Cross TG: 
83.1 ± 4.9 mmHg, n=4). Hypoxia only affected mSAP in BMPR2+/- mice where it caused a 
decrease in pressure (p<0.05) (figure 3.4A). 
 HR was similar amongst groups under normoxia (figure 3.4B). Under hypoxia, however, 
BMPR2+/- mice had significantly lower HR compared with the other groups (BMPR2+/-: 
297.8 ± 4.4 bpm, n=9, WT: 438.0 ± 12.6 bpm, n=9, 5-HTT+: 445.2 ± 18.3 bpm, n=9, 
Cross TG: 409.0 ± 43.7 bpm, n=4). Similar to the mSAP results, hypoxia caused a decrease 
in HR in BMPR2+/- mice (p<0.05) while the other groups were unchanged. 
 
3.2.3 Right ventr icular hypertrophy and vascular remodelling in male mice 
RVH and vascular remodelling data are presented in figure 3.5. There were no inter-group 
differences in RVH in either normoxic or hypoxic conditions. Hypoxia significantly 
increased RVH in BMPR2+/- (p<0.01) and Cross TG (p<0.01) mice. Remodelling was 
similar between groups in both normoxia and hypoxia. When comparing normoxic and 
hypoxic groups, there was a greater than 5 fold difference in each of the 4 genotype 
(p<0.001 for each group except BMPR2+/- where significance was p<0.01) groups.  
 
 
93 
 
0
10
20
30
40
50
WT
5-HTT+
BMPR2+/-
Cross TG
Normoxic                Hypoxic
**
***
*
***
††† †††
††
   Male
Sy
sto
lic
 R
VP
 (m
m
Hg
)
 
A 
 
 
0
5
10
15
20
25
WT
5-HTT+
BMPR2+/-
Cross TG
Normoxic                Hypoxic
††† †††
†
M
ea
n
 R
VP
 (m
m
Hg
)
 
B 
 
 
F igure 3.1 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2+/- and Cross TG male mice 
(n=4 to 8 mice per group) on sRVP (A) and mRVP (B). Results expressed as mean ± SEM. 
* p<0.05, ** p<0.01, *** p<0.001 using Newman-Keuls multiple comparison test. † 
p<0.05, †† p<0.01, ††† p<0.001 versus corresponding normoxic value using an unpaired 
two-tailed t-test.  
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F igure 3.2 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2+/- and Cross TG male mice 
(n=2 to 8 mice per group) on mSAP (A) and HR (B). Results expressed as mean ± SEM. 
Newman-Keuls multiple comparison test of inter-genotype differences and an unpaired 
two-tailed t-test comparison of normoxic and hypoxic groups revealed no significant 
differences.  
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F igure 3.3 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2+/- and Cross TG female 
mice (n=4 to 6 mice per group) on sRVP (A) and mRVP (B). Results expressed as mean ± 
SEM. * p<0.05 using Newman-Keuls multiple comparison test. † p<0.05, ††  p<0.01 
versus corresponding normoxic value using an unpaired two-tailed t-test. 
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F igure 3.4 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2+/- and Cross TG female 
mice (n=2 to 9 mice per group) on mSAP (A) and HR (B). Results expressed as mean ± 
SEM. * p<0.05, ** p<0.01, *** p<0.001 using Newman-Keuls multiple comparison test. † 
p<0.05 versus corresponding normoxic value using an unpaired two-tailed t-test. 
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3.2.4 Right ventr icular hypertrophy and vascular remodelling in female mice 
RVH and remodelling data for female mice are presented in figure 3.6. No significant 
differences were noted for RVH between groups under normoxia. Under hypoxia, 5-HTT+ 
mice had a higher degree of RVH compared with WT and Cross TG (WT: 0.35 ± 0.01, 
n=19, 5-HTT+: 0.39 ± 0.01, n=18, Cross TG: 0.33 ± 0.02, n=7) mice. Hypoxia increased 
RVH in WT (p<0.001), 5-HTT+ (p<0.001), BMPR2+/- (p<0.001) and Cross TG (p<0.05) 
mice. 5-HTT+ normoxic mice had more remodelled vessels than WT and BMPR2+/- (WT: 
3.3 ± 0.6%, n=4, 5-HTT+: 8.2 ± 1.2%, n=4, BMPR2+/-: 3.7 ± 0.7%, n=4) mice. There was 
considerable inter-group variability in remodelling in the hypoxic animals. 5-HTT+ mice 
had more remodelled vessels than WT and BMPR2+/- mice had more remodelled vessels 
than WT and 5-HTT+ mice. Cross TG mice had a similar level of remodelling to the 
BMPR2+/- mice and this value was significantly greater than WT and 5-HTT+ mice (WT: 
18.3 ± 1.1%, n=10, 5-HTT+: 24.7 ± 1.5%, n=10, BMPR2+/-: 36.3 ± 5.0%, n=4, Cross TG: 
35.4 ± 2.2%, n=4).  Hypoxia increased remodelling in all groups (p<0.001) compared with 
respective normoxic animals.  
 
3.2.5 Gender differences 
To determine if any gender differences existed, male vs female results were plotted for 
sRVP, mRVP, mSAP, HR, RVH and vascular remodelling (figures 3.7 to 3.12). Under 
normoxic conditions, WT female mice had lower sRVP compared with WT males (male: 
25.6 ± 0.9 mmHg, n=5, female: 15.9 ± 2.1 mmHg, n=4) (figure 3.7). A similar difference 
was noted under hypoxia (male: 38.4 ± 2.2 mmHg, n=6, female: 28.5 ± 2.2 mmHg, n=5).  
Cross TG female mice had higher sRVP under normoxia compared to Cross TG males 
(male: 15.8 ± 1.0 mmHg, n=6, female: 23.3 ± 1.5 mmHg, n=5) and although female Cross 
TG mice had higher sSVP compared with males following hypoxia, it did not reach  
 
98 
 
0.0
0.1
0.2
0.3
0.4
WT
5-HTT+
BMPR2+/-
Cross  TG
Normoxic                Hypoxic
††
††
Ra
tio
 (R
V/
LV
+S
)
  Male
 
A 
 
     
0
5
10
15
20
25
30
35
Normoxic                Hypoxic
WT
5-HTT+
BMPR2+/-
Cross TG
††† †††
†††
††
%
 o
f v
es
se
ls
 re
m
od
el
le
d
 
B 
 
 
F igure 3.5 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2+/- and Cross TG male mice 
(n=4 to 8 mice per group) on RVH (A) and remodelling (B). Results expressed as mean ± 
SEM. Newman-Keuls multiple comparison test of inter-genotype differences revealed no 
significant differences. ††  p<0.01, †††  p<0.001 versus corresponding normoxic value 
using an unpaired two-tailed t-test. 
 
 
 
99 
 
                                                Female 
0.0
0.1
0.2
0.3
0.4
WT
5-HTT+
BMPR2+/-
Cross TG
Normoxic                Hypoxic
* *
†††
††† †††
†
Ra
tio
 (R
V/
LV
+S
)
 
A 
 
  
0
5
10
15
20
25
30
35
40
45
Normoxic                Hypoxic
*
***
***
WT
5-HTT+
BMPR2+/-
Cross TG
**
* *
**
†††
†††
†††
†††
%
 o
f v
es
se
ls
 re
m
od
el
le
d
 
B 
F igure 3.6 Effect of 14 days hypoxia in WT, 5-HTT+, BMPR2+/- and Cross TG female 
mice (n=4 to 19 mice per group) on RVH (A) and remodelling (B). Results expressed as 
mean ± SEM.  * p<0.05, ** p<0.01, *** p<0.001 using Newman-Keuls multiple 
comparison test. †††  p<0.001 versus corresponding normoxic value using an unpaired 
two-tailed t-test. 
 
100 
 
significance (figure 3.7). There was a significant difference, however, between BMPR2+/- 
male and female mice under hypoxia with female mice having higher pressures (male: 15.1 
± 1.0 mmHg, n=5, female: 29.5 ± 3.2 mmHg, n=5). No such difference between male and 
female BMPR2+/- mice was observed under normoxia. Mean RVP data is presented in 
figure 3.8. Only for WT mice under normoxia, did the mean RVP closely parallel the 
sRVP results. 
Mean RVP was significantly lower in WT female mice compared with males (male: 13.6 ± 
0.7 mmHg, n=5, female: 8.3 ± 1.9 mmHg, n=4; figure 3.8). There was no difference 
between male and female WT mice under hypoxia but there was a substantial rise in 
mRVP in 5-HTT+ female mice compared with males under hypoxia (male: 19.1 ± 0.9 
mmHg, n=8, female: 30.1 ± 2.8 mmHg, n=5). No significant differences were observed 
between males and females for either BMPR2+/- or Cross TG mice under normoxia or 
hypoxia (figure 3.8).  
 Mean SAP was similar between male and female in all groups studied except WT mice 
under hypoxia where females had lower mean SAP than males (male: 100.6 ± 4.8 mmHg, 
n=5, female: 84.5 ± 2.2 mmHg, n=6) (figure 3.9).   
 Figure 3.10 displays HR by gender. 5-HTT+ female mice had a higher HR than males 
under normoxia (male: 377.2 ± 10.1 bpm, n=5, female: 461.2 ± 30.9 bpm) and hypoxia 
(male: 370.8 ± 16.3 bpm, n=8. female: 445.2 ± 18.3 bpm, n=9). There was also a small, but 
significant difference in HR in BMPR2+/- mice under hypoxia (male: 353.8 ± 18.8 bpm, 
n=5, female: 297.8 ± 4.4 bpm, n=4). 
 RVH data is presented in figure 3.11. The only gender difference noted was in 5-HTT+ 
hypoxic animals with female mice having a greater degree of RVH than males (male: 0.31 
± 0.02, n=8, female: 0.39 ± 0.01, n=18). 
 The remodelling results are outlined in figure 3.12. 5-HTT+ female mice had more 
remodelled vessels than males under normoxia (male: 3.1 ± 1.3%, n=4, female: 8.2 ± 1.2, 
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n=4) but not hypoxia. The only other gender difference observed was for WT mice under 
hypoxia where female mice had less remodelling than males (male: 24.9 ± 0.7%, n=4, 
female: 18.3 ± 1.1%, n=10). 
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F igure 3.7 Comparison of male and female sRVP in WT and 5-HTT+ mice (A) and in 
BMPR2+/- and Cross TG mice (B) (n= 4 to 8 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05, ** p<0.01 versus male 
using an unpaired two-tailed t-test. 
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F igure 3.8 Comparison of male and female mRVP in WT and 5-HTT+ mice (A) and in 
BMPR2+/- and Cross TG mice (B) (n= 4 to 8 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05, *** p<0.001 versus 
male using an unpaired two-tailed t-test. 
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F igure 3.9 Comparison of male and female mSAP in WT and 5-HTT+ mice (A) and in 
BMPR2+/- and Cross TG mice (B) (n= 2 to 6 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05 versus male using an 
unpaired two-tailed t-test. 
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F igure 3.10 Comparison of male and female HR in WT and 5-HTT+ mice (A) and in 
BMPR2+/- and Cross TG mice (B) (n= 4 to 9 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05, ** p<0.01 versus male 
using an unpaired two-tailed t-test. 
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F igure 3.11 Comparison of male and female RVH in WT and 5-HTT+ mice (A) and in 
BMPR2+/- and Cross TG mice (B) (n= 4 to 19 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  *** p<0.001 versus male using an 
unpaired two-tailed t-test. 
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F igure 3.12 Comparison of male and female remodelling in WT and 5-HTT+ mice (A) 
and in BMPR2+/- and Cross TG mice (B) (n= 4 mice per group) under both normoxic and 
hypoxic conditions. Results expressed as mean ± SEM.  * p<0.05, ** p<0.01 versus male 
using an unpaired two-tailed t-test. 
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3.3 Discussion 
There were two principle objectives in this series of experiments. The first was to monitor 
RVP in vivo in WT and TG animals followed by assessment of RVH and vascular 
remodelling post-mortem under normal room air conditions. The second was to determine 
the effect of hypoxia on these same parameters. Female 5-HTT+ mice were found to have 
elevated mRVP compared to WT mice under normoxia, a phenotype previously 
characterised in these mice (MacLean et al., 2004). This investigation, however, also 
showed that female 5-HTT+ mice have a greater number of remodelled vessels, the first 
time this phenotypic change has been observed in 5-HTT+ mice. Female 5-HTT+ mice 
also developed an exaggerated pulmonary hypertensive phenotype following hypoxia 
indicating an interaction between overexpression of the 5-HTT and a pulmonary 
hypertensive risk factor. These phenotypic changes in 5-HTT+ mice were unique to 
females with male mice showing similar results to WT. Interesting results were also 
obtained from BMPR2+/- animals. Both male and female normoxic BMPR2+/- mice were 
similar to WT in all parameters tested, however, both male and female BMPR2+/- mice 
were surprisingly less susceptible to hypoxic induced increases in mRVP.  The 
remodelling results in female BMPR2+/- hypoxic animals were markedly different, 
however, with these animals displaying significantly more remodelling following hypoxia 
than mice with normal BMPR2 levels. This enhanced hypoxic remodelling is a novel 
finding in the BMPR2+/- mouse. Despite these modulating effects of BMPR2 deficiency 
and 5-HTT overexpression on the pulmonary phenotype of mice, no synergistic effect 
between these two genetic changes was observed in either male or female Cross TG mice 
that resulted in a more severe pulmonary hypertensive phenotype compared with either 5-
HTT+ or BMPR2+/- mice.  
 It has been established that the proliferative effect of 5-HT on PASMCs is dependent on 
uptake via the 5-HTT (Lee et al., 1991; Eddahibi et al., 1999) and that 5-HTT levels are 
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increased in pulmonary arteries in FPAH/IPAH patients. The finding that 5-HTT levels are 
highest in vessels undergoing remodelling is convincing evidence for a central role of the 
5-HTT in this critical component of the disease (Eddahibi et al., 2001).  The increased 
vascular remodelling seen in 5-HTT+ normoxic mice is thought to occur following higher 
levels of 5-HT being taken up by PASMCs and subsequent activation of  ROS and p-
ERK1/2 which contributes to the mitogenic effect of 5-HT on PASMCs (Lee et al., 1999). 
The remodelling observed in female 5-HTT+ mice was relatively modest and is unlikely to 
make a significant contribution to the elevated RVP observed. The RVP in the female 5-
HTT+ mice was not higher than the RVP reported by MacLean et al., 2004 in which no 
remodelling was found. The mechanisms that underlie the increased RVP in 5-HTT+ mice 
is unknown. It maybe that overexpression of the 5-HTT has as yet unknown effects on 
other vasoactive mediators that may contribute to increasing RVP.   
 It has been shown previously that female 5-HTT+ mice have an exaggerated response to 
hypoxia compared with WT mice.  RVP, RVH and vascular remodelling are all higher in 
5-HTT+ mice than in WT mice following hypoxia (MacLean et al., 2004) and the results 
presented here are broadly in agreement with these findings. Hypoxia induced an increase 
in RVH in all female groups with 5-HTT+ mice displaying a greater degree of RVH than 
WT or Cross TG mice. 5-HTT+ hypoxic mice also had more remodelling and a trend 
towards a higher mRVP compared with WT. None of these phenotypic changes observed 
in 5-HTT+ female mice under either normoxic or hypoxic conditions were observed in 
respective male mice. 5-HTT inhibitors attenuate vascular remodelling in hypoxic induced 
pulmonary hypertensive mice (Marcos et al., 2003) and mice lacking the 5-HTT (5-HTT-/- 
mice) also develop less severe hypoxic PAH than WT mice (Eddahibi et al., 2000).  It 
would be logical to assume from these studies that perhaps hypoxia increases 5-HTT 
expression in the pulmonary vasculature but this has not been the case in several studies to 
date. 5-HTT transcription, receptor number and protein were decreased in both WT and 5-
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HTT+ mice following hypoxia (MacLean et al., 2004) and 5-HT uptake is reduced in the 
lungs of WT hypoxic mice (Launay et al., 2002).  Conflicting information has emerged 
from studies on hypoxic rats. Hypoxic rat PASMCs have increased expression of the 5-
HTT that is associated with a greater proliferative response to 5-HT (Eddahibi et al., 1999) 
yet 5-HT uptake is reduced in the lungs of hypoxic rats (Jeffery et al., 2000). Significant 
experimental differences such as strain, age, sex and duration of hypoxia are likely to be 
important factors in explaining these observed differences.  
 Hypoxia has previously been shown to increase circulating 5-HT levels in mice (Callebert 
et al., 2006) and infusion of 5-HT exaggerates the hypoxic pulmonary hypertensive 
phenotype of rats (Eddahibi et al., 1997).  Conversely, Tph1-/- mice, lacking peripheral 5-
HT, display attenuated RVP and vascular remodelling following hypoxia compared with 
WT mice (Morecroft et al., 2007).  It is clear from data presented here that overexpression 
of the 5-HTT is sufficient to induce elevated RVP and vascular remodelling in female 
mice. It maybe that hypoxia increases circulating 5-HT levels which results in a greater 
uptake of 5-HT into PASMCs activating vasoconstrictor and mitogenic pathways. The 
downregulation of the 5-HTT observed in hypoxic mice may be a compensatory 
mechanism for the rise in plasma [5-HT].  Overexpression of the 5-HTT may also affect 
other signalling pathways involved in inducing the pulmonary hypertensive phenotype. 
Mice that overexpress the 5-HTT in smooth muscle under the control of the SM22 
promoter develop spontaneous PAH which worsens with age (Guignabert et al., 2006). 
Moreover, these mice also develop more severe PAH following both hypoxia and MCT.  
The SM22-5-HTT+ mouse was found to have reduced expression of Kv1.5 and Kv2.1 in 
the lung which would reduce Kv current promoting vasoconstriction, proliferation and a 
reduction in apoptosis. It is not known if Kv channel subunits are downregulated in 
PASMCs in the 5-HTT+ mouse in a similar way to the SM22-5-HTT+ mouse. If they are, 
they are likely to contribute to the pulmonary hypertensive phenotype and may partly 
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explain the enhanced response to hypoxia despite an apparent reduction in 5-HTT 
expression. Hypoxia reduces Kv1.5 and Kv2.1 expression (Archer et al., 1998a; Platoshyn 
et al., 2001) and it maybe be the Kv current is impaired to a greater degree in hypoxic 5-
HTT+ mice compared with WT mice resulting in a greater degree of PAH. The study by 
Guignabert et al., 2006 also reveals that overexpression of the 5-HTT in smooth muscle 
alone is sufficient to induce PAH. This rules out changes in circulating 5-HT or 
bioavailability as a modulating factor in these mice.   
 Hypoxic 5-HTT+ female mice had higher mSAP than the other three groups; however, the 
pressure was still within the normal physiological range. The serotonin system is involved 
in controlling SAP at several levels. 5-HT acts neuronally to modulate the parasympathetic 
and sympathetic nervous systems thus influencing CO, HR and ventricular contractility. 5-
HT also acts via 5-HT1 and 5-HT2 receptors on peripheral systemic arteries to alter 
vascular tone (Cote et al., 2004). Given that there was no difference between 5-HTT+ and 
WT mice under normoxia, it may be that hypoxia increases circulating 5-HT levels as 
previously described (Callebert et al., 2006) and through a central or peripheral site of 
action, acts to increase mSAP.  
  Both male and female normoxic BMPR2+/- mice were similar to WT in all parameters 
tested. There was no evidence of increased RVP, RVH or vascular remodelling.  These 
results concur with earlier studies in the same BMPR2+/- mouse which found that the 
pulmonary vascular phenotype was similar to WT (Song et al., 2005; Long et al., 2006) but 
differ from results obtained by Beppu et al., 2004 whose BMPR2+/- mice had elevated 
PAP, PVR and an increased wall thickness of muscularised pulmonary arteries. SAP, like 
in this investigation was normal. The reasons for these discrepancies are unclear but are 
unlikely to be related to age as Song et al., 2005 compared RVP between WT and 
BMPR2+/- mice throughout the life cycle of the animals and the ages of mice utilised by 
Long et al., 2005 were comparable to those used by Beppu et al., 2004. Similar to this 
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investigation, Beppu et al., 2004 studied both male and female mice and found both 
genders displayed the altered pulmonary vascular phenotype and thus gender difference 
can be ruled out as a mitigating factor for the difference between this study and Beppu et 
al., 2004. The accumulated data for this particular BMPR2+/- mouse indicates that 
pulmonary vascular abnormalities are, at most, subtle. Given that the BMPR2+/- mouse is 
thought to mimic the haploinsufficiency seen in FPAH and that only a minority of human 
carriers of the BMPR2 mutation develop PAH, it is perhaps not surprising that the 
BMPR2+/- mouse does not display a pulmonary hypertensive phenotype under normal 
physiological conditions. 
  The BMPR2+/- mouse is, however, more susceptible to PAH following exposure to 
secondary risk factors such as 5-HT (Long et al., 2006) and the interaction of BMPR2 and 
the serotonergic system will be further investigated in subsequent chapters.  The study in 
this chapter uncovered an important interaction between dysfunctional BMPR2 and 
hypoxic induced vascular remodelling. BMPR2+/- female mice were more sensitive to 
hypoxic induced remodelling, having more remodelled vessels than mice with normal 
BMPR2 levels. Similar to the 5-HTT+ mice, this phenotypic change was not observed in 
male BMPR2 hypoxic mice which had a similar level of remodelling to WT mice. Taken 
together, these results from the 5-HTT+ and BMPR2+/- mice reveal an important 
interaction between gender and genetic changes relevant to PAH.  Unexpectedly, both 
male and female BMPR2+/- mice were more resistant to hypoxic induced increases in 
mRVP and mRVP was not significantly different to normoxic BMPR2+/- mice. Although 
female BMPR2+/- mice showed similar increases compared to WT, the power of the data is 
lower due to a lower n number and larger standard error which unfortunately is a weakness 
of the experiment. The mSAP and HR measurements, however, suggest an altered 
cardiovascular response in the BMPR2+/- mouse, at least in the females. Hypoxia decreased 
mSAP in BMPR2+/- female mice compared with their normoxic controls. HR was also 
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decreased in female BMPR2+/- mice following hypoxia to a level that was over 100 bpm 
slower than the other 3 genotypes.   A decrease in mSAP has previously been shown in 
BMPR2+/- mice following hypoxia (Beppu et al., 2004). BMPs are involved in normal 
heart development (Chen et al., 2004) and the changes observed in mSAP and HR may 
relate to a cardiac phenotypic change, currently uncharacterised in BMPR2+/- mice, that 
interacts with hypoxia. The pulmonary results presented here contradict those presented by 
Beppu et al., 2004 who found that pulmonary haemodynamics were similar between WT 
and BMPR2+/- mice following hypoxia but that vascular remodelling as assessed by wall 
thickness was less in hypoxic BMPR2+/- mice than in WT.  Long et al., 2006 also found 
that RVP and RVH were similar between WT and BMPR2+/- mice following hypoxia. It is 
unclear why the study by Beppu et al., 2004 found less vascular remodelling in BMPR2+/- 
animals following hypoxia which is in contrast to the greater degree of vascular 
remodelling seen in female BMPR2+/- mice in this thesis or to the levels similar to WT as 
seen in the males. The age range of the animals used by Beppu et al., 2004 was greater 
than that used in this study (2-5 months versus 5-6 months) and although the authors state 
that the pulmonary haemodynamic response was similar between male and female 
BMPR2+/- mice, it is unclear which gender was employed in the morphological 
examination of lung samples. Moreover, the duration of hypoxia differed between studies 
which may account for some of the discrepancies observed. Duration of hypoxia was found 
to be a factor in experiments using the BMPR2+/- mouse developed by Delot et al., 2003 
(BMPR2∆E2) which does have higher RVP and RVH following hypoxia but only after 5 
weeks exposure and these mice do not have increased vascular remodelling. No differences 
were observed in RVP, RVH or remodelling between BMPR2∆E2  and WT mice after 3 
weeks hypoxia or under normoxia (Frank et al., 2008).  There was also no difference in 
PVR between WT and BMPR2+/- mice (which may have indicted evidence of vascular 
remodelling) under hypoxia in the study by Long et al., 2006 but this study only used male 
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mice and no differences were noted in vascular remodelling between male BMPR2+/- and 
WT mice in this investigation.  
 PASMCs from BMPR2+/- and WT mice have similar levels of p-Smad1/5/8 (Beppu et al., 
2004; Long et al., 2006) and both display similar elevated expression of p-Smad1/5/8 
following hypoxia (Long et al., 2006). PASMCs from BMPR2+/- mice do, however, show 
less increase in p-Smad1/5/8 following incubation with BMP-2 than WT PASMCs (Beppu 
et al., 2004; Long et al., 2006) indicating impaired BMP signalling. BMP ligands have 
previously been shown to have anti-proliferative effects on human PASMCs (Zhang et al., 
2003), a process dependent on activation of p-Smad1 (Yang et al., 2005). The elevated p-
Smad1/5/8 seen in hypoxic murine PASMCs may act to try to counteract the proliferative 
response that hypoxia has on these cells. It is thought that hypoxia acts through numerous 
pathways to induce proliferation of PASMCs including G-protein mediated activation of 
ERK1/2 by mitogenic factors such as 5-HT and ET-1 released by PAECs and by growth 
factors and ROS released by PAFs (Stenmark et al., 2006). Hypoxia can also inhibit Kv 
channels present on PASMCs inducing vasoconstriction and promoting proliferation 
(Archer et al., 1998a; Platoshyn et al., 2001). As BMPR2 is decreased in all cells in the 
BMPR2+/- mouse, changes in BMP signalling in either the endothelium or smooth muscle 
layer of pulmonary arteries may facilitate hypoxic induced remodelling.  Using a smooth 
muscle specific dominant negative BMPR2 (SM22-tet-BMPR2delx4+) West et al., 2004 
showed that mice expressing dominant negative BMPR2 in smooth muscle have increased 
RVP, RVH and vascular remodelling at 2 months old indicating that severe loss of 
functional BMPR2 in smooth muscle is sufficient to induce PAH. The level of 
muscularistion of pulmonary arteries was relatively modest in the SM22-tet-BMPR2delx4+ 
mice and the increased RVP and RVH is likely to be related more to enhanced 
vasoconstriction than remodelling. A later study with these same TG mice showed that 
both males and females were equally susceptible to the pulmonary hypertensive phenotype 
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(Tada et al., 2007). From the results presented in this thesis, it can be determined that only 
female BMPR2+/- mice develop exaggerated remodelling following hypoxia and it may be 
that age is just as an important factor as gender. It may be that in mice of 2 months, 
vasoconstriction contributes more to the pulmonary hypertensive phenotype than 
remodelling but that mice that are 5-6 months old are more sensitive to vascular 
remodelling. If loss of BMPR2 in smooth muscle induces PAH in unchallenged mice but 
not in unchallenged BMPR2+/- mice, it may that other factors i.e. hypoxia in this case are 
required that further suppress BMPR2 signalling in PASMCs that lead to a loss of 
apoptosis and increased proliferation following stimulation by growth factors activated by 
hypoxia in the lung. Further studies using the SM22-tet-BMPR2delx4+ have shown that these 
animals have reduced whole lung Kv channel expression and that the elevated RVP could 
be brought back to control values by administration of Nifedipine, an L-type  Ca2+ channel 
blocker. Administration of BMP-2 to human PASMCs increased Kv1.5 expression 
indicating regulation of Kv channels by BMP signalling (Young et al., 2006). If Kv 
channels were decreased in PASMCs in BMPR2+/- mice then further suppression of these 
channels by hypoxia may promote an increase in intracellular Ca2+ concentration 
promoting vasoconstriction and proliferation of these cells. The SM22-tet-BMPR2delx4+ 
mouse also has elevated levels of IL-6 and TGF- β and BMP-2 reduces both these 
cytokines in human PASMCs (Hagen et al., 2007). It is unknown if the BMPR2+/- mice 
used here have higher than normal lung expression of TGF-β or IL-6 similar to SM22-tet-
BMPR2delx4+ mice. If they do, it could enhance the effect of hypoxia. Hypoxia increases 
both these agents (Stenmark et al., 2006) and both are implicated in the progression of 
PAH. IL-6 is increased in serum from PAH patients (Humbert et al., 1995) and 
administration of IL-6 induces a pulmonary hypertensive like phenotype in rats (Miyata et 
al., 2001). 
 Under normoxia, male Cross TG mice had similar mRVP to the other three groups. In 
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female mice, Cross TG animals had almost double the level of RVP compared to WT 
although this was not significant. This is possibly due to relatively low n numbers for the 
Cross TG mice due to the extreme difficulties in breeding these animals. There was no 
significant differences in mRVP between Cross TG mice and 5-HTT+ mice indicating that 
the presence of dysfunctional BMPR2 is not enhancing the predisposition towards 
enhanced mRVP in mice who are 5-HTT+. RVH and vascular remodelling were not 
present in Cross TG males. In female mice there was a trend towards an increase in RVH 
in Cross TG mice similar to that observed for 5-HTT+ mice. As for mRVP, the 
predominant factor for this increase is overexpression of the 5-HTT and the BMPR2+/- 
genotype confers no greater susceptibility. When the remodelling data is analysed, it 
appears that Cross TG mice have less remodelled vessels than 5-HTT+ mice and unlike the 
5-HTT+ mice, Cross TG mice did not have significantly more remodelling than WT mice.  
It is unlikely, however, that the presence of the BMPR2 mutation is offering any protection 
against vascular remodelling especially considering the data for remodelling in BMPR2+/- 
female mice following hypoxia. Moreover, half the Cross TG mice (2 of 4) assessed for 
remodelling had evidence of remodelling similar to that seen for 5-HTT+ mice. Individual 
variations between animals may be the source of the differences between the 5-HTT+ and 
Cross TG groups.   
 Cross TG mice did not display an exaggerated pulmonary hypertensive phenotype to 
hypoxia relative to the single transgenics. In fact, the effect of hypoxia on RVH was 
significantly less in female cross TG mice compared with female 5-HTT+ mice. 
Overexpression of the 5-HTT did not enhance the vascular remodelling in hypoxic Cross 
TG females compared with BMPR2+/- single transgenic animals. The only indicator of any 
worsening of PAH was a trend towards an increase in the percentage of remodelled vessels 
in male hypoxic animals. There does not appear to be any significant cross talk between 
the 5-HTT and dysfunctional BMPR2 in the mice studied here, at least none that influence 
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the parameters analysed. Long et al., 2005 found that 5-HT could downregulate p-Smad1/5 
in WT and BMPR2+/- PASMCs and increase p-ERK1/2 in PASMCs from BMPR2+/- mice. 
These effects are likely to contribute to the increased proliferation 5-HT had on BMPR2+/- 
PASMCs, an effect that was blocked by ketanserin but not by a 5-HTT antagonist. Thus, 
cross-talk between 5-HT and BMPR2 in the context of PASMC proliferation may be 5-
HT2A mediated and not 5-HTT mediated. There is currently little further data regarding the 
interactions between 5-HT and BMPR2 within the pulmonary vasculature and how a 
genetic change in one signalling system may affect the other. Urinary excretion of 5-HT is 
similar in the BMPR2+/- mouse utilised here compared with WT (Song et al., 2005) and 
mice that overexpress the 5-HTT in smooth muscle have normal expression levels of 
BMPR2, BMPR1A, BMPR1B, BMP-2 and BMP-4 (Guignabert et al., 2006). It has to be 
remembered also, that in human patients with PAH, both BMPR2 levels (in patients with 
mutations) and 5-HTT levels are lower and higher respectively than can be explained by 
genetic factors alone. More subtle changes in intracellular signalling molecules may occur 
via cross regulation between internalisation of 5-HT and BMPR2 pathways  that don’t by 
themselves uncover a pulmonary hypertensive phenotype. Evidence for this already exists 
in this thesis, in this chapter and in subsequent chapters related to the discovery that female 
mice are more prone to the pulmonary effects of the underlying genetic abnormalities. 
Some as yet unknown agent which differs between male and female mice alters the 
susceptibility of females to PAH relative to males perhaps through direct interactions with 
either the 5-HT or BMPR2 systems (see chapter 8 for more information on interactions 
between 5-HT, BMPR2 and gender). 
 As described in section 2.3.1, both sRVP and mRVP values were recorded. sRVP was, in 
general, more variable between experiments. This was partly related to inconsistent wave 
trace amplitudes recorded from animals in one experimental batch compared with animals 
in another which itself was related to experimental design and technical proficiency of the 
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procedure. mRVP, which should remain uniform regardless of wave amplitude is likely to 
be a better indicator for comparing RVP of different animals and will be solely used for 
interpreting pulmonary pressure data in this thesis. 
 To summarise, overexpression of the 5-HTT results in spontaneous elevation of mRVP 
and vascular remodelling. 5-HTT overexpression was also associated with a worsening of 
hypoxic PAH. BMPR2+/- mice are phenotypically normal in room air and were less 
susceptible to hypoxic induced rises in mRVP. Despite this, female BMPR2+/- mice did 
show elevated vascular remodelling following hypoxia compared with WT and 5-HTT+ 
mice, a result that highlights the important role BMPR2 has in modulating vascular 
integrity and how deficiency in BMPR2 can interact with an additional risk factor for PAH 
to promote vascular changes characteristic of the disease. This study also demonstrated 
through the use of the novel Cross TG mice that no synergistic effects were observed 
between BMPR2 deficiency and 5-HTT overexpression that resulted in a more pronounced 
pulmonary hypertensive phenotype.  Perhaps the most surprising and key finding from this 
work was the discovery that only female TG mice express the exaggerated pulmonary 
hypertensive changes indicating an important interaction between gender and genetic 
predisposition to cause the symptoms of PAH.  
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Chapter 4 
Dexfenfluramine dosing study in B MPR2+/- mice 
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4.1 Introduction 
While the risk of PAH is increased in people exposed to Dfen (Abenhaim et al., 1996), it is 
not known why some people develop PAH following Dfen and others do not.  Even a 23 
fold increased risk of PAH in long-term Dfen users (Abenhaim et al., 1996) still represents 
an extremely low risk of developing the disease suggesting genetic predisposition plays an 
important part. Humbert et al., 2002 analysed fenfluramine users with PAH for BMPR2 
mutations and found that 9% of patients carried BMPR2 mutations. As the authors 
acknowledge, the actual number of patients that may carry the BMPR2 mutation may be 
much higher due to incomplete screening of the BMPR2 gene. A BMPR2 mutation was 
also found in a patient that developed PAH following the ingestion of the appetite-
suppressant amfepramone (Abramowicz et al., 2003). The need for genetic predisposition 
in Dfen associated PAH is supported by animal data where administration of Dfen has 
failed to induce PAH in mice (Launay et al., 2002) and rats (Mitani et al., 2002; Rochefort 
et al., 2006). The BMPR2+/- mouse used in this thesis has previously been shown to be 
more susceptible to PAH induced by inflammatory stress. The inflammatory response was 
induced by adenovirus mediated pulmonary overexpression of 5-LO (Song et al., 2005). Of 
particular interest to this investigation was the discovery by Long et al., 2006 that infusion 
of 5-HT for 2 weeks increased RVP in BMPR2+/- mice but not in WT mice, an effect that 
was exaggerated in hypoxia. It would, therefore, be beneficial to determine if BMPR2+/- 
mice are susceptible to Dfen induced PAH. In this chapter WT and BMPR2+/- mice will be 
administered Dfen and assessed for evidence of a pulmonary hypertensive phenotype. The 
results in the last chapter clearly demonstrated the importance of gender in determining the 
pulmonary hypertensive phenotype. To determine if the response to Dfen is affected by 
gender, both male and female mice will be studied. 
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4.2 Methods  
Mice (male and female) were 2 months old at commencement of Dfen dosing and 3 
months old at time of experimental analysis. Mice were dosed with dexfenfluramine 
hydrochloride (Sigma-Aldrich Ltd, Poole, UK) (5 mg/kg/day) dissolved in H2O via oral 
gavage dosing for 28 days before analysis of pulmonary haemodynamics as described in 
section 2.3.  
 
4.3 Results 
4.3.1 Pulmonary and systemic haemodynamics in male mice 
sRVP and mRVP for WT and BMPR2+/- male mice dosed with Dfen or vehicle are 
presented in figure 4.1 Dfen caused a decrease in sRVP (vehicle: 23.7 ± 0.5 mmHg, n=19, 
Dfen: 18.4 ± 2.0 mmHg, n=9) and mRVP (vehicle: 12.7 ± 0.3 mmHg, n=19, Dfen: 10.8 ± 
0.7 mmHg, n=9) in WT mice but had no effect on either sRVP or mRVP in BMPR2+/- 
mice. There were no differences noted between WT and BMPR2+/- mice.  
 mSAP was similar between the 4 groups (figure 4.2A). Dfen increased HR in BMPR2+/- 
mice compared with Dfen treated WT mice (WT: 383.9 ± 12.9 bpm, n=9, BMPR2+/-: 428.3 
± 18.3 bpm, n=8) (figure 4.2B). 
 
4.3.2 Pulmonary and systemic haemodynamics in female mice 
sRVP and mRVP for WT and BMPR2+/- female mice dosed with Dfen or vehicle are 
presented in figure 4.3. Dfen increased sRVP (vehicle: 17.3 ± 1.5 mmHg, n=8, Dfen: 32.0 
± 0.5 mmHg, n=7) and mRVP (vehicle: 11.6 ± 0.9 mmHg, n=8, Dfen: 18.3 ± 1.1 mmHg, 
n=7) in WT mice. sRVP (vehicle: 17.5 ± 2.2 mmHg, n=7, Dfen: 27.9 ± 3.1 mmHg, n=6) 
and mRVP (vehicle: 12.7 ± 1.3 mmHg, n=7, Dfen: 20.2 ± 2.6 mmHg, n=6) were also 
increased in Dfen treated BMPR2+/- mice. There were no significant differences in sRVP 
or mRVP between WT and BMPR2+/- animals. There was insufficient data for a 
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F igure 4.1 Effect of Dfen ingestion in WT and BMPR2+/- male mice (n = 7 to 19 mice per 
group) on sRVP (A) and mRVP (B). Results expressed as mean ± SEM. * p<0.05, ** 
p<0.01 versus WT vehicle using Bonferroni multiple comparison test. 
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F igure 4.2 Effect of Dfen ingestion in WT and BMPR2+/- male mice (n = 3 to 19 mice per 
group) on mSAP (A) and HR (B). Results expressed as mean ± SEM. * p<0.05 versus WT 
Dfen using Bonferroni multiple comparison test. 
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F igure 4.3 Effect of Dfen ingestion in WT and BMPR2+/- female mice (n = 6 to 8 mice per 
group) on sRVP (A) and mRVP (B). Results expressed as mean ± SEM. ** p<0.01, *** 
p<0.01 versus WT vehicle, † p<0.01 versus BMPR2+/- vehicle using Bonferroni multiple 
comparison test. 
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F igure 4.4 Effect of Dfen ingestion in WT and BMPR2+/- female mice (n = 6 to 8 mice per 
group) on HR. Results expressed as mean ± SEM. * p<0.05 versus WT vehicle, ** p<0.01 
versus WT Dfen using Bonferroni multiple comparison test. 
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comparison of mSAP in female mice but HR was lower in BMPR2+/- mice, both for  
vehicle (WT: 445.0 ± 16.0 bpm, n=8, BMPR2+/-: 392.1 ± 8.9 bpm, n=7) and Dfen (WT: 
436.1 ± 10.8 bpm, n=7, BMPR2+/-: 358.5 ± 18.7 bpm, n=6) treated animals (figure 4.4). 
 
4.3.3 Right ventr icular hypertrophy and vascular remodelling in male mice 
Figure 4.5 illustrates RVH and vascular remodelling data for male mice. There were no 
differences observed for RVH between groups. BMPR2+/- mice dosed with Dfen had 
approximately twice the number of remodelled vessels compared to WT mice treated with 
Dfen and BMPR2+/- vehicle treated mice (WT Dfen: 3.0 ± 0.9%, n=4, BMPR2+/- vehicle: 
3.1 ± 0.7%, n=4, BMPR2+/- Dfen: 6.0 ± 0.3%, n=4) 
 
4.3.4 Right ventr icular hypertrophy and vascular remodelling in female mice 
Female RVH and remodelling data is shown in figure 4.6. RVH was not significantly 
different between groups. There was, however, a substantial increase in remodelling 
following Dfen in both WT (vehicle: 3.2 ± 0.3%, n=4, Dfen: 12.1 ± 1.2%, n=4,) and 
BMPR2+/- (vehicle: 4.0 ± 0.7%, n=4, Dfen: 12.5 ± 1.2, n=4) mice with similar levels 
between the two genotypes.  
 
4.3.5 Gender differences 
The preceding data was subjected to a gender analysis and is presented in figures 4.7 to 
4.9. The most striking gender difference noted regarding RVP was the increase in sRVP 
elicited by Dfen in the females compared with the males (figure 4.7A). This occurred in 
both WT (male: 18.4 ± 2.0 mmHg, n=9, female: 32.0 ± 0.5 mmHg, n=7) and BMPR2+/- 
(male: 17.4 ± 1.0 mmHg, n=7, female: 27.9 ± 3.1 mmHg, n=6) mice. Similar differences 
also occurred for mean RVP (WT male: 10.8 ± 0.7 mmHg, n=9, WT female: 18.3 ± 1.1 
mmHg, n=7, BMPR2+/- male: 11.0 ± 0.8 mmHg, n=7, BMPR2+/- female: 20.2 ± 2.6 
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F igure 4.5 Effect of Dfen ingestion in WT and BMPR2+/- male mice (n = 4 to 18 mice per 
group) on RVH (A) and remodelling (B). Results expressed as mean ± SEM. ** p<0.01 
versus WT Dfen and BMPR2+/- vehicle using Bonferroni multiple comparison test.  
 
128 
 
0.0
0.1
0.2
0.3
WT vehicle
WT Dfen
BMPR2+/- vehicle
BMPR2+/- Dfen
Group
Ra
tio
 (R
V/
LV
+S
)
 Female
 
A  
 
0
5
10
15
WT vehicle
WT Dfen
BMPR2+/- vehicle
BMPR2+/- Dfen
 ***
†
Group
%
 o
f v
es
se
ls
 re
m
od
el
le
d
 
B 
 
F igure 4.6 Effect of Dfen ingestion in WT and BMPR2+/- female mice (n = 4 to 13 mice 
per group) on RVH (A) and remodelling (B). Results expressed as mean ± SEM. *** 
p<0.001 versus WT vehicle, † p<0.001 versus BMPR2+/- vehicle using Bonferroni multiple 
comparison test. 
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mmHg, n=6) (figure 4.7B). In vehicle treated animals, male WT animals had higher sRVP 
than females (male: 23.7 ± 0.5 mmHg, n=19, female: 17.3 ± 1.5 mmHg, n=8). There was, 
however, no such difference for mean RVP. 
There was insufficient data to do a male versus female comparison for mean SAP except 
for vehicle dosed BMPR2+/- mice where there was no significant difference (male: 82.4 ± 
2.0 mmHg, n=5, female: 78.4 ± 7.4 mmHg, n=4). Variations in HR were noted between 
males and females treated with Dfen (figure 4.8). There was an increased HR in female 
WT mice compared with males (male: 383.9 ± 12.9 bpm, n=9, female: 436.1 ± 10.8 bpm, 
n=7) and a decreased HR in female BMPR2+/- mice compared with males (male: 428.3 ± 
18.3 bpm, n=8, female: 358.5 ± 18.7 bpm, n=6). 
 RVH was higher in male WT mice in both vehicle treated (male: 0.28 ± 0.01, n=18, 
female: 0.22 ± 0.01, n=13) and Dfen treated (male: 0.26 ± 0.01, n=11, female: 0.21 ± 0.01, 
n=9) groups (figure 4.9A). The extent of RVH was similar in all four BMPR2+/- groups.  
Remodelling data is shown in figure 4.9. Dfen significantly increased the number of 
remodelled vessels in female WT mice compared to males (male: 3.0 ± 0.9%, n=4, female: 
12.1 ± 1.2 %, n=4). There was also a marked increase in remodelling in female BMPR2+/- 
mice compared to males (male: 6.0 ± 0.3 %, n=4, female: 12.5 ± 1.2 %, n=4) (figure 4.9B). 
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F igure 4.7 Comparison of male and female sRVP (A) and mRVP (B) in vehicle and Dfen 
treated WT and BMPR2+/- mice (n= 6 to 9 mice per group). Results expressed as mean ± 
SEM. ** p<0.01 versus male, *** p<0.001 versus male using an unpaired two-tailed t-test. 
 
131 
 
 
 
 
 
 
 
0
100
200
300
400
500
                      vehicle        Dfen             vehicle       Dfen
      WT               BMPR2+/-
**
*
male
female
He
ar
t  
Ra
te
 (b
pm
)
 
 
 
F igure 4.8 Comparison of male and female HR in vehicle and Dfen treated WT and 
BMPR2+/- mice (n = 6 to 19 mice per group). Results expressed as mean ± SEM. * p<0.05, 
** p<0.01 versus male using an unpaired two-tailed t-test. 
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F igure 4.9 Comparison of male and female RVH (A) and remodelling (B) in vehicle and 
Dfen treated WT and BMPR2+/- mice (n=8 to 18 mice per group). Results expressed as 
mean ± SEM. ** p<0.01 versus male, *** p<0.001 versus male using an unpaired two-
tailed t-test. 
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4.4 Discussion 
This study shows Dfen to be a robust inducer of a pulmonary hypertensive phenotype in 
both WT and BMPR2+/- female mice. Results were similar between both genotypes 
indicating BMPR2 haploinsufficiency in this genetic model does not lead to a worsening of 
PAH in female mice. Neither WT nor BMPR2+/- male mice developed PAH following 
Dfen, indicating a critical role for female gender in Dfen induced PAH. Male BMPR2+/- 
mice did, however, show susceptibility, although at a lower level, to Dfen induced vascular 
remodelling.  
 Dfen induced PAH in female WT mice, increasing both mRVP and vascular remodelling 
but without causing RVH. Male WT mice were not susceptible to either of these effects 
and actually showed a decrease in mRVP following administration of Dfen. This decrease 
was very modest and perhaps partly related to a vasodilator response in the male 
vasculature acting to compensate the Dfen/5-HT induced vasoconstriction. The finding 
here, that male mice are resistant to Dfen induced pulmonary hypertension may help to 
explain why some previous animal studies that may have employed male rodents have 
failed to induce Dfen associated pulmonary hypertension. The Dfen data presented here 
indicates that female mice are more prone to a pulmonary hypertensive phenotype when 
challenged with a disease risk factor. There was no evidence at all in male WT mice for 
PAH. The results in chapter 3 showed that male WT mice did develop hypoxic induced 
PAH.  Dfen appears to be a less potent inducer of PAH at the dose tested than hypoxia, 
with hypoxia causing a higher increase in mRVP and a greater degree of remodelling in 
female mice compared with Dfen. Male mice; therefore, may require a greater pulmonary 
challenge to overcome an inherent protective mechanism before a pulmonary hypertensive 
phenotype emerges.  
 No differences were noted between female WT and BMPR2+/- mice with both mRVP and 
vascular remodelling increased by a similar margin in both genotypes. Interestingly, male  
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BMPR2+/- mice did show a small but significant increase in the number of remodelled 
vessels following Dfen, something not observed in WT males. As outlined in the last 
chapter and shown by Beppu et al., 2004 there may be subtle vascular changes in 
BMPR2+/- mice that predispose these animals to an increase in remodelling. This is shown 
quite convincingly by the hypoxic female data and now also demonstrated in the Dfen 
treated BMPR2+/- males. The previous study by Long et al., 2006 that found a mild 
pulmonary hypertensive phenotype in BMPR2+/- mice infused with 5-HT utilised male 
mice, indicating that male BMPR2+/- mice are more susceptible to the mitogenic and 
vasoconstrictor effect of 5-HT which is thought to be the major mediator of Dfen induced 
PAH (see chapter 5 for further information on the mechanism of action of Dfen).  
  It is unclear if underlying mutations in BMPR2 increase the risk of developing PAH 
following anorexigen administration. Current evidence regarding human patients is 
inconclusive. BMPR2 mutations have been found in patients taking fenfluramines 
(Humbert et al., 2002). The duration of fenfluramine exposure was relatively short in 
patients with BMPR2 mutation, further indicating a facilitation of PAH through interaction 
with BMPR2 mutation and anorexigen use (Humbert et al., 2002). The majority of 
mutations recorded in the fenfluramine using patients do not, however, appear to be as 
detrimental on protein function as other mutations found in FPAH (Machado et al., 2006).  
Missense mutations in the ligand binding domain of BMPR2 in FPAH patients result in 
cysteine residue substitution with negative consequences for protein structure but cysteine 
residues are not affected by the missense mutations found in APAH patients. Some of the 
missense mutations discovered in APAH patients appear to occur in regions of the protein 
with no known functional significance. Similarly, of the three kinase domain mutations 
found, only 1 is proven to have a negative effect on kinase function (Machado et al., 2006). 
A mutation in the cytoplasmic domain with more functional significance (Machado et al., 
2006) was found in a patient who had been exposed to amfepramone (a sympathomimetic 
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amphetamine-like anorexigen) and Abramowicz et al., 2003 suggest the time course of 
disease development and ingestion of amfepramone are a link that indicates the drug was 
the causative agent (Abramowicz et al., 2003). The fact that this is an isolated case makes 
any conclusion regarding a link between amfepramone and PAH impossible and it is far 
from certain that amfepramone was the cause of the disease.  Moreover, in a large study 
performed in the USA, only fenfluramines were associated with the diagnosis of PAH. 
Other anorexigens, including amfepramone, were not associated with an increased risk of 
PAH (Rich et al., 2000).  Proving a link between BMPR2 mutations and anorexigen use in 
humans is a difficult task and will require more accurate information on the distribution of 
BMPR2 mutations. Studies to date that have analysed APAH patients for BMPR2 
mutations did not analyse the entire gene (Humbert et al., 2002) thus raising the possibility 
that the percentage of BMPR2 mutant carriers in this population may be greater. More 
detailed information on the functional consequences of the mutations that have been found 
in APAH patients and information on the varying penetrance of distinct BMPR2 mutations 
will all help to better characterise the interaction of BMPR2 mutations with other risk 
factors. It has been suggested that a pre-existing deficiency in pulmonary NO levels may 
act as a risk factor for Dfen APAH (Archer et al., 1998b). Inhibition of NO increases the 
pressor response to Dfen in rat lung (Weir et al., 1996) and Dfen users who develop PAH 
have been found to have lower levels of NO in the lung compared with control subjects 
(Archer et al., 1998b). This was found to be in contrast to patients with FPAH/IPAH who 
had increased lung expression of NO which is theorised to act as a counterbalance to the 
vasoconstriction observed in the diseased lung. The decreased levels of NO were found to 
persist for years after discontinuation of the anorectic agent perhaps indicating that the NO 
deficiency was independent of drug use and perhaps was an underlying genetic deficiency 
that on its own was of no clinical concern but interacted with Dfen to cause PAH (Archer 
et al., 1998b). This question can not be answered as NO levels were unknown prior to 
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disease onset but deserves more investigation. A further interesting discovery related to 
dysfunctional NO signalling in fenfluramine APAH comes from one fenfluramine user 
with PAH who carried a loss of function mutation in the 5-HT2B receptor (Blanpain et al., 
2003). This receptor induces NO in several cell lines through C-terminus dependent 
activation of eNOS and iNOS (Manivet et al., 2000) and mediates vasorelaxation in pig 
porcine arteries, a receptor that shares 95% homology with the human 5-HT2B receptor 
(Glusa and Pertz, 2000). It could be speculated that this patient would have impaired 5-
HT2B mediated NO synthesis (assuming 5-HT2B receptors were to mediate NO release in 
human pulmonary arteries) reducing the vascular protective effect of NO in PAH.  The 5-
HT2B receptor has, however also been highlighted as playing a role in promoting vascular 
remodelling in animal models of the disease and partly mediating the effects of NDfen. 
The next chapter will discuss further the role of 5-HT receptors in fenfluramine APAH. 
 To conclude, this study reveals Dfen to be a robust inducer of PAH in female WT and 
BMPR2+/- mice. The pulmonary hypertensive effect of Dfen was completely negated in 
male WT mice while BMPR2+/- males did develop limited vascular remodelling but 
without elevated RVP. These results suggest female gender is a critical risk factor for 
development of Dfen APAH. Presence of BMPR2 mutation did not affect the degree of 
PAH in female mice but may pre-dispose the male vasculature to Dfen induced 
remodelling.  
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Chapter 5 
Role of per ipheral 5-H T in PA H 
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5.1 Introduction 
The development of the Tph1-/- mouse offers a valuable genetic model for assessing the 
contribution of peripheral 5-HT in the development of PAH. As mentioned previously, 
levels of TPH1 in PAECs are increased in cells from IPAH patients compared to control 
subjects and this is associated with increased 5-HT release (Eddahibi et al., 2006). It has 
also recently been shown that hypoxic PAH is diminished in Tph1-/- mice compared with 
WT mice (Morecroft et al., 2007; Izikki et al., 2007).  
 As outlined previously, Dfen has complex effects on the serotonergic system. It is a 5-HT 
releaser (Zolkowska et al., 2006), a 5-HTT substrate (Rothman et al., 1999) and is 
converted to NDfen that induces vasoconstriction through activation of 5-HT2A receptors 
(Ni et al., 2005). It is unclear, however, whether Dfen induced PAH is caused by 5-HT 
release, through a direct vasoconstrictor/mitogenic action of Dfen or through NDfen 
induced activation of 5-HT receptors. It is possible that a combination of these factors 
coupled with an inhibition of K+ channels contribute to Dfens mechanism of action. By 
utilising the Tph1-/- mouse, it should be possible to determine whether Dfen induces PAH 
through a direct 5-HT independent effect or whether peripheral 5-HT synthesis and release 
by Dfen is the mode of action. To answer this, female Tph1-/- mice were dosed with Dfen 
and pulmonary haemodynamics measured as in sections 2.3 and 4.2. The decision to use 
female mice was arrived at following the results obtained in the last chapter that showed 
only female mice develop Dfen associated PAH. 
 Morecroft et al., 2007 performed pharmacological experiments on pulmonary arteries 
from normoxic and hypoxic Tph1-/- mice. That study showed that 5-HT induced 
vasoconstriction is increased in Tph1-/- mice compared with WT. Unlike WT mice, where 
5-HT induced vasoconstriction was enhanced following hypoxia, there was no difference 
in response to 5-HT between normoxic and hypoxic Tph1-/- mice. It would be useful to 
further determine pharmacological differences between WT and Tph1-/- mice and if 
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administration of Dfen affects the pharmacology of pulmonary arteries in either group.  
To better understand any interaction that may exist between peripheral 5-HT, 
administration of Dfen and activity of 5-HT vasoconstrictor receptors, pulmonary arteries 
from WT and Tph1-/- female mice dosed with vehicle and Dfen were used to construct 
cumulative concentration-response curves (CCRCs) to 5-HT, Dfen and NDfen.  
 The final part of this study sought to investigate any cross-talk that might exist between 5-
HT and BMPR2 signalling pathways. This involved western blot analysis of BMPR2 and 
p-Smad1/5/8 in tissue samples (IPAs + main pulmonary arteries) isolated from WT and 
Tph1-/- male mice. Both main pulmonary artery and IPA was utilised for analysis to ensure 
adequate protein expression for detection. Male mice were used due to availability of TG 
animals owing to the large number of female animals utilised in the in vivo study. Despite 
female mice being a necessity for studying the in vivo effects of Dfen in Tph1-/- mice, male 
mice were deemed sufficient for studying the interaction of 5-HT and BMPR2 signalling. 
This is derived from previous work studying the interaction of these two pathways in both 
whole lung and isolated PASMCs in BMPR2+/- and WT mice, a study that utilised only 
male mice (Long et al., 2006).  Due to the important role p-ERK1/2 has in 5-HT mediated 
proliferation in PASMCs, it was also examined.  
 
5.2 Methods 
5.2.1 Animals 
Mice (female) were 2 months old at commencement of Dfen dosing and 3 months old at 
time of experimental analysis. Western blotting experiments were performed on 2 month 
old male mice. 
 
5.2.2 Myography 
IPAs were isolated from mice from each of the four treatment groups and used for wire 
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myography experiments as described previously.  
Following attainment of maximal contractile response to KCl as outlined in section 2.6.1.5, 
vessels were left to equilibrate for 30 minutes before CCRCs were performed for 5-HT 
(Sigma-Aldrich Ltd, Poole, UK), Dfen or NDfen (National Institute of Health, Maryland, 
USA).  All drugs were dissolved in H2O to give a solution of 10-2 M from which serial 
dilutions were created up to 10-6 M giving the range necessary for a 1 nM- 300 M CCRC 
to be constructed. Each vessel segment was subjected to only one treatment.  
 
5.3 Results 
5.31 Dfen dosing study in T ph1-/- mice 
Dfen dramatically increases both sRVP and mRVP in female WT mice (figure 5.1). In 
Tph1-/- female mice, however, Dfen has no effect on either sRVP (vehicle: 15.5 ± 1.0 
mmHg, n=8, Dfen: 14.1 ± 1.0 mmHg, n=9) or mRVP (vehicle: 11.4 ± 0.9 mmHg, n=8, 
Dfen: 9.5 ± 1.0 mmHg, n=9). 
 Tph1-/- vehicle dosed mice had a lower HR compared with WT vehicle treated animals 
(WT: 445 ± 16 bpm, n=8, Tph1-/-: 388.9 ± 21.7 bpm, n=8) (figure 5.2). There was no 
difference between the Dfen treated groups or between Dfen treated animals and respective 
controls.  
 RVH was similar between the four groups (figure 5.3A). Unlike the WT female mice that 
show substantial remodelling following Dfen, Tph1-/- mice dosed with Dfen have a similar 
level of remodelling to vehicle dosed mice (vehicle: 3.1 ± 0.4 %, n=4, Dfen: 3.6 ± 0.4 %, 
n=4) (figure 5.3B). 
 
5.3.2 Assessment of contractile response to 5-H T , Dfen and NDfen in IPAs 
Contractions in IPAs were measured relative to the contraction induced by 50 mM KCl. 
No significant differences were observed in KCl response between groups (WT veh: 2.2 ± 
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0.3 mN, n=6, WT Dfen: 2.3 ± 0.2 mN, n=6, Tph1-/- veh: 2.1 ± 0.3 mN, n=6, Tph1-/- Dfen: 
1.9 ± 0.2 mN, n=6). CCRCs for 5-HT are presented in figure 5.4. The potency (pEC50) of 
5-HT was greater in WT mice compared with Tph1-/- mice.  This was true for the vehicle 
dosed group (WT: 7.7 ± 0.1, n=6, Tph1-/- : 7.2 ± 0.0, n=6) and for the Dfen dosed group 
(WT: 7.7 ± 0.1, n=6, Tph1-/-: 7.3 ± 0.1, n=6). There was no difference between Dfen dosed 
and vehicle dosed animals. Despite the potency of 5-HT being greater in the WT mice, 
Tph1-/- mice dosed with Dfen did show a greater maximal response (Emax) to 5-HT 
compared with the respective WT group (WT: 122.5 ± 4.8 % of the contraction induced by 
50 mM KCl, n=6, Tph1-/-: 138.0 ± 5.3 %, n=5). There was no such difference between 
vehicle dosed animals.   
 Results for the CCRCs to Dfen are presented in figure 5.5. A maximum response to Dfen 
was not obtained at the concentrations tested so neither pEC50 nor Emax could be 
calculated. No significant differences were found between groups at any of the 
concentrations used. 
 Results for the CCRCs to NDfen are presented in figure 5.6. pEC50 values were lower for 
mice dosed with Dfen than for vehicle dosed mice. This was true for both WT (vehicle: 6.1 
± 0.1, n=6, Dfen: 5.8 ± 0.1, n=6) and Tph1-/- (vehicle: 6.4 ± 0.0, n=6, Dfen: 6.0 ± 0.0, n=6) 
mice.  Emax was significantly lower in WT mice dosed with Dfen compared with the 
vehicle dosed mice (vehicle: 103.0 ± 4.4 % of the contraction induced by 50 mM KCl, 
n=6, Dfen: 88.2 ± 5.0 %, n=6). Similar results were obtained for Tph1-/- mice (vehicle 
109.1 ± 1.6 %, n=6, Dfen: 95.8 ± 3.2 %, n=6) however it did not reach significance. No 
significant differences were observed between WT and Tph1-/- mice in either treatment 
group. 
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F igure 5.1 Effect of Dfen ingestion in WT and Tph1-/- female mice (n = 7 to 9 mice per 
group) on sRVP (A) and mRVP (B). Results expressed as mean ± SEM.  *** p<0.001 
versus WT vehicle and Tph1-/- Dfen using Bonferroni multiple comparison test. 
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F igure 5.2 Effect of Dfen ingestion in WT and Tph1-/- female mice (n = 7 to 9 mice per 
group) on HR. Results expressed as mean ± SEM.  * p<0.05 versus WT vehicle using 
Bonferroni multiple comparison test.  
 
 
 
 
 
 
 
 
144 
 
                                       Female 
 
0.00
0.05
0.10
0.15
0.20
0.25
WT vehicle
WT Dfen
Tph1-/- vehicle
Tph1-/- Dfen
Group
Ra
tio
 (R
V/
LV
+S
)
 
A 
 
      
0
5
10
15
WT vehicle
WT Dfen
Tph1-/- vehicle
Tph1-/- Dfen
 ***
Group
%
 o
f v
es
se
ls 
re
m
od
ell
ed
 
 
B 
 
F igure 5.3 Effect of Dfen ingestion in WT and Tph1-/- female mice (n = 9 to 17 mice per 
group) on RVH (A) and remodelling (B). Results expressed as mean ± SEM.  *** p<0.001 
versus WT vehicle and Tph1-/- Dfen using Bonferroni multiple comparison test. 
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F igure 5.4 Effect of Tph1-/- gene knockout and Dfen ingestion on 5-HT induced 
contraction in female mouse IPAs (n = 6 mice per group). Results expressed as mean ± 
SEM. pEC50: ** p<0.01 versus WT Dfen, *** p<0.001 versus WT vehicle. Emax: † 
p<0.05 versus WT Dfen using Bonferroni multiple comparison test. 
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F igure 5.5 Effect of Tph1-/- gene knockout and Dfen ingestion on Dfen induced 
contraction in female mouse IPAs (n = 6 mice per group). Results expressed as mean ± 
SEM. Bonferroni multiple comparison test revealed no significant differences at any 
concentration tested. 
 
 
 
 
 
 
147 
 
 
 
 
 
 
 
-10 -9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
WT vehicle
WT Dfen **, †
TPH1-/- vehicle
TPH1-/- Dfen ***
NDfen [log M]
Re
sp
on
se
 (%
 50
m
M 
KC
l)
 
 
 
F igure 5.6 Effect of Tph1-/- gene knockout and Dfen ingestion on NDfen induced 
contraction in female mouse IPAs (n = 6 mice per group). Results expressed as mean ± 
SEM. pEC50: ** p<0.01 versus WT vehicle, *** p<0.001 versus Tph1-/- vehicle. Emax: † 
p<0.05 versus WT vehicle using Bonferroni multiple comparison test. 
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5.3.3 Influence of per ipheral 5-H T on 5-H T and B MPR2 signalling proteins 
Tph1-/- samples had visibly more BMPR2 protein expression than WT samples (figure 
5.7). There was, however, no significant differences in the densitometric analysis between 
groups (figure 5.7). Data for p-Smad1/5/8 is presented in figure 5.8. While some 
experiments had visibly more p-Smad1/5/8 in Tph1-/- samples compared to WT, others 
showed no visible difference. This was reflected in the densitometry which yielded no 
significant differences between groups. Finally, p-ERK1/2 expression was assessed (figure 
5.9).  In the majority of experiments, p-ERK1/2 expression was visibly greater in WT mice 
compared with Tph1-/- mice. No significant differences emerged from the densitometry.  
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F igure 5.7 Representative autoradiograms (one from each of the three separate groups of 
tissue samples) and densitometric analysis of BMPR2 expression in WT and Tph1-/- male 
mouse IPAs + main pulmonary arteries (n=7). Results expressed as mean ± SEM. An 
unpaired two-tailed t-test revealed no significant difference between groups.                                               
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F igure 5.8 Representative autoradiograms (one from each of the three separate groups of 
tissue samples) and densitometric analysis of p-Smad1/5/8 expression in WT and Tph1-/- 
male mouse IPAs + main pulmonary arteries (n=8). Results expressed as mean ± SEM. An 
unpaired two-tailed t-test revealed no significant difference between groups.                                                                   
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F igure 5.9 Representative autoradiograms (one from each of the three separate groups of 
tissue samples) and densitometric analysis of p-ERK 1/2 expression in WT and Tph1-/- 
male mouse IPAs + main pulmonary arteries (n=10). Results expressed as mean ± SEM. 
An unpaired two-tailed t-test revealed no significant difference between groups.                                                                  
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5.4 Discussion 
This study has demonstrated a critical role for peripheral 5-HT synthesis in Dfen 
associated PAH with Tph1-/- mice completely protected against Dfen induced increases in 
RVP and vascular remodelling. This study also reveals previously uncharacterised 
pharmacological differences between WT and Tph1-/- mice and between mice that received 
Dfen and those that did not. Finally, the role of peripheral 5-HT on 5-HT and BMPR2 
signalling molecules was examined. While no significant differences emerged, the results 
are suggestive of an inhibiting influence of 5-HT on BMPR2 which was found to be 
expressed more than two-fold  higher in Tph1-/- mice compared with WT.  
 Dfen, as one of the few proven pharmaceutical risk factors for PAH is an extremely useful 
research tool for understanding the pathophysiology of the disease. As demonstrated in the 
previous chapter, Dfen induces a pulmonary hypertensive phenotype in female WT and 
BMPR2+/- mice. Understanding Dfens mechanism of action can help us gain insights into 
the underlying mechanisms of PAH. The fact that female Tph1-/- mice were resistant to the 
effects of Dfen on the pulmonary vasculature provides important data on how Dfen may be 
acting within the lung. It is clear from this study that Dfen requires the presence of 
peripheral 5-HT synthesis to exert its pulmonary hypertensive effect in mice (this data has 
been published in Dempsie et al., 2008). As a compound with multiple mechanisms of 
action, the ability of Dfen to release 5-HT from pulmonary vascular cells is determined to 
be a critical component of its action. Dfen is a potent 5-HTT substrate and 5-HTT 
substrates induce a much greater increase in extracellular 5-HT concentration compared 
with 5-HTT inhibitors (Rothman and Baumann, 2002). Moreover, the increase in plasma 
concentration of 5-HT induced by amphetamine analogues is proportional to their potency 
as 5-HTT substrates (Zolkowska et al., 2006). 5-HTT substrates release 5-HT by two 
mechanisms. The first involves carrier mediated exchange with 5-HT at the plasma 
membrane 5-HTT and the second involves interaction with the vesicular monoamine 
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transporter type 2 (VMAT2) present on intracellular vesicles resulting in 5-HT being 
transported out of the vesicle and into the cytoplasm raising intracellular 5-HT levels 
(Partilla et al., 2006).  This not just increases the available 5-HT in the cell for carrier 
mediated exchange out of the cell but also raises the possibility of increased activation of 
5-HT dependent intracellular pathways.  MDMA (3, 4-methylenedioxymethamphetamine 
or ecstasy), which has a mechanism of action very similar to the fenfluramines has also 
been shown to act on the VMAT2 causing 5-HT release. The effect of MDMA was found 
to be dependent on an existing pool of vesicular 5-HT which MDMA released through a 
direct inhibition of VMAT2 and a disruption of the transmembrane pH gradient that drives 
5-HT uptake into the vesicle (Mlinar and Corradetti, 2003). Of these two mechanisms, a 
direct interaction with VMAT2, not dissimilar to the carrier mediated exchange that occurs 
at the 5-HTT, is thought to be the most important factor in 5-HT vesicular release (Partilla 
et al., 2006). The resulting action of Dfen following i.v. administration in the rat is a large 
(19 fold at 1.0 mg/kg) increase in plasma 5-HT concentration reaching a peak 
concentration of 20 nM. This is above the threshold required to induce mitogenesis of 
human PASMCs (Zolkowska et al., 2006) and a sustained increase in plasma 5-HT 
concentration induced by Dfens role as a 5-HTT and VMAT2 substrate may promote 
proliferation of PASMCs.  
 5-HTT substrates differ from 5-HTT inhibitors such as fluoxetine in two crucial ways. The 
1st being the magnitude of increase in extracellular 5-HT. The 2nd being the uptake of 
compound into the cell and subsequent release of 5-HT from intracellular vesicles inducing 
a rise in 5-HT concentration in the cytoplasm. The combination of increased intracellular 
and extracellular 5-HT could be important in the development of vascular remodelling. 
This is a consequence of cross-talk between 5-HT1B/1D and 5-HTT signalling.  In human 
PASMCs activation of 5-HT1B receptors results in phosphorylation of ERK1/2. The signal 
for nuclear translocation of p-ERK1/2 is dependent on 5-HT uptake by the 5-HTT, MAO 
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and ROS generation (Lawrie et al., 2005). As mentioned in section 1.2.3.1.3, this is in 
contrast to the methods by which p-ERK1/2 is nuclear translocated in bovine PASMCs. 
Both human and bovine PASMCs do, however, require both 5-HT1B/1D receptors and the 5-
HTT for nuclear translocation of p-ERK1/2, both of which are likely to be activated by the 
elevated 5-HT induced by 5-HTT substrates such as Dfen. In the nucleus, p-ERK1/2 
interacts with transcription factors such as GATA-4 (Suzuki et al., 2003) to upregulate 
gene transcription of proteins involved in PASMC proliferation such as S100A4/Mts1 
(Lawrie et al., 2005). S100A4/Mts1 is upregulated in PASMCs in pulmonary hypertensive 
patients in arterial lesions with neointimal proliferation. Additionally, 5% of mice 
overexpressing S100A4/Mts1 display occlusive intimal lesions (Greenway et al., 2004). 
The role of Dfen as a 5-HTT substrate appears a critical factor in Dfen induced PAH in 
mice but it may not be the only factor in its effect. The 5-HTT substrate m-
chlorophenylpiperazine (mCPP) which is a greater 5-HT releaser in vitro than Dfen or its 
metabolites is not associated with PAH. mCPP also has activity at multiple 5-HT2 
receptors similar to NDfen. Unlike the fenfluramines, however, mCPP does not induce 
noradrenaline release and is not an amphetamine analogue (Rothman and Baumann, 2002). 
In addition to differences in ability to release noradrenaline, there are likely to be other 
pharmacological differences between non amphetamine and amphetamine 5-HTT 
substrates, perhaps including their regulation of unique Kv channel subunits and their 
effect on whole cell Kv current that determine their ability to induce PAH.  
 There are several unknown factors regarding the interaction of Dfen and the serotonin 
system in WT and Tph1-/- mice. The rate of uptake of Dfen into PASMCs in Tph1-/- mice 
compared to WT for example. This may be influenced significantly by intracellular 5-HT 
levels. The expression of the 5-HTT and 5-HT receptors may also differ between mice 
with normal and mice with no or minimal peripheral 5-HT although evidence shows that 
the function of the 5-HTT is similar in WT and Tph1-/- mice (Ni et al., 2005).  Little is also 
155 
 
known regarding the effects of chronic Dfen treatment on the expression of 5-HT 
receptors. Most studies assessing the effects of Dfen on the serotonergic system have 
focussed on extracellular 5-HT levels following acute administration. Performing CCRCs 
to 5-HT, Dfen and NDfen on WT and Tph1-/- mice treated chronically with and without 
Dfen as performed in this investigation has provided some evidence of altered serotonergic 
function. Interestingly, the potency of 5-HT was reduced in Tph1-/- mice irrespective of 
treatment with Dfen. This is in contrast to experiments performed by Morecroft et al., 2007 
who found an increased contractile response to 5-HT in IPAs from Tph1-/- mice. The 
animals used in that investigation were 5-6 months old (personal communication, Ian 
Morecroft) whereas the animals used here were 3 months at the time of being culled which 
may explain this difference. An enhanced response to 5-HT might be expected if 
vasoconstrictor 5-HT receptors were upregulated in response to a lack of extracellular 5-
HT. A decreased response to 5-HT in Tph1-/- mice may be due to a component of 
vasoconstriction in WT mice being due to 5-HT release or higher expression of either 
vasoconstrictor receptors or intracellular signalling molecules associated with 
vasoconstriction, a process that would be absent in Tph1-/- mice. A downregulation of 5-
HT receptors in Tph1-/- mice is also not inconceivable. In relation to the 5-HTT, 5-HT 
promotes stability in transporter expression and a loss of 5-HT results in downregulation of 
the transporter in HEK239 cells (Ni and Watts, 2006). Similar processes may occur in 
relation to the 5-HT1B or 5-HT2A receptors in mice.  
 Consistent with its low affinity for 5-HT receptors (Rothman and Baumann, 2002), Dfen 
induced vasoconstriction only at high concentrations (>10 µM). The vasoconstrictor 
response to Dfen is only partly mediated by 5-HT2 receptors and a direct action on K+ 
channels is also likely to be an important mediator of Dfen induced vasoconstriction 
(Belohlavkova et al., 2001). No differences were observed in the response to Dfen in any 
of the 4 groups indicating the dominant factor underlying Dfen induced vasoconstriction is 
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similar between groups. This could be expression and activity of Kv channels or even a 
direct effect of Dfen inside the cell (Lee et al., 2001). At 10 µM Dfen is likely to be 
transported inside the cell and accumulate to a high level where it may activate 5-HT 
signalling pathways such as ROCK promoting vasoconstriction. Dfen has been shown to 
mimic 5-HT in fibroblasts by activating mitogenic compounds such as ERK1/2 (Lee et al., 
2001) and this may also occur in relation to vasoconstrictor signalling molecules. If a 
direct action of Dfen in the cell was to be the major factor in Dfen induced 
vasoconstriction it would mean that the 5-HTT is similarly expressed in WT and Tph1-/- 
mice, is unaffected by chronic dosing with Dfen and that Dfen uptake by the 5-HTT is not 
influenced by intracellular 5-HT. A combination of an intracellular action and  a 
contribution from either 5-HT1B or 5-HT2A receptors that owing to the low affinity of Dfen 
at these receptors only induce vasoconstriction at high concentrations may mediate the 
vasoconstriction induced by Dfen (see next chapter for more on Dfen mechanism of 
action).  
 The arterial contraction induced by NDfen, unlike the responses to 5-HT and Dfen was 
influenced by chronic administration of Dfen. The potency of NDfen was lower in both 
WT and Tph1-/- mice dosed with Dfen and the Emax of NDfen was lower in WT mice 
dosed with Dfen compared with controls. NDfen is a potent 5-HT2B and 5-HT2C agonist 
and has moderate potency at 5-HT2A receptors (Rothman and Baumann, 2002). NDfen 
stimulation of 5-HT2C receptors most likely contributes to its anorectic properties (Curzon 
et al., 1997; Vickers et al., 1999) and activation of 5-HT2B receptors may contribute to 
vascular remodelling in mice but without influencing vasoconstriction (Launay et al., 
2002). A direct action at 5-HT2A receptors is the most likely explanation for NDfen 
induced vasoconstriction and this has been shown to underlie NDfen induced 
vasoconstriction in mouse aorta, an effect independent of endogenous 5-HT release (Ni et 
al., 2005). This is similar to results presented here where no significant differences in 
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NDfen contractile response between WT and Tph1-/- mice were found. Combining the 
pharmacological results for 5-HT, Dfen and NDfen leads to some interesting conclusions 
regarding 5-HT receptor expression between WT and Tph1-/- mice and in Dfen and non-
Dfen treated mice.  5-HT response was reduced in Tph1-/- mice whereas the response to 
NDfen was not and indeed, an observable trend towards an enhanced response to NDfen 
was noted in the Tph1-/- animals. We can conclude from this that 5-HT and NDfen are 
exerting their vasoconstrictor response through different mechanisms. This may be 5-HT1B 
receptors mediating 5-HT and 5-HT2A receptors mediating NDfen induced 
vasoconstriction. The 5-HT1B receptor is involved in hypoxic induced vasoconstriction, 
vascular remodelling and RVH in mice (Keegan et al., 2001) and may be decreased in 
young adult Tph1-/- mice. Assuming the 5-HT1B receptor is mediating the vasoconstriction 
to 5-HT, it is unaffected by chronic administration of Dfen. This is in contrast to the 5-
HT2A receptor, thought to underlie the NDfen vasoconstriction. Mice dosed with Dfen may 
have decreased expression of 5-HT2A receptors. This downregulation occurred in Tph1-/- 
mice as well as WT indicating a direct action by Dfen or NDfen in downregulating the 5-
HT2A receptor perhaps as a compensatory mechanism to the potent continuous agonist 
action of NDfen over the 28 day treatment at this receptor.  
 The Tph1-/- mouse can further be utilised to examine the role that peripheral 5-HT has on 
expression of signalling molecules relevant to PAH. In this chapter, pulmonary arteries 
from Tph1-/- mice were examined for protein expression of BMPR2 and p-Smad1/5/8 and 
compared with WT so that the influence of 5-HT on these key regulators of vascular 
function could be assessed. An influence of 5-HT on BMPR2 expression may also be 
relevant to Dfen induced PAH. The Tph1-/- mouse has provided important data on the role 
of peripheral 5-HT in Dfen associated PAH and BMPR2 mutations are found in some Dfen 
users who develop PAH (Humbert et al., 2002). A discovery of altered BMPR2 expression 
between WT and Tph1-/- mice may indicate cross-talk between 5-HT and BMPR2 to 
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support the hypothesis that enhanced serotonergic function interacts with BMPR2 
deficiency in PAH. The mitogenic mediator p-ERK1/2 is activated by 5-HT and Dfen (Lee 
et al., 1999; Lee et al., 2001) and by analysing expression of p-ERK1/2 in pulmonary 
arteries from Tph1-/- mice, it can be determined if 5-HT has a basal effect on maintaining 
p-ERK1/2 level. As described previously, Long et al., 2006 uncovered evidence of cross-
talk between 5-HT and BMPR2 signalling in male PASMCs including 5-HT depressing 
BMP-2 induced phosphorylation of Smad1/5 and  an increase in 5-HT induced ERK1/2 
activation in BMPR2+/- PASMCs compared with WT PASMCs, an effect thought to 
mediate 5-HT induced proliferation of these cells. Although no significant differences were 
observed in this study between WT and Tph1-/- animals, there is a strong suggestion of an 
influence of 5-HT on BMPR2. Expression of BMPR2 in Tph1-/- pulmonary arteries was 
almost double the level seen in WT arteries although a large variation was seen in results 
within the Tph1-/- group. A large standard error was also associated with both p-Smad 
1/5/8 results and those results suggest no notable differences in expression between groups. 
A trend towards decreased p-ERK1/2 expression was noted in Tph1-/- mice and this was 
visible on some of the blots. A decrease in p-ERK1/2 in Tph1-/- pulmonary arteries would 
not be surprising given it is activated by 5-HT. Activation of p-ERK1/2 may also 
participate in 5-HT induced negative regulation of the BMPR2 pathway. p-ERK1/2 is a 
negative regulator of Smad-1. It binds to a region of the Smad-1 protein which it 
phosphorylates causing a form of Smad-1 incapable of nuclear translocation (Massague, 
2003). An increase in p-ERK1/2 induced by 5-HT would therefore suppress the p-
Smad1/5/8 pathway. The BMPR2 receptor is expressed at a lower level in the lungs of 
PAH patients than genetics would predict. There was visibly more BMPR2 expression in 
pulmonary arteries from Tph1-/- mice compared with WT mice perhaps indicating 
peripheral 5-HT also acts to control expression of mature BMPR2 and that elevated 5-HT 
acting via the 5-HTT or 5-HT2A receptors suppresses BMPR2 and p-Smad1/5/8 in PAH 
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 patients leading to a proliferative phenotype. 
 The discovery that Dfen requires peripheral 5-HT to exert its pulmonary hypertensive 
effect supports the evidence in favour of the ‘serotonin hypothesis’ of PAH. This is further 
supported by other recent data looking at peripheral 5-HT synthesis in pulmonary 
hypertension both in humans and in animals. The finding that hypoxia increases Tph1 
expression in rabbit lung 3 fold (Pan et al., 2006) and hypoxic PAH is attenuated in Tph1-/- 
mice (Morecroft et al., 2007; Izikki et al., 2007) coupled with human data indicating TPH1 
is upregulated in PASMCS in IPAH patients (Eddahibi et al., 2006) all favour a role for 
increased peripheral 5-HT in PAH.  
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Chapter 6 
Investigation of pharmacological response to dexfenfluramine and 
nordexfenfluramine  
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6.1 Introduction 
Dfen has previously been shown to be a pulmonary vasoconstrictor (Belohlavkova et al., 
2001), an effect attributed to either 5-HT release, a direct action on 5-HT receptors or 
through inhibition of K+ channels. Dfen is known to be a partial or full agonist at many 
different 5-HT receptors but shows only low affinity for the vasoconstrictor 5-HT1B and 5-
HT2A receptors (Fitzgerald et al., 2000; Rothman et al., 2000). As determined in the 
previous chapter, Dfen is a poor vasoconstrictor in WT and Tph1-/- mice, inducing 
vasoconstriction only at concentrations >10 µM. To discover whether Dfen induced 
vasoconstriction may be increased by the genetic changes relevant to PAH, IPAs from WT, 
5-HTT+, BMPR2+/- and Cross TG mice were all exposed to CCRCs to Dfen. Experiments 
were performed in IPAs from male and female mice so a gender comparison could be 
performed.  
 As already mentioned, Dfen undergoes metabolism to NDfen, a metabolite with twice the 
plasma half life of Dfen (Caccia et al., 1985). NDfen is thought to induce vasoconstriction 
through activation of 5-HT2A receptors (Ni et al., 2005) and NDfen has a significantly 
higher affinity for this receptor than Dfen (Fitzgerald et al., 2000; Rothman et al., 2000). It 
is, therefore, important to also test the pulmonary vasoconstrictor response to this 
metabolite and this was performed in the same manner as for Dfen. There were, however, 
insufficient TG animals available for a gender comparison to NDfen or to use just one 
gender so both male and female mice were used in this experiment (see discussion for 
further information on gender comparison experiments).  
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6.2 Methods 
6.2.1 Animals 
All mice were age 5-6 months 
 
6.2.2 Myography 
IPAs were isolated from mice from each of the four genotypes and used for wire 
myography experiments as described previously.  
Following attainment of maximal contractile response to KCl as outlined in section 2.6.1.5, 
vessels were left to equilibrate for 30 minutes before CCRCs were performed for Dfen or 
NDfen. All drugs were dissolved in H2O to give a solution of 10-2 M from which serial 
dilutions were created up to 10-6 M giving the range necessary for a 1 nM- 300 M CCRC 
to be constructed. Each vessel segment was subjected to only one treatment.  
 
6.3 Results 
Contractions in IPAs were measured relative to the contraction induced by 50 mM KCl. 
No significant differences were observed in KCl response between genotypes or gender 
(WT male: 3.7 ± 0.3 mN, n=6, WT female: 3.0 ± 0.3 mN, n=6, 5-HTT+ male: 3.4 ± 0.5 
mN, n=6, 5-HTT+ female: 2.7 ± 0.3 mN, n=6, BMPR2+/- male: 3.4 ± 0.6 mN, n=6, 
BMPR2+/- female: 3.0 ± 0.2 mN, n=6, Cross TG male: 2.8 ± 0.3 mN, n=6, 3.0 ± 0.2 mN, 
n=6). 
 
6.3.1 Dfen 
CCRCs were performed for Dfen in male mice (figure 6.1) and female mice (figure 6.2). 
Results did not allow calculation of pEC50 or Emax so each concentration tested was 
statistically compared between groups. There were no significant differences between 
genotypes at any concentration tested for male mice (figure 6.1). In female mice, Dfen 
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exerted a significantly greater contraction in Cross TG mice at 1 μM (WT: 2.0 ± 1.2% of 
the contraction induced by 50 mM KCl, n=5, 5-HTT+: 3.7 ± 2.1%, n=7, BMPR2+/-: 1.3 ± 
0.9%, n=6, Cross TG: 33.5 ± 11.5%, n=4), 3 μM (WT: 2.8 ± 1.7%, n=5, 5-HTT+: 7.1 ± 
5.0%, n=7, BMPR2+/-: 1.8 ± 1.2%, n=4, Cross TG: 50.5 ± 11.1%, n=4), 10 μM (WT: 5.0 ± 
1.9%, n=5, 5-HTT+: 9.0 ± 3.4%, n=7, BMPR2+/-: 3.3 ± 1.6%, n=6, Cross TG: 48.8 ± 8.8%, 
n=4),  and  30  μM  (WT:  19.6 ± 9.9%, n=5, 5-HTT+: 9.7 ± 1.9%, n=7, BMPR2+/-: 6.5 ± 
3.4%, n=6, Cross TG: 35.8 ± 7.0%, n=6) compared to the other three genotypes (figure 
6.2).  Figures 6.3 and 6.4 show a male versus female comparison for each genotype. There 
were no differences between male and female WT mice at any concentration used (figure 
6.3A). Dfen exerted a greater contraction in IPAs in male 5-HTT+ mice compared to 
female 5-HTT+ mice at 10 μM (male: 37.8 ± 10.6% of the contraction induced by 50 mM 
KCl, n=6, female: 9.0 ± 3.4%, n=7), 30 μM (male: 38.8 ± 8.8%, n=6, female: 9.7 ± 1.9%, 
n=7) and 100 μM (male: 31.8 ± 8.9%, n=6,  female: 9.0 ± 3.4%, n=7) (figure 6.3B). The 
only notable difference between genders in BMPR2+/- mice was at 100 μM with male IPAs 
having the greatest contractile response (male: 45.0 ± 7.2%, n=4, female: 19.7 ± 6.6%, 
n=6) (figure 6.4A). In relation to the Cross TG mice, female IPAs were more sensitive to 
Dfen than male IPAs at 1 μM (male: 2.8 ± 1.7%, n=5, female: 33.5 ± 11.4%, n=4) and 3 
μM (male: 13.2 ± 8.1%, n=5, female: 50.5 ± 11.1%, n=4) (figure 6.4B). 
 
6.3.2 NDfen 
CCRCs were performed for NDfen and the data is presented in figure 6.5. NDfen was 
significantly more potent in all TG mice compared to WT (pEC50; WT:  5.7 ± 0.1, n=6, 5-
HTT+: 6.0 ± 0.1, n=6, BMPR2+/-: 6.1 ± 0.0, n=6, Cross TG: 6.1 ± 0.0, n=6).  BMPR2+/- 
mice displayed a higher Emax to NDfen compared with WT and Cross TG (WT: 82.2 ± 
5.8% of the contraction induced by 50 mM KCl, n=6, BMPR2+/-: 106.2 ± 2.4%, n=6, Cross 
TG: 86.8 ± 1.6%, n=6) groups. 
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F igure 6.1 Cumulative concentration-response curves to Dfen in IPAs from WT, 5-HTT+, 
BMPR2+/- and Cross TG male mice (n = 4 to 6 mice per group). Results expressed as mean 
± SEM. Newman-Keuls multiple comparison test revealed no significant differences 
between groups at any concentration tested.  
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F igure 6.2 Cumulative concentration-response curves to Dfen in IPAs from WT, 5-HTT+, 
BMPR2+/- and Cross TG female mice (n = 4 to 7 mice per group). Results expressed as 
mean ± SEM. * p<0.05, *** p<0.001 versus corresponding concentration in WT, 5-HTT+ 
and BMPR2+/- mice using Newman-Keuls multiple comparison test. 
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F igure 6.3 Comparison of male and female cumulative concentration-response curves to 
Dfen in IPAs from WT (A) and 5-HTT+ (B) mice (n = 4 to 7 mice per group). Results 
expressed as mean ± SEM. * p<0.05, ** p<0.01 versus corresponding concentration in 
female mice using an unpaired two-tailed t-test. 
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F igure 6.4 Comparison of male and female cumulative concentration-response curves to 
Dfen in IPAs from BMPR2+/- (A) and Cross TG (B) mice (n = 4 to 6 mice per group). 
Results expressed as mean ± SEM. * p<0.05 versus corresponding concentration in female 
mice, † p<0.05 versus corresponding concentration in male mice using an unpaired two-
tailed t-test.  
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F igure 6.5 Cumulative concentration-response curves to NDfen in IPAs from WT, 5-
HTT+, BMPR2+/- and Cross TG male/female mice (n = 6 mice per group). Results 
expressed as mean ± SEM. pEC50:  *** p<0.001 versus WT, Emax: * p<0.05 versus WT 
and Cross TG using Newman-Keuls multiple comparison test. 
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6.4 Discussion 
Several interesting observations emerged from this series of experiments involving the role 
of gender and how the genetics of the mouse influenced which gender was more sensitive 
to Dfen. Perhaps the most interesting and important results came in the Cross TG mice 
where females were more sensitive to Dfen induced vasoconstriction than males. In the 
female Cross TG mice, Dfen induced vasoconstriction at a lower concentration than any 
other group (>30% of KCl at 1 µM). The maximum vasoconstriction recorded in the Cross 
TG females was over 50% of KCl response measured at 3µM Dfen. This was 40% higher 
than in males at the same concentration and the highest recorded contractile response to 
Dfen measured across all experiments. Results in the Cross TG mice were in contrast to 
results in the 5-HTT+ mice where Dfen induced greater vasoconstriction in male mice at 
several concentrations tested compared with females. There was a slight male gender 
influence on Dfen in the BMPR2+/- mice also with a greater response to Dfen at 100 µM. 
No differences, however, were noted in Dfen response between WT male and females 
where the response was similar to that observed in the 2-3 month old WT females in 
chapter 5. 
 The 5-HTT, unsurprisingly, is a major determinant in these experiments to the response of 
Dfen. Although no significant differences were noted between genotypes in the male group 
due to the large variability in Dfen response and low n numbers there is a clear trend 
towards enhanced vasoconstriction to Dfen in the 5-HTT+ and Cross TG mice compared 
with WT and BMPR2+/- mice at lower concentrations. Interestingly, the 5-HTT+ females 
were unremarkable in their response to Dfen compared with WT. It was only when 
dysfunctional BMPR2 was combined with overexpressed 5-HTT that the enhanced 
sensitivity to Dfen emerged. These results suggest that in males, dysfunctional BMPR2 
may protect against the 5-HTT mediated enhanced response to Dfen whereas in females 
dysfunctional BMPR2 enhances the Dfen response. The result in the Cross TG mice is 
170 
 
particularly interesting as significant vasoconstriction occurred to Dfen at clinically 
relevant plasma concentrations. The optimum plasma concentration for Dfen to induce 
weight loss is ~ 1 µM. Cross TG females were the only group to show significant 
vasoconstriction at this concentration. Assuming human pulmonary arteries were to 
respond to Dfen in a similar way, then females with a BMPR2 mutation and 
overexpression of the 5-HTT would have pulmonary vasoconstriction following 
administration of Dfen. Dfen induced a biphasic CCRC in mice overexpressing the 5-HTT, 
an effect most likely related to multiple sites of action. As this biphasic response was only 
observed in mice overexpressing the 5-HTT, a heightened interaction between Dfen and 
the 5-HTT would seem to cause this effect. A combination of a 5-HTT inhibitor and 5-HT 
receptor antagonists would be useful in the presence of Dfen to better understand the 
pharmacology of Dfen induced vasoconstriction. One hypothesis for the biphasic response 
is that the initial enhanced vasoconstriction observed in 5-HTT+ mice is due to either an 
intracellular effect of Dfen on vasoconstrictor pathways or an action on Kv channels that 
are perhaps already dysfunctional in 5-HTT+ mice. The secondary vasoconstriction could 
be the result of a direct effect of Dfen on vasoconstrictor 5-HT receptors that is only 
attainable at high concentrations. 
  It was during the course of the Dfen pharmacology experiments in this chapter that clear 
differences emerged in results obtained in male and female mice. These were the first of 
many experiments outlined in this thesis to look at the influence of gender as a modifying 
factor. The availability of TG animals meant that direct gender analysis experiments could 
not be performed for every experiment and priority was given to the in vivo experiments in 
preceding chapters. For this reason, a gender comparison was not performed for NDfen in 
these sets of experiments and a mixture of male and female mice, determined by 
availability of animals, was used. A direct male versus female comparison for NDfen in 
WT mice can be found in the set of experiments looking at the influence of sex hormones 
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on pulmonary vasoconstriction in chapter 8.   
 The potency of NDfen was greater in all TG groups with Emax also increased in 
BMPR2+/- mice. Interestingly, the Emax of NDfen in BMPR2+/- mice was significantly 
greater than Cross TG mice. As discussed in the preceding chapter, NDfen induced 
vasoconstriction is thought to occur via the 5-HT2A receptor (Ni et al., 2005). Ni et al., 
2005 showed that in isolated aorta, NDfen induces vasoconstriction via 5-HT2A receptors 
and that vasoconstriction was independent of any 5-HTT activity. The increase in Emax in 
BMPR2+/- mice may indicate an increase in 5-HT2A receptor number which supports 
pharmacological experiments on IPAs from BMPR2+/- mice conducted by Long et al., 
2006 that demonstrated an increased contractile response to the 5-HT2A agonist, α–methly-
5-HT, compared to WT mice. Given the important role 5-HT2A receptors have in 
vasoconstriction and proliferation of PASMCs, any increase in activity or receptor number 
in pulmonary arteries would enhance serotonergic signalling. Despite NDfen induced 
aortic vasoconstriction being independent of 5-HTT activity, this does not necessarily 
apply to pulmonary arteries and a direct intracellular action of NDfen on serotonergic 
vasoconstrictor pathways or Kv channels may also contribute to the enhanced 
vasoconstriction observed in the TG animals.   
 The most important finding in this chapter was the genetic synergy between 
overexpression of the 5-HTT and BMPR2+/- that increased the contractile response to Dfen 
in Cross TG mice. This effect only occurred in female mice supporting female gender as a 
risk factor for Dfen induced vasoconstriction when combined with genetic pre-disposition. 
The other key finding was that all TG groups demonstrated enhanced vasoconstriction to 
NDfen, possibly indicating enhanced 5-HT2A receptor activity in IPAs from these mice.  
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Chapter 7 
Investigation of pharmacological response to 5-H T , B MP-2 and 
linopirdine 
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7.1 Introduction 
5-HT acting via 5-HT2A and/or 5-HT1B/1D  receptors is a pulmonary vasoconstrictor, 
however, the plasma concentration of 5-HT that would be required to induce 
vasoconstriction is higher than physiological 5-HT plasma concentrations (Zolkowska et 
al., 2006).  As described in section 1.2.3.1.2, it is still a matter of debate whether the 
plasma concentration of 5-HT is a good indicator of any potential pathological role for 5-
HT in the disease progression. Moreover, plasma [5-HT] may not reflect local 5-HT 
concentrations in the lung with PAECs synthesising and releasing 5-HT locally at a rate 
which increases in IPAH (Eddahibi et al., 2006). It may also be the case that other factors 
act to enhance 5-HT induced vasoconstriction in PAH. Important support for this theory 
comes from the finding that pulmonary arteries from BMPR2+/- mice show a greater 
maximum contractile response to 5-HT than corresponding vessels from WT mice (Long et 
al., 2006). Dysfunctional BMPR2 may, therefore, enhance 5-HT receptors or signalling 
molecules associated with vasoconstriction. In this chapter, the contractile response to 5-
HT and possible influencing factors upon that vasoconstriction are investigated. In the first 
part of this study, the contractile response to 5-HT was assessed in WT, 5-HTT+, 
BMPR2+/- and Cross TG mice. To further elucidate any interaction that may exist between 
BMPR2 and 5-HT induced vasoconstriction, the effect of BMP-2 on the contractile 
response to 5-HT was assessed in the four genotypes. 
 As outlined in the introduction Kv channel currents on PASMCs regulate vasoconstriction 
in addition to proliferation and apoptosis. While members of the Kv1-6, Kv8-9 group such 
as Kv1.5 and Kv2.1 have been studied most extensively in relation to PASMC K+ current 
and PAH, the Kv7.1-7.5 (KCNQ) group have recently been found to contribute to the  
resting Vm in PASMC and inhibition of these channels results in pulmonary 
vasoconstriction (Joshi et al., 2006). Changes in expression of the 5-HTT and BMPR2 can 
directly influence Kv channel subunit expression. Both Kv1.5 and Kv2.1 are decreased in 
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the lungs of mice that overexpress 5-HTT in smooth muscle (Guignabert et al., 2006) and 
mice that lack BMPR2 in smooth muscle have decreased expression of Kv1.1, Kv1.5 and 
Kv4.3 (Young et al., 2006).  It is not known if KCNQ channel current is affected by 
genetic changes in the 5-HTT or BMPR2.  To help determine this, CCRCs were performed 
to the KCNQ channel blocker linopirdine in WT, 5-HTT+, BMPR2+/- and Cross TG mice 
to look for any differences in KCNQ mediated vasoconstriction between genotypes. 
 Activation of 5-HT vasoconstrictor receptors results in G protein mediated changes in ion 
channel function (Varghese et al., 2006) but the role of Kv channels in 5-HT induced 
vasoconstriction remains unclear. To assess the role of KCNQ channels in 5-HT induced 
vasoconstriction, CCRCs to 5-HT were performed in WT, 5-HTT+, BMPR2+/- and Cross 
TG mice in the presence and absence of linopirdine.   
 
7.2 Methods 
7.2.1 Animals 
All mice were age 5-6 months. As mentioned in chapter 6, the restricted number of TG 
animals meant that groups containing both male and female mice had to be used in the 
conduct of the following experiments.  
 
7.2.2 Myography 
IPAs were isolated from mice from each of the four genotypes and used for wire 
myography experiments as described previously.  
 Following attainment of maximal contractile response to KCl as outlined in section 
2.6.1.5, vessels were left to equilibrate for 30 minutes. For BMP-2 (R & D Sytsems, 
Abingdon, UK) experiments, BMP-2 (2.34 x 10-6 M) or H2O vehicle was added following 
equilibration and left for 3 hours before CCRCs to 5-HT were performed. To assess the 
contractile response to linopirdine (Tocris Bioscience, Bristol, UK) CCRCs were 
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performed for linopirdine. To determine the effect of linopirdine on 5-HT induced 
vasoconstriction, linopirdine (10-7 M) or H2O vehicle was added to vessels following 
equilibration and left for 15 minutes before CCRCs to 5-HT were performed. For 5-HT 
and linopirdine CCRCs, drugs were dissolved in H2O to give a solution of 10-2 M from 
which serial dilutions were created up to 10-6 M giving the range necessary for a 1 nM- 300 
M CCRC to be constructed. Each vessel segment was subjected to only one treatment.  
 
7.3 Results 
Contractions in IPAs were measured relative to the contraction induced by 50 mM KCl. As 
stated in section 6.3, no significant differences were observed in KCl response between 5-6 
month WT, 5-HTT+, BMPR2+/- and Cross TG mice or between genders. 
 
7.3.1 E ffect of 2.34 x 10-6 M B MP-2 on C C R C to 5-H T 
CCRCs to 5-HT were performed in WT and TG mice following BMP-2 (2.34 x 10-6 M) or 
vehicle (figure 7.1). Both groups of mice overexpressing the 5-HTT+ had lower pEC50 
values for 5-HT than mice with normal 5-HTT expression. This was true for both vehicle 
treated animals (WT: 7.3 ± 0.1, n=6, 5-HTT+: 6.0 ± 0.1, n=6, BMPR2+/-: 7.6 ± 0.1, n=6, 
Cross TG: 6.0 ± 0.1, n=6) and for BMP-2 treated animals (WT: 7.2 ± 0.1, n=6, 5-HTT+: 
6.0 ± 0.1, n=5, BMPR2+/-: 7.2 ± 0.3, n=6, Cross TG: 6.0 ± 0.1, n=6). The presence of the 
BMPR2 mutation did not affect the potency of 5-HT in either BMPR2+/- mice or in Cross 
TG mice. Only the potency of 5-HT was affected by overexpression of the 5-HTT with 
Emax values not significantly different between groups. The Hill coefficient differed 
significantly (p<0.05) between the BMP-2 treated BMPR2+/- group and the BMP-2 treated 
Cross TG group (BMPR2+/-: 0.5 ± 0.2, n=6, Cross TG: 1.2 ± 0.2, n=6). BMP-2 did not alter 
the pEC50 or maximal response of 5-HT in any of the four genotypes (figure 7.1). 
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7.3.2 C C R C to linopirdine 
CCRCs to linopirdine are presented in figure 7.2. CCRCs did not follow a classical 
sigmoidal shape and the Hill equation was not applied to the data. pEC50 and Emax 
values, therefore, were not determined so each concentration tested was statistically 
compared between groups. Linopirdine induced vasoconstriction was greater in WT mice 
compared with all three TG groups. At 300 nM, linopirdine induced vasoconstriction in 
WT mice was significantly greater than in BMPR2+/- mice (WT: 12.7 ± 6.5% of the 
contraction induced by 50 mM KCl, n=6, BMPR2+/-: 0.75 ± 0.3%, n=8).  The contractile 
response was greater in WT mice at 1 M (WT: 51.0 ± 14.9%, n=6, 5-HTT+: 1.5 ± 0.5%, 
n=6, BMPR2+/-: 0.75 ± 0.31%, n=8, Cross TG: 1.7 ± 1.3%, n=6), 3 M (WT: 63.2 ± 
17.0%, n=6, 5-HTT+: 7.7 ± 5.5%, n=6, BMPR2+/-: 9.4 ± 5.9%, n=8, Cross TG: 15.2 ± 
9.6%, n=6), 10 M (WT: 75.5 ± 13.3%, n=6, 5-HTT+: 21.5 ± 10.5%, n=6, BMPR2+/-: 20.4 
± 8.9%, n=8, Cross TG: 29.2 ± 17.7%, n=6) and 30 M (WT: 77.3 ± 13.7%, n=6, 5-HTT+: 
33.8 ± 9.1%, n=6, BMPR2+/-: 32.3 ± 5.5%, n=8, Cross TG: 43.0 ± 16.1%, n=6) compared 
with the three TG groups. Vasoconstriction to linopirdine was also greater in WT mice 
compared with BMPR2+/- mice at the highest concentrations of 100 M (WT: 69.8 ± 
12.3%, n=6, BMPR2+/-: 20.4 ± 4.6%, n=8) and 300 M (WT: 33.2 ± 5.1%, n=6, BMPR2+/-
: 6.6 ± 2.2%, n=8). 
     
7.3.3 E ffect of 10-7M linopirdine on C C R C to 5-H T 
CCRCs to 5-HT were performed in WT and TG mice following linopirdine (10-7M) or 
vehicle (figure 7.3). The potency of 5-HT was greater in BMPR2+/- mice compared with 
the other three groups. This was true for vehicle treated animals (pEC50; WT: 6.6 ± 0.1, 
n=6, 5-HTT+: 5.6 ± 0.1, n=6, BMPR2+/-: 7.3 ± 0.0, n=6, Cross TG: 5.7 ± 0.0, n=6) and for 
linopirdine treated animals (pEC50; WT: 6.7 ± 0.1, n=6, 5-HTT+: 6.1 ± 0.0, n=6, 
BMPR2+/-: 7.7 ± 0.3, n=6, Cross TG: 5.8 ± 0.1, n=6). There were also significant 
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differences in pEC50 values between WT and 5-HTT+ and between WT and Cross TG 
mice, with 5-HT being more potent in WT mice. This was independent of linopirdine 
treatment in Cross TG mice but only in the vehicle treated 5-HTT+ animals was 5-HT less 
potent than the corresponding WT group. No differences were observed between 5-HTT+ 
and Cross TG animals. The maximum response to 5-HT also differed between groups. 
Emax values for 5-HT were higher in BMPR2+/- vehicle treated animals compared with 
WT and 5-HTT+ vehicle treated animals (WT: 95.3 ± 8.0% of the contraction induced by 
50 mM KCl, n=6, 5-HTT+: 97.3 ± 4.5%, n=6, BMPR2+/-: 117.3 ± 4.6%, n=6). In the 
linopirdine treated groups, the only significant difference observed in Emax values was 
between 5-HTT+ and BMPR2+/- mice with BMPR2+/- mice having the higher Emax (5-
HTT+: 97.7 ± 4.9%, n=6, BMPR2+/-: 120.2 ± 4.7%, n=6). A significant difference in the 
Hill coefficient (p<0.01) was observed between BMPR2+/- vehicle treated mice and Cross 
TG vehicle treated mice (BMPR2+/-: 0.6 ± 0.2, n=6, Cross TG: 1.5 ± 0.2, n=6). Linopirdine 
did not significantly affect either pEC50 or the Emax of 5-HT in any of the four groups.  
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F igure 7.1 Cumulative concentration-response curves to 5-HT following BMP-2 (2.34 x 
10-6M) or vehicle in IPAs from WT (A), 5-HTT+ (B), BMPR2+/- (C) and Cross TG (D) 
mice (n= 5 to 6 mice per group). Results expressed as mean ± SEM. pEC50: *** p<0.001 
versus WT vehicle and BMPR2+/- vehicle, $ p<0.001 versus WT BMP-2 and BMPR2+/-  
BMP-2, # p<.0001 versus WT vehicle and BMPR2+/- vehicle, † p<0.001 versus WT BMP-
2 and BMPR2+/- BMP2 using Bonferroni multiple comparison test. 
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F igure 7.2 Cumulative concentration-response curves to linopirdine in IPAs from WT, 5-
HTT+, BMPR2+/- and Cross TG mice (n = 6 to 8 mice per group). Results expressed as 
mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001 versus corresponding concentration in 5-
HTT+, BMPR2+/- and Cross TG mice. †  p<0.05, # p<0.01 versus corresponding 
concentration in BMPR2+/- mice using Newman-Keuls multiple comparison test. 
 
 
 
 
 
 
180 
 
 
 
 
 
-10 -9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
140
WT vehicle
WT lino
5-HT [log M]
Re
sp
on
se
 (%
 50
m
M 
KC
l)
-10 -9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
140
5-HTT+ vehicle **
5-HTT+ lino
5-HT [log M]
Re
sp
on
se
 (%
 50
m
M 
KC
l)
-10 -9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
140
Cross TG vehicle **, †
Cross TG lino , ‡
5-HT [log M]
Re
sp
on
se
 (%
 50
m
M 
KC
l)
-10 -9 -8 -7 -6 -5 -4 -3
0
20
40
60
80
100
120
140
BMPR2+/- vehicle *, $, §,¥
BMPR2+/­ lino ***, #, €
5-HT [log M]
Re
sp
on
se
 (%
 50
m
M 
KC
l)
A                                                             B
  C                                                             D
 
 
 
 
 
F igure 7.3 Cumulative concentration-response curves to 5-HT following linopirdine (10-
7M) or vehicle in IPAs from WT (A), 5-HTT+ (B), BMPR2+/- (C) and Cross TG (D) mice 
(n= 6 mice per group). Results expressed as mean ± SEM. pEC50: * p<0.05, ** p<0.01 
versus WT vehicle, ƒ p<0.01, *** p<0.001 versus WT lino, $, p<0.001 versus 5-HTT+ 
vehicle, # p<0.001 versus 5-HTT+ lino, † p<0.001 versus BMPR2+/- vehicle, ‡ p<0.001 
versus BMPR2+/- lino. Emax: § p<0.01 versus WT vehicle, ¥ p<0.05 versus 5-HTT+ 
vehicle, € p<0.01 versus 5-HTT+ lino using Bonferroni multiple comparison test. 
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7.4 Discussion 
Overexpression of the 5-HTT had a dramatic effect on 5-HT induced vasoconstriction in 
both 5-HTT+ and Cross TG mice. The decreased potency of 5-HT in mice overexpressing 
the 5-HTT can be reversed by the 5-HTT inhibitor citalopram (Dempsie et al., 2008) 
indicating the decreased potency of 5-HT is due to overexpression of the 5-HTT. The most 
likely explanation for this effect is a greater uptake of 5-HT into the cell removing 5-HT 
available for activation of 5-HT2A and 5-HT1B receptors. Interestingly, the pEC50 and 
Emax of 5-HT was increased in BMPR2+/- IPAs compared with WT mice. This 
observation, however, only occurred in the set of experiments involving linopirdine (figure 
7.3) and not in the experiments involving BMP-2 (figure 7.1). The ratio of male to female 
mice used for the WT and BMPR2+/- analysis was similar between the two sets of 
experiments so gender difference can be ruled out as a mitigating factor for the 
discrepancy. An inspection of figures 7.1 and 7.3 reveals a similar response to 5-HT in the 
BMPR2+/- mice in both the linopirdine and BMP-2 experiments and that it is, in fact, the 
response to 5-HT in WT mice that differs between experiments with a greater contractile 
response to 5-HT  in the BMP-2 control experiments. The reason for this discrepancy is not 
known. The only difference in experimental protocol was a longer period of time during 
which the vessel was in the Krebs solution on the myograph in the BMP-2 experiments 
(owing to the longer incubation of BMP-2 and consequently H2O vehicle). This is unlikely, 
however, to make a significant difference to 5-HT induced vasoconstriction, especially in 
WT but not in BMPR2+/- animals. The result is most likely due to batch differences in the 
WT mice due to natural variations in pulmonary artery phenotype within a population. The 
enhanced vasoconstrictor effect of 5-HT in BMPR2+/- IPAs  confirm the results obtained 
by Long et al., 2006 who found an increased maximum response to 5-HT and 5-HT2A 
agonist   α–methly-5-HT in IPAs from BMPR2+/- mice. Long et al., 2006 did not find an 
increase in potency to 5-HT or α–methly-5-HT but did see a leftward shift in the CCRC to 
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the 5-HT1 agonist 5-CT in BMPR2+/- mice. Both the pEC50 and Emax of 5-HT were 
increased in IPAs from BMPR2+/- vessels in this investigation and likely reflects an 
involvement of both 5-HT2A and 5-HT1B receptors and blockade of either of these receptors 
attenuates the 5-HT response in BMPR2+/- IPAs (Long et al., 2006). A change in the Hill 
coefficient was observed between BMPR2+/- and Cross TG mice. The Hill coefficient is a 
measure of the nature of ligand binding to receptor(s) complexes. The change in Hill 
coefficient indicates different binding characteristics for 5-HT between the two genotypes, 
perhaps reflecting a change in the respective utilisation of 5-HT1B and 5-HT2A receptors or 
a change in receptor activation following 5-HT binding, which may be secondary to 
overexpression of the 5-HTT.  
 Linopirdine, a selective KCNQ channel inhibitor induced vasoconstriction in WT mice 
reaching a maximum contraction at 30 µM before inducing vasorelaxation at higher 
concentrations. Vasoconstriction to linopirdine was significantly less in all TG groups at 1 
– 30 µM with additional differences noted between WT and BMPR2+/- groups at 300 nM, 
100 µM and 300 µM. No significant differences were noted between TG groups. The 
vasoconstriction induced by linopirdine in WT mice is independent of endothelial and 
neuronal derived factors (Joshi et al., 2006) and is via a direct action on KCNQ channels 
on PASMCs, an effect attributable to membrane depolarisation and voltage-gated Ca2+ 
entry (Joshi et al., 2009). The effect of linopirdine on systemic vessels appears to be 
significantly less although results have been inconsistent in studies to date. Linopirdine and 
XE991 induced vasoconstriction was found to be minimal or completely absent in systemic 
vessels such as carotid and mesenteric arteries in studies by Joshi et al., 2006 and Joshi et 
al., 2009. This data agrees with results by Yeung et al., 2007 who found that XE991 
induced minimal contraction in femoral and carotid arteries and no contraction in 
mesenteric arteries in the absence of pre-tone. Interestingly, in the presence of pre-tone 
XE991 did induce contraction of mesenteric arteries (Yeung et al., 2007). Contradictory 
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results were demonstrated by Mackie et al., 2008 who found that linopirdine did induce 
vasoconstriction in mesenteric arteries on a pressure myograph. The maximum 
vasoconstriction induced by linopirdine in rat mesenteric arteries was ~ 35% of KCl 
response (Mackie et al., 2008) opposed to the near 100% of KCl response induced by 
linopirdine in rat pulmonary arteries (Joshi et al., 2009).  
 The enhanced vasoconstriction to linopirdine in pulmonary arteries over systemic arteries 
may be may be attributable to the KCNQ4 subunit which is expressed at a higher level than 
other KCNQ channel subunits in pulmonary arteries (Joshi et al., 2009) and is expressed 
more than 10 fold higher in pulmonary arteries compared with mesenteric arteries (Joshi et 
al., 2009). The results by Joshi et al., 2006 and confirmed here indicate that KCNQ 
channels are open at rest and are a major contributor to the resting membrane potential in 
murine PASMCs.  
 One possibility for the decreased response to linopirdine in TG mice is that PASMCs in 
these animals are hyperpolarised relative to WT PASMCs and therefore a greater number 
of KCNQ channels must be blocked to depolarise the cell membrane to a level sufficient to 
induce activation of VDCC.  Alternatively, KCNQ channel subunit expression or activity 
may be lower in the TG animals compared with WT reducing the effect of linopirdine. 
This may or may not be associated with electrophysiological changes. BMP-2 increases 
whole-cell K+ current in human PASMCs and divergently regulates expression of many Kv 
subunits, altering expression of certain subunits >10 fold (Young et al., 2006; Fantozzi et 
al., 2006). Loss of BMPR2 may result in a decrease in whole-cell K+ current and changes 
in KCNQ channel expression. The increase in whole-cell K+ current induced by BMP-2 
would result in a shift to an apoptotic, anti-mitogenic and pro-relaxant cellular phenotype 
and thus, loss of BMPR2 would have the opposite effects. The molecular mechanism by 
which BMPR2 interacts with Kv channel subunits is unknown but may involve the 
presence or absence of SMAD and c-myc binding sites in the promoter regions of Kv 
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channel genes. This could account for the divergent effects BMP-2 has on various Kv 
channel genes (Fantozzi et al., 2006). Overexpression of the 5-HTT+ was sufficient to 
reduce linopirdine induced vasoconstriction at 1 - 30 µM compared with WT.  
Overexpression of the 5-HTT in smooth muscle is sufficient to reduce Kv1.5 and Kv2.1 in 
the lungs of mice (Guignabert et al., 2006) and thus it is conceivable that other Kv channel 
subunits such as KCNQ may also be downregulated by 5-HTT overexpression. Results in 
the Cross TG mice were similar to both 5-HTT+ and BMPR2+/- groups indicating KCNQ 
channel function/expression is not additively altered by 5-HTT overexpression and 
BMPR2 downregulation. 
 The evidence in this thesis that linopirdine induces vasoconstriction of mouse IPAs 
supports previous work indicating that linopirdine not only contracts isolated pulmonary 
arteries but also increases PAP in vivo (Joshi et al., 2009). Moreover, the discovery that 
KCNQ channel activators can induce relaxation of pulmonary arteries (Joshi et al., 2009) 
provides further evidence that KCNQ channels are involved in regulating pulmonary artery 
tone. Due to this important role for KCNQ channels in the pulmonary circulation, 
experiments were performed to assess how linopirdine would affect the vasoconstrictor 
response to 5-HT in WT and TG mice. Linopirdine did not alter the 5-HT response in any 
group which would indicate that 5-HT induced vasoconstriction is not dependent on the 
state of KCNQ channels. The relative contribution of voltage-dependent and voltage-
independent pathways that mediate 5-HT induced vasoconstriction is not known in detail 
and conflicting evidence in this area of research has emerged (Varghese et al., 2006). For 
example, 5-HT inhibits Kv current and depolarises the cell membrane in rat PASMCs and 
Ltk- cells expressing cloned human Kv1.5, effects attenuated by several compounds 
including ketanserin and PKC inhibitors (Cogolluda et al., 2006). Moreover, 5-HT induced 
vasoconstriction of rat pulmonary arteries is also inhibited by ketanserin and PKC 
inhibitors in addition to L-type Ca2+ channel blockers (Cogolluda et al., 2006). 5-HT partly 
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induces vasoconstriction of canine pulmonary arteries through L-type Ca2+ channel 
activation, an effect also mediated by 5-HT2A receptors (Wilson et al., 2005). In contrast to 
these studies, Guibert et al., 2004 found that 5-HT2A mediated vasoconstriction of rat 
pulmonary arteries was independent of voltage-gated Ca2+ channels. Factors other than 
inhibition of Kv current could account for 5-HT induced vasoconstriction in the murine 
IPAs studied in this investigation such as Ca2+ release from intracellular stores and Ca2+ 
sensitisation via ROCK (Rodat-Despoix et al., 2008). The vasoconstrictor pathways 
activated by 5-HT may also depend on the relative expression of 5-HT1B and 5-HT2A 
receptors. 5-HT induced vasoconstriction in rat pulmonary arteries can be inhibited by 5-
HT1B and 5-HT2A antagonists but 5-HT induced inhibition of Kv currents is only prevented 
by 5-HT2A antagonists (Cogolluda et al., 2006). It maybe that Kv channels are more 
important in 5-HT induced vasoconstriction in arteries with a higher concentration of 5-
HT2A receptors although this may be species specific. 
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Chapter 8 
 Gender as a modifying factor in PA H 
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8.1 Introduction 
The increased risk of PAH in women of child bearing age suggests that circulating female 
sex hormones may underlie the increased risk. Experiments utilising both the MCT and 
hypoxic models, however, have generally shown that female mice are more resistant to 
developing PAH  than males and that female sex hormones attenuate the development of 
both hypoxic and MCT PAH through vasodilator and anti-mitogenic effects.  
 The effect of sex hormones on vascular tone appears dependent on species, gender, 
vascular origin of artery and whether the artery has intact endothelium. Estradiol relaxes 
isolated perfused rat tail arteries pre-contracted with noradrenaline in female rats but not in 
males and this effect is dependent on an intact endothelium (McNeill et al., 1996). This 
may indicate that estradiol modulates adrenergic effects in vivo in female rats.  Estradiol is 
also a vasodilator of human coronary arteries where it also acts via an endothelium 
dependent process (Gilligan et al., 1994). The endothelium dependent effect of estrogens is 
thought to occur either through the rapid release of NO via a non genomic estrogen 
receptor (ER) mediated process (Chen et al., 1999; Stefano et al., 2000) or via a non ER 
cell surface receptor involving stereospecific interactions with an unknown receptor at the 
cell surface that induces vasodilation independent of NO and prostaglandins (Teoh et al., 
2000a; Shaw et al., 2000). Alternatively, estradiol can induce vasodilation in endothelium 
denudated vessels (Sudhir et al., 1995; Chester et al., 1995), a process governed by K+ and 
Ca2+ channels (Sudhir et al., 1995). The discrepancy in these results most likely involves 
differences in tissue preparation, vascular origin of tissue, sex of animal and species. 
Estradiol can also act as a vasoconstrictor enhancing the vasoconstriction of several 
common vasoconstrictors (Vargas et al., 1995). Whether estrogens act as vasoconstrictors 
or vasodilators may be regional specific, for example, in the rabbit, estradiol relaxes pre-
constricted coronary and ear arteries but increases the contractile force of pre-constricted 
pulmonary and thoracic arteries. The vasoconstrictor effect of estradiol was attenuated by 
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indomethacin indicating a role for prostaglandins in this process (Opgaard et al., 2002). 
Estradiol also modulates both HPV and ET-1. For example, estradiol reduces HPV in 
sheep (Sylvester et al., 1985) and rats (Lahm et al., 2007). Estradiol also reduces lung 
levels of ET-1 and prevents hypoxia induced increases in ET-1 by preventing the action of 
HIF-1  (Earley and Resta, 2002). Estradiol undergoes metabolism via several enzyme 
pathways to form non-estrogenic metabolites (Dubey et al., 2004). As mentioned in section 
1.2.3.2.4, one of these metabolites, 2-ME, has demonstrated to be protective in animal 
models of PAH. The vasoactive role of 2-ME in systemic and pulmonary arteries has yet to 
be determined in detail but sufficient evidence exists that it may be as important or more 
important than estradiol in modulating vasoactive compounds. 2-ME is a more potent 
inhibitor of ET-1 (Dubey et al., 2001) and a more potent inducer of prostacyclin synthesis 
(Seeger et al., 1999) compared with estradiol in endothelial cells.  
  Testosterone has also been studied for its vasoactive properties in different vessel types 
including pulmonary and coronary arteries from several species (Littleton-Kearney and 
Hurn, 2004). While there is data supporting a vasodilator role for testosterone (Honda et 
al., 1999; English et al., 2001; Ding and Stallone, 2001), a process thought to involve 
activation of NO or a direct action on ion channels present on smooth muscle cells 
(Littleton-Kearney and Hurn, 2004), there is also opposing data favouring a 
vasoconstrictor role for testosterone (Quan et al., 1999; Teoh et al., 2000a; Teoh et al., 
2000b), a process possibly related to an inhibition of prostacyclin or inhibition of Kv 
channels (Littleton-Kearney and Hurn, 2004).  
 The concentration of sex hormones required to induce vasodilation or vasoconstriction in 
isolated tissue preparations are usually within the pharmacological range, however, HPV is 
reduced in extralobar pulmonary arteries from rats during the proestrus menstrual phase 
(Lahm et al., 2007) indicating that small changes in circulating estrogen levels can alter the 
vascular response to a vasoconstrictor stimulus. Additionally, physiological concentrations 
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(1-30 nM) of estradiol and testosterone can influence 5-HT and ET-1 induced 
vasoconstriction in porcine coronary arteries (Teoh et al., 2000a).  
 The experimental evidence just outlined offers the possibility for interaction of sex 
hormones with potential mediators of PAH. There have been relatively few studies 
examining the role of gender in animal models of PAH and the effect that male hormones 
such as testosterone and female hormones such as estradiol and 2-ME have on pulmonary 
arteries and on PAECs and PASMCs. Many animal studies in PAH have used only male 
gender for experimental procedures or mixed gender populations that do not discriminate 
between males and females.  Indeed, several of the in vitro pharmacology experiments in 
this thesis used mixed gender groups of animals due to the limited number of TG animals 
available. It was during these in vitro experiments that clear gender differences emerged in 
the response to vasoconstrictors that subsequently resulted in specific male versus female 
comparisons being performed for the hypoxic studies in chapter 3 and the Dfen in vivo and 
in vitro pharmacology work in chapters 4 and 6. The results of these experiments coupled 
with the importance of female gender as a modifying risk factor for PAH warranted further 
experimental analysis. In this chapter, the vasoconstrictor/vasodilator properties of both 
male and female sex hormones and their effect on 5-HT vasoconstriction were analysed in 
pulmonary arteries of both male and female mice. To further determine any modulating 
effect estradiol might have on serotonergic induced vasoconstriction relevant to PAH, 
CCRCs were also performed to NDfen in the presence and absence of estradiol.  Male and 
female mouse lungs were also analysed for any differences in 5-HT and BMPR2 signalling 
molecules.   
 
 
 
 
190 
 
8.2 Methods 
8.2.1 Animals  
Animals were age 2-3 months 
 
8.2.2 Myography 
IPAs were isolated from male and female WT mice and used for wire myography 
experiments as described previously. 
Following attainment of maximal contractile response to KCl as outlined in section 2.6.1.5, 
vessels were left to equilibrate for 30 minutes.  
To assess the vasoconstrictor properties of sex hormones, CCRCs to estradiol (Sigma-
Aldrich Ltd, Poole, UK), 2-ME (Sigma-Aldrich Ltd, Poole, UK), testosterone (Sigma-
Aldrich Ltd, Poole, UK) and vehicle were performed in IPAs from male and female mice. 
To assess the vasodilator properties of sex hormones CCRCs were performed in IPAs from 
male and female mice pre-constricted with phenylephrine (a concentration in the range 10-8 
– 10-7 M dissolved in H2O that induced vasoconstriction equal to 70% of 50 mM KCl). All 
hormones were dissolved in ethanol to give a solution of 10-3 M from which serial 
dilutions were created in H2O up to 10-8 M giving the range necessary for a 10 pM – 10  
M CCRC to be constructed. 
 Following the final concentration of hormone (10-5 M) added during the experiments 
assessing vasoconstriction, vessels were left for 20 minutes before a CCRC to 5-HT was 
performed to assess the effects of sex hormones on 5-HT induced vasoconstriction.  
 Separate experiments were performed to assess the effect of a physiological concentration 
(1 nM) of estradiol and testosterone on 5-HT. Hormones or ethanol vehicle were incubated 
for 20 minutes before a CCRC to 5-HT was constructed. 
 Finally, 1 nM of estradiol or ethanol vehicle was incubated for 20 minutes prior to CCRCs 
for NDfen being performed in IPAs from male and female mice. 
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5-HT and NDfen were dissolved in H2O to give a solution of 10-2 M from which serial 
dilutions were created up to 10-6 M giving the range necessary for a 1 nM- 300 M CCRC 
to be constructed 
 As stated above, CCRCs to 5-HT following 10-5 M of estradiol/2-ME/testosterone were 
performed on vessels following the initial CCRC to each hormone. For all other 
experiments vessels were subjected to only one treatment.  
 
8.3 Results 
Contractions in IPAs were measured relative to the contraction induced by 50 mM KCl. 
No significant differences were observed in KCl response between genders (male: 2.5 ± 
0.3 mN, n=6, female: 2.4 ± 0.2 mN, n=6). 
 
8.3.1 Assessment of contractile response to estradiol, 2-M E and testosterone in male 
and female IPAs 
CCRCs to estradiol, 2-ME and testosterone are presented in figure 8.1. No vasoconstriction 
was observed up to 10-5 M for any hormone tested in either male or female mice.  
 
8.3.2 Assessment of vasodilator response to estradiol, 2-M E and testosterone in male 
and female IPAs 
Figure 8.2A shows CCRCs for each hormone in IPAs from male mice pre-constricted with 
phenylephrine. All three hormones displayed significant vasodilator effects at 
concentrations equal to or greater than 0.1 µM in male mice and this data is presented in 
table 8.1A.  The only significant difference noted between hormones in the relaxation 
response was at 10 µM where estradiol induced a greater degree of relaxation (p<0.05) 
compared with 2-ME (figure 8.2A). In female IPAs (figure 8.2B) testosterone induced a 
significant vasodilator effect at 3 µM and above with both female hormones exerting a 
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significant vasodilator effect from 10 µM (table 8.1B).  No significant differences were 
observed between hormones.  The only gender differences to emerge were for estradiol. 
The vasodilation induced by estradiol was greater in male mice (p<0.05) compared with 
female mice at 100 nM (male: -6.9 ± 2.9% of phenylephrine induced pre-constriction, n=6, 
female: 2.8 ± 0.7%, n=6), 300 nM (male: -6.1 ± 2.4%, n=6, female: -0.2 ± 0.8%, n=6), 1 
µM (male: -10.2 ± 2.6%, n=6, female: -0.7 ± 2.1%, n=6) and 10 µM (male: -38.6 ± 4.7%, 
n=6, female: -24.3 ± 2.8%, n=6).  
 
8.3.3 Influence of a high concentration (10-5 M) of estradiol, 2-M E and testosterone on 
5-H T induced vasoconstr iction. 
Following the CCRCs to each hormone, an additional CCRC to 5-HT was performed in the 
presence of 10-5 M estradiol, 2-ME and testosterone (figure 8.3). In male mice (figure 
8.3A), the pEC50 of 5-HT was decreased (p<0.05) in estradiol treated vessels compared 
with vehicle (vehicle: 7.5 ± 0.1, n=7, estradiol: 7.1 ± 0.1, n=6) and there was a significant 
difference (p<0.05) in the pEC50 between the estradiol and testosterone treatment groups 
with the greater pEC50 being in animals that had been treated with testosterone (estradiol: 
7.1 ± 0.1, n=6, testosterone: 7.4 ± 0.1, n=6). Hormones affected the maximal response to 5-
HT to a much greater degree than pEC50 with each hormone significantly (p<0.001) 
reducing the Emax of 5-HT compared with vehicle (vehicle: 124.0 ± 4.2% of the 
contraction induced by 50 mM KCl, n=7, estradiol: 93.3 ± 5.9%, n=6, 2-ME: 98.3 ± 6.1%, 
n=6, testosterone: 92.0 ± 7.5%, n=6). There were no differences, however, in the maximal 
response to 5-HT between the estradiol, 2-ME or testosterone groups  
   In female IPAs, testosterone increased (p<0.01) the pEC50 of 5-HT compared with 
estradiol and 2-ME (estradiol: 7.2 ± 0.1, n=6, 2-ME: 7.2 ± 0.1, n=7, testosterone: 7.6 ± 0.1, 
n=6) but did not differ significantly from the vehicle group.  The only significant 
difference in Emax was between the testosterone and estradiol groups with testosterone 
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increasing (p<0.05) the Emax of 5-HT compared to estradiol (estradiol: 93.5 ± 5.2%, n=6, 
testosterone: 120.2 ± 6.9%, n=6) (figure 8.3B). 
Data was analysed to determine any differences between 5-HT response in male and 
female IPAs. No differences were found in pEC50 values but Emax values did differ 
significantly (p<0.05) in the testosterone groups (male: 92.0 ± 7.5%, n=6, female: 120.2 ± 
6.9%, n=6). 
 
 8.3.4 Influence of a low concentration (10-9 M) of estradiol and testosterone on 5-H T 
induced vasoconstr iction 
The effect of a physiological (10-9 M) concentration of estradiol and testosterone was tested 
on the vasoconstrictor effect of 5-HT in male and female IPAs (figure 8.4). No differences 
were observed in pEC50 or Emax in 5-HT response following estradiol or testosterone in 
either male or female mice. There were also no differences between male and female 
groups for respective hormones or vehicle.  
 
 8.3.5 Influence of a low concentration (10-9 M) of estradiol on NDfen induced 
vasoconstr iction 
To determine whether a physiological concentration of estradiol could influence the 
vasoconstriction induced by NDfen, CCRCs to NDfen were performed in the presence of 
10-9 M estradiol in male and female IPAs (figure 8.5). NDfen was significantly more potent 
in IPAs from male mice in both vehicle (pEC50; male: 6.1 ± 0.1, n=7, female: 5.5 ± 0.1, 
n=7) and estradiol (pEC50; male: 6.0 ± 0.0, n=6, female: 5.3 ± 0.1, n=6) treated groups 
with maximal response unaffected. Estradiol had no effect on vasoconstriction in either 
gender.  
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8.3.6 Expression of 5-H T and B MPR2 signalling molecules in male and female mouse 
lung. 
Expression of p-Smad1/5/8 (figure 8.6), p-p38 MAPK (figure 8.7) and p-ERK1/2 (figure 
8.8) were analysed by western blotting in male and female whole mouse lung. p-
Smad1/5/8 and p-p38 MAPK expression did not differ between genders but p-ERK1/2 was 
expressed more strongly in female mouse lung.  
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F igure 8.1 Cumulative concentration-response curves to estradiol, 2-ME, testosterone and 
ethanol vehicle in IPAs from male (A) and female (B) WT mice (n=6-9 mice per group). 
Results expressed as mean ± SEM. Newman-Keuls multiple comparison test revealed no 
significant differences between groups at any concentration tested.  
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F igure 8.2 Cumulative concentration-response curves to estradiol, 2-ME, testosterone and 
ethanol vehicle in IPAs (pre-constricted with phenylephrine) from male (A) and female (B) 
WT mice (n=6 mice per group). Results expressed as mean ± SEM (Results corrected to 
account for ethanol vehicle response). * p<0.05, ** p<0.01, *** p<0.001 versus 
corresponding concentration for ethanol vehicle. † p<0.05 versus 2-ME using Newman-
Keuls multiple comparison test. 
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  A 
T reatment 3 µM 10 µM 30 µM 
vehicle -0.8 ± 2.0 -4.2 ± 2.2 -2.7 ± 1.2 
estradiol -11.8 ± 3.0 -24.3 ± 2.8 * -41.2 ± 5.7 ** 
2-M E -9.3 ± 3.6  -23.7 ± 8.5 * -43.8 ± 9.3 *** 
testosterone -15.0 ± 4.8 * -32.5 ± 6.6 * -58.3 ± 7.6 *** 
 
 B 
 
Table 8.1 Significant vasodilator effect of estradiol, 2-ME and testosterone in vessels pre-
constricted with phenylephrine in male (A) and female (B) IPAs (n=6 mice per group). 
Results expressed as mean (% of pre-constriction) ± SEM (Results corrected to account for 
ethanol vehicle response). * p<0.05, ** p<0.01, *** p<0.001 versus corresponding vehicle 
value. † p<0.05 versus 2-ME using Newman-Keuls multiple comparison test. 
 
T reatment    100 nM 300 nM 1 µM 3 µM 
vehicle  4.2 ± 2.1  2.8 ± 1.2 4.4 ± 1.3 4.4 ± 1.4 
estradiol -6.9 ± 2.9 ** -6.1 ± 2.4 ** -10.2 ± 2.6 *** -18.6 ± 2.6 *** 
2-M E -6.5 ± 1.8 ** -7.3 ± 1.6 ** -10.1 ± 1.9 *** -10.6 ± 3.1 *** 
testosterone -4.4 ± 1.0 * -3.1 ± 1.2 * -9.2 ± 0.9 *** -12.1 ± 1.7 *** 
T reatment    10 µM 30 µM   
vehicle  7.6 ± 1.9  11.2 ± 3.3   
estradiol -38.6 ± 4.7 ***,† -53.7 ± 5.8 ***   
2-M E -24.3 ± 3.8 *** -39.2 ± 4.9 ***   
testosterone -31.1 ± 3.5 *** -55.4 ± 6.9 ***   
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F igure 8.3 Cumulative concentration-response curves to 5-HT following selected sex 
hormones (10-5 M) and ethanol vehicle in IPAs from male (A) and female (B) mice (n= 6-7 
mice per group). Results expressed as mean ± SEM. Male pEC50: * p<0.05 versus 
testosterone and vehicle. Male Emax: *** p<0.001 versus vehicle. Female pEC50: ** 
p<0.05 versus estradiol and 2-ME. Female Emax: * p<0.05 versus estradiol using 
Newman-Keuls multiple comparison test. 
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F igure 8.4 Cumulative concentration-response curves to 5-HT following selected sex 
hormones (10-9 M) and ethanol vehicle in IPAs from male (A) and female (B) mice (n= 4-6 
mice per group). Results expressed as mean ± SEM. Newman-Keuls multiple comparison 
test revealed no significant difference in pEC50 or Emax between groups. 
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F igure 8.5 Cumulative concentration-response curves to NDfen following estradiol (10-9 
M) and ethanol vehicle in IPAs from male and female mice (n=6-7 mice per group). 
Results expressed as mean ± SEM. pEC50: *** p<0.001 versus respective male treatment 
group using Bonferroni multiple comparison test.  
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F igure 8.6 Representative autoradiograms and densitometric analysis of p-Smad1/5/8 
expression in male and female mouse lung (n=6 mice per group). Results expressed as 
mean ± SEM. An unpaired two-tailed t-test revealed no significant difference between 
groups. 
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F igure 8.7 Representative autoradiograms and densitometric analysis of p-p38 expression 
in male and female mouse lung (n=6 mice per group).  Results expressed as mean ± SEM. 
An unpaired two-tailed t-test revealed no significant difference between groups. 
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F igure 8.8 Representative autoradiograms and densitometric analysis of p-ERK1/2 
expression in male and female mouse lung (n=6 mice per group).  Results expressed as 
mean ± SEM. * p<0.05 versus male using an unpaired two-tailed t-test. 
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8.4 Discussion 
The key findings from this chapter are the discovery that steroid sex hormones from both 
male and female mice have a vasodilator effect on pulmonary arteries pre-constricted with 
phenylephrine. A pharmacological concentration of 10-5 M (10-5 M was chosen as a 
concentration that should reliably uncover any rapid non-genomic 
vasodilator/vasoconstrictor effect each hormone may have. It would also allow a 
comparison with a physiological concentration giving greater insight into the vasoactive 
effects of each hormone) estradiol, 2-ME and testosterone reduced the vasoconstriction to 
5-HT in IPAs from male mice but not in female mice. Estradiol and testosterone at a 
physiological concentration of 10-9 M, however, were without effect on 5-HT in either 
gender. Estradiol at 10-9 M was also without effect on NDfen which was found to be a 
more potent vasoconstrictor in male mice. Finally, p-ERK1/2 was found to be increased in 
female mouse lung compared with males with p-Smad1/5/8 and p-p38 MAPK levels 
similar between genders. 
 The first series of myography experiments designed to assess the vasoactive effects of sex 
hormones conclusively show that both male (testosterone) and female (estradiol and 2-ME) 
sex hormones have vasorelaxant effects on murine IPAs. This is further evidence for the 
ability of steroid hormones to induce rapid non-genomic vasoactive effects on vascular 
tissue. Both estradiol and testosterone have previously been shown to dilate rat pulmonary 
vessels pre-contracted with prostaglandin-F-2α  with  testosterone  inducing  the  largest 
relaxation, an effect found to be greater in male pulmonary arteries (English et al., 2001). 
This differs to the mouse IPAs pre-constricted with phenylephrine utilised in this 
investigation where there was no difference in testosterone induced relaxation between 
male and female IPAs and no significant differences emerged between testosterone and 
estradiol in either gender. There was an enhanced response to estradiol in male mice 
compared with female mice at several concentrations tested. This would indicate a greater 
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activation of vasodilator pathways in male mice. The fact that the three hormones did not 
differ significantly in effect (with the exception of a greater relaxation induced by estradiol 
at 10 µM compared with 2-ME in male IPAs) may indicate that similar pathways were 
utilised in inducing the vasorelaxation. These may involve NOS and NO activation which 
has been demonstrated to be involved in estradiol induced vasorelaxation in several 
vascular beds (McNeill et al., 1996; Chen et al., 1999; Stefano et al., 2000; Scott et al., 
2007). Other studies, however, have found the vasoactive properties of sex hormones to be 
independent of NO (Chester et al., 1995; Sudhir et al., 1995; Naderali et al., 1999; Teoh et 
al., 2000a; Teoh 2000b; Shaw et al., 2000). There is sufficient evidence that estradiol 
exerts its vasoactive effects by different mechanisms depending on gender (Chester et al., 
1995; McNeill et al., 1996), species, arterial location (Opgaard et al., 2002), the inducer of 
vasoconstriction used in the experiment (Teoh et al., 2000a) and even depending on 
whether the animal is pregnant or not (Scott et al., 2007). A more consistent finding across 
the literature on the vasoactive properties of sex hormones is the high concentration 
(relative to physiological concentrations) of hormone necessary to induce significant 
vasodilation. Generally, supraphysiological (>0.1 µM, more commonly  >3 µM) 
concentrations have been required to induce significant relaxation (Naderali et al., 1999; 
Shaw et al., 2000; Opgaard et al., 2002; Scott et al., 2007). The results presented in this 
thesis agree with this conclusion.  0.1 µM and 3 µM in male and female mice respectively 
was the lowest concentration of hormone that induced significant vasorelaxation. Although 
each of the three hormones induced vasodilation in male mice at lower concentrations than 
in female mice, the extent of the vasodilation was small (< 10% of phenylephrine pre-
constriction at concentrations less than 1 µM). Even the concentrations required to induce 
a small response, therefore, are higher than the normal physiological concentration of 
estradiol in females (<2 nM) and the plasma testosterone concentration (10-38 nM) in 
males. It is unlikely, therefore, that any rise or fall in either male or female sex hormones 
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would directly affect the tone of pulmonary arteries. As outlined in the introduction, 
however, physiological concentrations of estradiol can influence HPV (Lahm et al., 2007) 
and both estradiol and testosterone (1-30 nM) alters 5-HT and ET-1 induced 
vasoconstriction in porcine pulmonary arteries (Teoh et al., 2000a). In this investigation, 
both pharmacological (10-5 M) and physiological (10-9 M) concentrations of male and 
female sex hormones were tested in their respective abilities to alter the vasoconstriction 
induced by 5-HT in IPAs. Estradiol, 2-ME and testosterone decreased the Emax of 5-HT at 
10-5 M in male IPAs, consistent with the vasodilator effect of these hormones at this 
concentration with estradiol having the most pronounced effect. Hormones had more 
divergent effects at 10-5 M when tested in female IPAs. While no hormone affected the 5-
HT response compared with vehicle, there was a trend towards enhanced vasoconstriction 
for testosterone and a trend towards decreased vasoconstriction for estradiol. This resulted 
in significant differences between testosterone and estradiol and between testosterone and 
2-ME. Similar results have previously been reported for porcine coronary arteries with 
estradiol reducing 5-HT induced vasoconstriction and testosterone enhancing it (Teoh et 
al., 2000a).  
 Interestingly, testosterone was the only hormone to alter 5-HT response between male and 
female IPAs with testosterone increasing the Emax of 5-HT in females compared with 
male IPAs. It would appear that the ability of testosterone to reduce 5-HT induced 
vasoconstriction is strongly male specific with no such effect and even a trend toward 
enhanced vasoconstriction occurring in females. This may indicate different mechanisms 
of action for testosterone in male and female IPAs and it is certainly clear that testosterone 
induces different signalling systems in different species and vascular beds. NO, Ca2+ and 
K+ channels, prostacyclin and androgen receptor (AR) mediated processes have all been 
suggested as modulators of testosterone action (Littleton-Kearney and Hurn, 2004). 
Testosterone and estradiol at 10-9 M had no significant effect on the 5-HT CCRCs in either 
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male or female IPAs. There was an observable trend, however, towards enhanced 5-HT 
induced vasoconstriction following 10-9 M estradiol, an interesting observation as it is a 
trend in the opposite direction from the reduced vasoconstriction 10-5 M estradiol had on 5-
HT. It is unclear if this is evidence of a true pharmacological effect. Enhanced 
vasoconstriction to phenylephrine has been observed in rabbit pulmonary arteries 
following estradiol but only at concentrations exceeding 10-6 M (Opgaard et al., 2002). 
Additionally, a physiological concentration (7 nM) of estradiol can increase the pressor 
response to noradrenaline in rat mesenteric arteries (Vargas et al., 1995). As described in 
the introduction to this chapter, the effects of estradiol can differ between vascular beds 
and the study by Vargas et al., 1995 did not study pulmonary arteries. Currently, there is no 
evidence for a direct vasoconstrictor effect of estradiol in mouse IPAs.  A similar 20 
minute exposure to 1 nM testosterone has previously been shown to reduce vasorelaxation 
induced by bradykinin and calcium ionophore A23187 (Teoh et al., 2000b) and to enhance 
vasoconstriction induced by 5-HT, ET-1 and U46619 (Teoh et al., 2000a). This latter study 
also tested estradiol at 10-9 M and found this concentration was sufficient to reduce 
vasoconstriction induced by 5-HT, ET-1 and U46619. Both studies were performed on 
mixed gender porcine coronary arteries which may be more sensitive to the vasoactive 
effects of sex hormones than murine IPAs. A final study examining whether estradiol (10-9 
M) would act as a risk or modulating factor for NDfen induced vasoconstriction failed to 
show any influence of estradiol on NDfen. In fact, female gender acted as a protecting 
factor against the effect of NDfen with the potency of NDfen being greater in male IPAs 
possibly indicating enhanced activation of 5-HT2A mediated pathways in IPAs in young 
adult male mice.  
 Estradiol and its metabolites also affect vascular SMC proliferation with the effect being 
anti-mitogenic in most studies to date. Multiple mechanisms of actions are suggested for 
the anti-mitogenic, anti-migratory effects of estrogens including inhibition of MAPK 
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pathways, decreased release of mitogens such as ET-1 and PDGF in addition to an 
inhibition of ROS production (Dubey and Jackson, 2001). Interaction with pathways such 
as these in PASMCs possibly explains the beneficial role estradiol and 2-ME have in 
animals models of PAH as outlined in section 1.2.3.2.4.  The effect on endothelial cell 
growth by estradiols appears concentration dependent. Lower concentrations (10-100 nM) 
of estradiol metabolites can induce proliferation of vascular endothelial cells whereas 
higher concentrations (>100 nM) inhibit endothelial cell proliferation (Dubey and Jackson, 
2001). In rat lung ECs, estradiol induced proliferation of both male and female cultured 
cells at physiologically relevant concentrations (3-30 nM) while testosterone only induced 
proliferation of male ECs. The extent of proliferation induced by estradiol depended on the 
relevant ratio of estradiol to both progesterone and testosterone with testosterone 
increasing the proliferative effect of estradiol on female ECs in a 1:1 ratio. Estradiol 
induced proliferation in these cells was dependent on ERs (Liu et al., 2002) highlighting 
the complexity of hormonal effects on cellular functions.  2-ME but not estradiol induces 
apoptosis of bovine PAECs. This was partly dependent on stress-activated protein kinase 
(SAPK). The EC50 value for inducing apoptosis was 0.45 M which is similar to the 
concentration required for inhibition of proliferation (Yue et al., 1997). Fas, Bcl-2, - 
galactosidase and ROS scavenging may also contribute to its role in preventing apoptosis 
(Yue et al., 1997; Tsukamoto et al., 1998; Dubey and Jackson, 2001).  
 There is currently no direct link between sex hormones and the development of PAH. If 
hormonal agents do play a role, the effects are likely to be more subtle than those observed 
in animal models using high plasma concentrations. It may be that alterations in the 
balance between estradiol and its metabolites, progesterone and testosterone or their 
receptors are more important than any single rise or fall in hormone concentration. 
Evidence for this is supported by the finding that progesterone receptors are present within 
the intimal lesions in human PAH but ERs are absent. Neither of these receptors are 
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present in healthy lung tissue (Barberis et al., 1995). As mentioned above, the relevant 
ratio of progesterone and testosterone to estradiol modulates the proliferative effect of 
estradiol on vascular ECs. The balance of circulating hormones can affect the response to 
other circulating vasoconstrictors and growth factors. Female mesenteric arteries from rats 
display increased responsiveness to vasoconstrictors compared with males and pre-
treatment of males with estradiol increases the responsiveness of male arteries (Altura, 
1975).  Inherent differences in many of the candidate systems put forward as modulators in 
the pathophysiology of PAH may also exist between male and females that increase the 
risk in females when challenged with pulmonary hypertensive risk factors. It is already 
established that estrogens can modulate MAPK pathways including ERK1/2 and p38. To 
determine if these two pathways, relevant to both 5-HT and Dfen induced proliferation of 
pulmonary cells and dysfunctional BMPR2 signalling, differs in male and female mouse 
lung, western blot analysis of these proteins were performed. The canonical BMPR2 
signalling protein: p-Smad1/5/8 was also analysed. Only p-ERK1/2 was significantly 
different, being raised in female mouse lung compared with males. p-ERK1/2, as 
previously described throughout this thesis, is implicated in 5-HT induced proliferation of 
PASMCs (Lee et al., 1999; Liu et al., 2004; Lawrie et al., 2005), BMP-2 and BMP-7 
induced proliferation of PASMCs in IPAH patients (Takeda et al., 2004) and also perhaps 
in Dfens mechanism of action (Lee et al., 2001). It could be hypothesised that if the 
increased p-ERK1/2 observed in female mouse lung was raised in PASMCs these cells 
may be less resistant to any factor that increases p-ERK1/2 promoting proliferation and 
also acting to suppress the anti-proliferative p-Smad1/5/8 pathway through direct inhibition 
(Massague, 2003). It may also be that a combination of small differences between male 
 and female physiology are additive in creating a pulmonary vasculature at greater risk of 
PAH and some of these differences will be discussed in the final chapter.  
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Chapter 9 
 General discussion 
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9.1 General discussion 
 
Recent years have provided extensive knowledge in understanding the pathophysiology of 
PAH including genetic, cellular and molecular advances. The result of this research has 
been the discovery of BMPR2 mutations as the principal genetic basis for the disease, the 
identification of candidate molecular mechanisms that modulate the severity of the disease 
and the emergence of new vasodilator therapies for improving survival and quality of life.  
Furthermore, PAH has revealed itself to be a multifactorial disease with neither one factor 
or mutation responsible for the severe disease phenotype observed in human patients.  The 
creation of the BMPR2+/- mouse as a genetic model to mimic the haploinsufficent state of 
FPAH in humans offers the opportunity to assess how a proven genetic risk factor may 
interact with other genetic or acquired factors speculated to be causative or modulating in 
the disease progression.  The large body of evidence outlined previously in this thesis 
implicating the serotonergic system, in particular heightened expression of the 5-HTT as a 
contributor to PAH and the existence of a 5-HTT+ mouse led to a new 5-HTT+/BMPR2+/-  
mouse being developed to further explore genetic interaction and subsequent interaction 
with possible secondary risk factors.   
 In chapter 3, the pulmonary phenotype of cross TG mice and single TG animals was 
extensively assessed in both male and female mice and the pulmonary vascular response to 
14 days hypoxia compared with WT animals. The most significant finding from this set of 
experiments was the divergent effect that overexpression of the 5-HTT and BMPR2 
deficiency had on pulmonary phenotype and that these effects were only evident in female 
animals.  5-HTT+ overexpression caused a rise in mRVP and vascular remodelling in 
room air in females and these animals had a more severe pulmonary hypertensive 
phenotype under hypoxia. The increase in vascular remodelling in female 5-HTT+ mice is 
a novel finding and further strengthens a role for the 5-HTT as a modulating factor in 
PAH. Future studies will need to address the question of what molecular mechanisms are 
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responsible for linking the 5-HTT to an increase in RVP and remodelling. Indeed, studies 
such as these are already under way with the recent discovery that Kv1.5 downregulation 
by the 5-HTT in PASMCs is dependent on the nuclear factor of activated T-cells (NFAT) 
c2 transcription factor (Guignabert et al., 2009). NFATc2 was found to mediate 5-HTT 
downregulation of Kv1.5 in both human PASMCs and in PASMCs from the SM22-5-
HTT+ mice discussed in chapter 3. Moreover, gene expression studies have been 
performed on 5-HTT-/- mice that indicate a decrease in inflammatory genes and changes in 
cell cycle genes that tend towards lower proliferation (Crona et al., 2009). The logical 
progression from this study would be a similar analysis of gene expression in the 5-HTT+ 
mouse used in this investigation that may identify genes or groups of genes that contribute 
to the pulmonary hypertensive phenotype.  Female BMPR2+/- mice, while phenotypically 
normal in room air, did develop more severe vascular remodelling following hypoxia than 
mice without BMPR2 deficiency. As discussed in chapter 3, this investigation is the first to 
show heightened vascular remodelling in the BMPR2+/- mouse following hypoxia, a 
particularly important and relevant finding to PAH in humans as it demonstrates that the 
interaction of two known risk factors for PAH (namely BMPR2 mutation and female 
gender) can predispose the pulmonary vasculature to more extensive changes following 
hypoxia, a factor in several diseases associated with PAH.   No synergy was observed 
between overexpression of the 5-HTT and BMPR2 deficiency in the in vivo experiments 
that resulted in an exaggerated pulmonary hypertensive phenotype. Developing a suitable 
model for PAH has proven difficult with neither the hypoxic or MCT rodent models 
reproducing the full complexity of vascular lesions observed in human patients and genetic 
models also have limitations. Despite mimicking the genetic background of a 
haploinsufficent FPAH patient with L/L allele genotype for 5-HTT, the level of BMPR2 
and 5-HTT in Cross TG mice are higher and lower respectively than levels seen in PAH 
patients.  It may be that synergistic effects in PASMCs from Cross TG mice that 
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predispose these cells to proliferation and vasoconstriction are too subtle to create a more 
pronounced pulmonary hypertensive phenotype following the hypoxic challenge used in 
this investigation. Long et al., 2006 demonstrated that BMPR2+/- mice develop a 
pulmonary hypertensive phenotype following 2 weeks of 5-HT infusion and that PASMCs 
from these mice proliferate to a greater degree than WT PASMCs following 5-HT. Taken 
together, these results indicate that loss of BMPR2 can enhance the deleterious effect of 5-
HT in murine PASMCs.  The proliferative effect of 5-HT and inhibition of p-Smad1/5/8 
was dependent on 5-HT2A receptor activation rather than 5-HT uptake via the 5-HTT 
which may explain the lack of synergy in the Cross TG mice used in this investigation, 
however, the 5-HTT may have contributed to the PAH observed in vivo in the study by 
Long et al., 2006.  It would be useful in future studies to infuse female BMPR2+/- mice 
with 5-HT in the same way Long et al., 2006 did for the males. These results could be 
compared for gender differences and could subsequently be compared with the Dfen 
results presented in this thesis. This would provide further information on the interaction 
between BMPR2 deficiency, gender and the serotonergic system as well as offer clues as 
to whether 5-HT alone mediates the in vivo effects of Dfen. 
 Enhancement of 5-HT2A signalling is supported by experimental results in IPAs from 5-
HTT+, BMPR2+/- and Cross TG mice that demonstrated greater vasoconstriction to the 5-
HT2A agonist NDfen compared with WT IPAs.  The greatest vasoconstriction was 
observed in BMPR2+/- mice supporting the work by Long et al., 2006 of enhanced 5-HT2A 
mediated serotonin signalling in these mice. An enhancement of 5-HT2A receptor 
signalling may be an important factor in transducing the genetic changes of 5-HTT+ and 
BMPR2+/- into pathophysiological changes in the pulmonary vasculature, both in the TG 
animals in this thesis and also in human patients. This is due to its diverse contributory role 
in 5-HT (Maclean et al., 1996; Long et al., 2006) and NDfen (Ni et al., 2005) induced 
vasoconstriction, hypoxic induced proliferation of PAFs (Welsh et al., 2004) and 5-HT 
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induced proliferation of PASMCs, an effect associated with enhanced activation of p-
ERK1/2 (Long et al., 2006) (figure 9.1).  
 Further support for cross-talk between 5-HT and BMPR2 pathways in murine PASMCs 
came from the Dfen pharmacology experiments in chapter 6. IPAs from female Cross TG 
mice were significantly more sensitive to Dfen induced vasoconstriction than WT or single 
TG animals and displayed vasoconstriction at clinically relevant concentrations. Unlike the 
pulmonary hypertensive phenotype observed in WT and BMPR2+/- mice following 
treatment with Dfen, the vasoconstriction exerted by Dfen was independent of peripheral 
5-HT synthesis (at least in WT and Tph1-/- mice). The enhanced vasoconstriction observed 
in Cross TG mice may reflect an enhancement of intracellular serotonergic signalling 
capable of being activated by Dfen, enhancement of 5-HT receptors or a direct inhibitory 
action of Dfen on Kv channel function.  
This investigation has found evidence of abnormal KCNQ channel mediated 
vasoconstriction in 5-HTT+, BMPR2+/- and Cross TG mice. Changes in KCNQ channel 
expression and/or function related to 5-HTT overexpression or loss of BMPR2 may 
contribute to the pathophysiology of PAH given the importance of K+ channels in PASMC 
vasoconstriction, remodelling and apoptosis and the negative effect that factors such as 
hypoxia, 5-HT and Dfen have on Kv channels in PASMCs.  The recent finding that 
flupirtine, a KCNQ channel activator, can reduce hypoxic PAH and the pulmonary 
hypertensive phenotype of 5-HTT+ mice (Morecroft et al., 2009) indicates a possible 
involvement of KCNQ dysfunction in the disease and offers a new target for potential 
therapeutic research. 
 Experiments in Tph1-/- mice conclusively showed that Dfen requires peripheral 5-HT 
synthesis to induce PAH, a process thought to involve massive 5-HT release related to 
Dfens role as a 5-HTT substrate. This is a key discovery that not only answers an 
important question regarding the mechanism of action of Dfen but also supports the 
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‘serotonin hypothesis’ of PAH. This  is also  the first investigation  to  look at  the effect of 
BMPR2 haploinsufficiency on Dfen APAH in vivo. BMPR2+/- mice were not any more 
susceptible to the cardiopulmonary effects of Dfen with the exception of small but 
significant levels of remodelling in male BMPR2+/- following Dfen compared with WT.  
Evidence linking BMPR2 deficiency and Dfen induced PAH in human patients is 
inconclusive. As mentioned in chapter 4 the functional significance of many of the BMPR2 
mutations found in PAH patients who had taken anorexigens is not clear.  The very fact 
that BMPR2 mutations have been found in APAH patients taking Dfen and that they 
correlate with a shorter exposure time would indicate some level of interaction between 
BMPR2 mutation and Dfen induced PAH although this may be dependent on the nature of 
the BMPR2 mutation.  
 The interaction between 5-HT and BMPR2 was further explored in chapter 5 by analysing 
expression of BMPR2, p-SMAD1/5/8 and p-ERK1/2 in IPAs from Tph1-/- mice. Although 
no significant differences were found between Tph1-/- and WT mice, there was a trend 
(more than two fold increase) towards heightened BMPR2 expression in Tph1-/- mice. This 
result is suggestive, although not conclusive, of a reciprocal influence between the two 
pathways (figure 9.1). Increased BMPR2 expression in Tph1-/- mice may contribute to the 
attenuated hypoxic induced PAH observed in these mice (Morecroft et al., 2007). 
 The in vivo experiments revealed that a 50% reduction in BMPR2 in all cells can enhance 
vascular remodelling following hypoxia in female mice. More severe loss of BMPR2 in 
PAECs or PASMCs would be thought to exaggerate the predisposition to vascular 
remodelling and experiments over the last several years are beginning to confirm this 
hypothesis.  As discussed in chapter 3, severe loss of BMPR2 in PASMCs through 
dominant negative inhibition induces a pulmonary hypertensive phenotype in mice, both 
male and female (West et al., 2004; Tada et al., 2007). The SM22-tet-BMPR2delx4+ mouse 
develops more severe PAH following hypoxia, further supporting an interaction between 
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genetic and environmental elements (West et al., 2004), however, the SM22-tet-
BMPR2delx4+ mouse displays relatively minor vascular remodelling. More recently, West et 
al., 2008a developed a mouse expressing a smooth muscle specific BMPR2R899X mutation.  
This is an arginine to stop mutation present in the cytoplasmic tail of BMPR2 and is also 
found in FPAH.  This is in contrast to the BMPR2delx4+ mutation which results in a 
premature stop 18 amino acids into the kinase domain resulting in loss of the entire 
intracellular domain including kinase activity. About one third of the mutant SM22-rtTA x 
TetO7-BMPR2R899X   mice had increased RVP and these mice had extensive vascular 
remodelling. The structural changes observed may partly be the result of the elevated p-
ERK1/2 and p-p38 MAPK observed in the lungs of the TG mice (West et al., 2008a). This 
evidence highlights an important point regarding the mutation specific effects of BMPR2 
disruption. Different BMPR2 mutations will have different effects on the stoichiometry of 
BMP cell surface receptor expression and the nature of intracellular signalling such as the 
degree of Smad activation and proteins controlled by the cytoplasmic tail such as LIMK-1.  
As more data is acquired on the mutation specific effect of BMPR2 mutations, this will 
allow new genetic models to be created and the pulmonary hypertensive phenotype to be 
compared between models. For example, the mouse used in this investigation mimics the 
haploinsufficent state that occurs in the majority (~70%) of human FPAH patients 
(Machado et al., 2006; Morrell, 2006). That still leaves 30% of FPAH patients who carry 
missense mutations that may lead to a dominant negative effect. Missense mutations have 
recently been shown to correlate with a more severe disease phenotype in human patients 
compared with mutations resulting in haploinsufficiency (Austin et al., 2009a). Creating a 
mouse carrying a dominant negative mutation in all somatic cells will allow a comparative 
study to be performed with the haploinsufficent BMPR2+/- mouse offering new insights 
into the interaction of specific mutation types with other risk factors. Microarray studies 
may also uncover potential genes of interest that are divergently modified between the 
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 different genetic models. 
  Gender emerged unexpectedly as a crucial and in some experiments the most critical 
factor in determining the extent of vasoconstriction, vascular remodelling or RVP present 
in mice. The effect of gender was also dependent on the genetic background of the animal. 
In the hypoxic in vivo study in chapter 3 female TG mice often had a greater pulmonary 
hypertensive phenotype than the males, a situation most marked in the 5-HTT+ mouse. 
Female 5-HTT+ mice also had increased RVP and vascular remodelling in room air, a 
phenotype not present in the males. The interaction of genetics and gender was also 
observed during the Dfen pharmacology experiments in chapter 6 (Dfen induced 
vasoconstriction was similar in male and female WT mice, greater in male 5-HTT+ mice, 
marginally greater in male BMPR2+/- mice but greater in female Cross TG mice which 
were the most sensitive of all mice to Dfen induced vasoconstriction) and NDfen 
pharmacology experiments in chapter 8 (where male mice were more sensitive to NDfen). 
The most profound result of all regarding gender differences was the absence of a 
pulmonary hypertensive phenotype in male WT and BMPR2+/- animals following Dfen 
which induced robust vascular remodelling and elevated RVP in females.  BMPR2+/- male 
mice did show remodelling following Dfen but only at 50% of the level observed in 
females and this was not accompanied by elevated RVP.  The experiments just outlined 
indicate an interaction between female gender and 5-HTT and BMPR2 pathways. In 
chapter 8, protein expression of p-ERK1/2 was found to be elevated in the lungs from 
female WT mice compared with males. As shown in figure 9.1, p-ERK1/2 can be 
increased in the context of dysfunctional BMP mediated signalling and increased 
serotonergic signalling. Increased p-ERK1/2 activity in female PASMC that are BMPR2+/- 
or that have increased expression of the 5-HTT and 5-HT2A/5-HT1B/1D receptors may 
further shift the balance of the cell towards proliferation and increased vascular 
remodelling (figure 9.1). Elevated p-ERK1/2 may be one of many factors that act 
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collectively to increase the risk of PAH in female mice and human female PAH patients. 
One candidate gene that may also contribute to the increased risk of PAH in females is 
Cytochrome P450 1B1 (CYP1B1), an enzyme involved in the breakdown of estrogens and 
expressed in the lung. CYP1B1 has been found to be decreased up to 10 fold in 
immortalised lymphoblastic cell lines derived from female FPAH patients with BMPR2 
mutation compared with male affected BMPR2 mutation carriers or unaffected BMPR2 
mutation carriers (West et al., 2008b). More recently, a polymorphism in CYP1B1 
resulting in decreased activity and previously linked to several cancers was associated with 
a 4 fold higher penetrance of PAH in BMPR2+/- females (Austin et al., 2009b). BMPR2+/- 
females with PAH were found to have an altered balance in estrogen metabolites compared 
with unaffected BMPR2+/- females. The balance was shifted so that the proportion of 16α-
hydroxyestrone (16α- OHE1) was greater. 16α- OHE1 is a significantly greater mitogenic 
compound than other estrogen metabolites and its increase is thought to be a direct 
consequence of diminished CYP1B1 (Austin et al., 2009b).  Similar to data outlined in the 
discussion in chapter 8 regarding the balance between testosterone, estradiol and 
progesterone, it may be that the balance between pro-proliferative and anti-proliferative 
estrogen metabolites is critical to the overall effect on vascular cells. The discovery that 
decreased CYP1B1 interacts with BMPR2 deficiency in human PAH patients offers the 
potential for future animal models in which to further explore the interaction of BMPR2 
mutation with female gender. This may involve creating a mouse that is BMPR2+/- and 
deficient in CYP1B1 and then exposing this model to additional modifying factors such as 
5-HT, hypoxia and Dfen. It is interesting to note that in addition to the discovery of 
CYP1B1 polymorphisms in human female FPAH patients, it has recently been shown that 
PAH patients with BMPR2 mutations have an earlier age at diagnosis compared with non- 
carriers, but that this only occurs for women. Within the male subgroup, no statistical 
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F igure 9.1 Interaction of serotonergic and B MPR2 signalling pathways on pulmonary 
smooth muscle cell proliferation. 
The balance between p-ERK1/2 and p-Smad1/5/8 is thought to be crucial in determining 
the proliferative state of a PASMC. Evidence from BMPR2+/- cells or cells from PAH 
patients suggests there is enhancement of p-ERK1/2 signalling, secondary to an increase in 
serotonergic activity or aberrant BMPR1A/1B (BR1) and BMPR2 (BR2) signalling. This 
promotes proliferation. Conversely, a decrease in p-Smad1/5/8 further shifts the balance 
towards proliferation. The elevated p-ERK1/2 expression in female mouse lung may 
contribute to the greater risk associated with female gender, especially when combined 
with dysfunctional BMPR2 or enhanced 5-HT signalling. The dashed arrow represents a 
potential new level of cross-talk between 5-HT and BMPR2 suggested by a trend towards 
enhanced BMPR2 expression in pulmonary arteries from Tph1-/- mice. This will require 
greater clarification in future studies.  
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differences emerged in age at diagnosis between BMPR2 mutant carriers and non carriers 
(Austin et al., 2009a). 
  Direct interactions may also exist between BMPR2 or the 5-HTT and estrogens. Estradiol 
has been shown to suppress BMPR2/p-Smad1/5 signalling in several cell lines through 
Smad inhibition by ER-α  (Yamamoto  et  al.,  2002).  The cytoplasmic tail of BMPR2 
contains estrogen sulfotransferase binding sites (Hassel et al., 2004) and this enzyme has a 
high affinity for estrogens and is involved in controlling local estrogen concentration 
(Song, 2001). The state of the 5-HTT can also be influenced by estrogens with increased 
circulating levels of estradiol upregulating 5-HTT expression in the brains of rats 
(McQueen et al., 1997; Rivera et al., 2009).  It is still unclear why the female pulmonary 
vasculature is more susceptible to PAH and what interactions may occur between loss of 
BMPR2 or heightened serotonergic signalling and estrogenic effects in the lung. The use of 
genetic models in animals can offer clues as to which molecular pathways may warrant 
further study. Microarray studies have indicated increased expression of cytokines and 
markers of immune response in SM22-tet-BMPR2delx4+ mice, an effect most prominent in 
female mice; with 8 week old SM22-tet-BMPR2delx4+ female mice having twice the 
expression of IL-6 than males (Tada et al., 2007).  Further studies such as this will help 
characterise pathways that differ between males and female and which are likely to 
contribute to disease progression. 
 To conclude, this investigation has uncovered important interactions between genetic pre-
disposition, gender and modifying factors in PAH that implicate the serotonergic system 
(both overexpression of the 5-HTT and peripheral 5-HT synthesis) as an important 
modulating factor in PAH. BMPR2 haploinsufficiency alone is not sufficient to induce 
PAH or to worsen Dfen associated PAH but is a risk factor for hypoxic induced vascular 
remodelling.  This investigation also uncovered increased vasoconstriction to NDfen in all 
TG mice and an increased contractile response to 5-HT in BMPR2+/- mice. This is an 
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important finding since increased pulmonary vasoconstriction is thought to be an important 
aspect in the initial stages of PAH. The enhanced vasoconstriction may partly relate to 
changes in K+ channel function and this investigation found impaired KCNQ channel 
function in TG mice, an alteration that may have detrimental consequences in the 
pulmonary vasculature given the recent discovery of the role these channels play in setting 
the resting Vm of PASMCs and the ability of KCNQ activators to reduce the symptoms of 
PAH in animal models. The resistance of male mice to many of the changes characteristic 
of PAH is something that was unexpected and also an important consideration for future 
studies in animal models of PAH. Gender must be considered an essential component in 
experimental design and interpreting results, especially in studies using hypoxia or Dfen. 
The female vasculature appears more susceptible to the changes characteristic of PAH and 
an increase in p-ERK1/2 may be an important candidate in raising this risk. The use of 
novel genetic animal models containing mutations or polymorphisms derived from human 
PAH patients have provided and will continue to provide new data on the cellular and 
molecular mechanisms underlying a highly complex disease. Future genetic models 
utilising haploinsufficent and dominant negative BMPR2 dysfunction combined with 
conditional knockout studies to unravel the complex cellular specific roles of such 
mutations will provide the basis for exploring the interaction of modulating factors such as 
5-HT, K+ channels and female gender both at the genetic and pharmacological level. 
Identification of the modifying factors that interact with BMPR2 deficiency and the 
unravelling of the molecular pathways that underlie those interactions will allow a better 
understanding of the pathophysiology of PAH and to aid the search for targeted therapies.  
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